University of Vermont

UVM ScholarWorks
Graduate College Dissertations and Theses

Dissertations and Theses

2019

Characterization Of Epigenetic Plasticity And Chromatin
Dynamics In Cancer Cell Models
Diana Lea Gerrard
University of Vermont

Follow this and additional works at: https://scholarworks.uvm.edu/graddis
Part of the Molecular Biology Commons

Recommended Citation
Gerrard, Diana Lea, "Characterization Of Epigenetic Plasticity And Chromatin Dynamics In Cancer Cell
Models" (2019). Graduate College Dissertations and Theses. 1060.
https://scholarworks.uvm.edu/graddis/1060

This Dissertation is brought to you for free and open access by the Dissertations and Theses at UVM
ScholarWorks. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized
administrator of UVM ScholarWorks. For more information, please contact scholarworks@uvm.edu.

CHARACTERIZATION OF EPIGENETIC PLASTICITY AND CHROMATIN
DYNAMICS IN CANCER CELL MODELS

A Dissertation Presented

by
Diana Lea Gerrard
to
The Faculty of the Graduate College
of
The University of Vermont

In Partial Fulfilment of the Requirements
For the Degree of Doctor of Philosophy
Specializing in Cellular, Molecular, and Biomedical Sciences
May, 2019

Defense Date: March 8, 2019
Dissertation Examination Committee:
Seth Frietze, Ph.D., Advisor
Sayyed Kaleem Zaidi, Ph.D., Chairperson
Frances Carr, Ph.D.
Jessica Heath, M.D.
Cynthia J. Forehand, Ph.D., Dean of the Graduate College

ABSTRACT
Cancer progression is driven by cumulative changes that promote and maintain
the malignant phenotype. Epigenetic alterations are central to malignant transformation
and to the development of therapy resistance. Changes in DNA methylation, histone
acetylation and methylation, noncoding RNA expression and higher-order chromatin
structures are epigenetic features of cancer, which are independent of changes in the
DNA sequence. Despite the knowledge that these epigenetic alterations disrupt essential
pathways that protect cells from uncontrolled growth, how these modifications
collectively coordinate cancer gene expression programs remains poorly understood. In
this dissertation, I utilize molecular and informatic approaches to define and characterize
the genome-wide epigenetic patterns of two important human cancer cell models. I
further explore the dynamic alterations of chromatin structure and its interplay with gene
regulation in response to therapeutic agents.
In the first part of this dissertation, pancreatic ductal adenocarcinoma (PDAC) cell
models were used to characterize genome-wide patterns of chromatin structure. The
effects of histone acetyltransferase (HAT) inhibitors on chromatin structure patterns were
investigated to understand how these potential therapeutics influence the epigenome and
gene regulation. Accordingly, HAT inhibitors globally target histone modifications and
also impacted specific gene pathways and regulatory domains such as super-enhancers.
Overall, the results from this study uncover potential roles for specific epigenomic
domains in PDAC cells and demonstrate epigenomic plasticity to HAT inhibitors.
In the second part of this dissertation, I investigate the dynamic changes of
chromatin structure in response to estrogen signaling over a time-course using Estrogen
Receptor (ER) positive breast cancer cell models. Accordingly, I generated genome-wide
chromatin contact maps, ER, CTCF and regulatory histone modification profiles and
compared and integrated these profiles to determine the temporal patterns of regulatory
chromatin compartments. The results reveal that the majority of alterations occur in
regions that correspond to active chromatin states, and that dynamic chromatin is linked
to genes associated with specific cancer growth and metabolic signaling pathways. To
distinguish ER-regulated processes in tamoxifen-sensitive and in tamoxifen-resistant
(TAMR) cell models, we determined the corresponding chromatin and gene expression
profiles using ER-positive TAMR cancer cell derivatives. Comparison of the patterns
revealed characteristic features of estrogen responsiveness and show a global
reprogramming of chromatin structure in breast cancer cells with acquired tamoxifen
resistance.
Taken together, this dissertation reveals novel insight into dynamic epigenomic
alterations that occur with extrinsic stimuli and provides insight into mechanisms
underlying the therapeutic responses in cancer cells.

CITATIONS
Materials from this dissertation have been published in the following form:
Gerrard, D. L., Hawkinson, A., Sherman, T., Modahl, C. M., Hume, G., Campbell, C. L.,
. . . Frietze, S.. (2017). Transcriptomic Signatures of Tacaribe Virus-Infected Jamaican
Fruit Bats. mSphere, 2(5). doi:10.1128/mSphere.00245-17
Gerrard, D. L., Wang, Y., Gaddis, M., Zhou, Y., Wang, J., Witt, H., . . . Frietze, S. E..
(2018). Three-dimensional analysis reveals altered chromatin interaction by enhancer
inhibitors harbors TCF7L2-regulated cancer gene signature. J Cell Biochem.
doi:10.1002/jcb.27449

AND
Materials from this dissertation are “in press” for publication in the following form:
Gerrard, D. L., Zhou, Y., Wang, J., Li, T., Yang, Y., Fritz, A.J., . . . Frietze, S., Jin, V.X..
(2019). Temporal dynamic reorganization of 3D chromatin architecture in hormone
induced breast cancer and endocrine resistance. Nature Communications.

AND
Materials from this dissertation are “in review” for publication in the following form:
Gerrard, D.L., Boyd, J.R., Stein, G.S., Jin, V.X., and Frietze, S.. (2019). Disruption of
broad epigenetic domains in PDAC cells by HAT inhibitors. Scientific Reports.

ii

DEDICATION
I dedicate this dissertation to my father, Master Chief Leslie James Gerrard
(retired), for his never-ending support and encouragement; my sister, Dr. Crystal Lynn
Gerrard, for her guidance through dedication and perseverance; and my mother,
Florentina Cook, for her persistence in love and internal value for the educational
opportunities available in the USA. You have each contributed a significant amount of
yourselves to me, which has built me into who I am and have yet to become. Your never
ending commitment to me and passion for what you love inspires me.

iii

ACKNOWLEDGEMENTS
First, I must express my immense appreciation for my dissertation mentor, Dr.
Seth Frietze, who has selflessly invested in my education while I aimed to establish
myself and grow as a research scientist. Thank you, Seth, for always giving me
opportunity and allowing me to advance the skills and expertise that I need and desire to
build my future. You have been supportive and a great captain for my journey. I am
forever grateful for the lessons you have given me within intellectual scientific creativity,
technical skills and laboratory management. The mentorship opportunities you have
trusted me with allowed me to foster the concept of being a collaborative scientist. I also
want to extend my gratitude for the rest of the Frietze family. Having had roots in
Vermont, you made sure that this Texan settled properly and have continued to support
me throughout my time in the Frietze laboratory. I am so honored to have been trained
and mentored by you, Seth, and feel pride for the opportunity to represent you in my
future career.
I am extremely fortunate to have had Dr. Sayyed Kaleem Zaidi as a mentor
throughout my PhD studies as the chair of my committee. Kaleem is the most holistic
mentor I could have ever dreamed of having throughout these last five years and I am
confident that he will continue to play an integral part of my future endeavors. Not only
is he an inspirational scientist who provides critical evaluation and comprehensive
perspectives on scientific concepts, but he also has inspired me to constantly challenge
my perception of my life as a scientist within the bigger picture. Kaleem, I really want to
express my sincere gratitude to you for continuously providing a listening ear and for
always being
iv

ready to follow that listening with VERY VALID ‘reality checks’. You are an extremely
great mentor and I am forever grateful for you. Dr. Jessica Heath and Dr. Frances Carr
are two Women in Science that I have been blessed to be mentored by. Dr. Heath’s
immense dedication to her career as a Physician and a Research Scientist is truly
inspiring. Thank you, Jess, for always igniting the confidence within me to strive for
greatness. Dr. Carr has dedicated her life to several different facets of the scientific
community and has thrived as an eminent researcher. Thank you Fran for always being
receptive of ideas and for providing valuable feedback, encouragement and for
continuously challenging me to consider my future.
I am grateful to have shared this process with two other graduate students in the
Frietze lab, Michael Mariani and Princess Rodriguez. Thank you Mike for encouraging
me daily and for helping in many Tron ways. My uttermost gratitude goes to Princess.
You have been the best ‘ride or die’ and I am completely grateful for the support we have
given each other through the last four years. The effort and the stamina needed to
complete these projects was definitely inspired by your encouragement. We have done
this together and I cannot wait to continue to encourage you throughout the rest of your
PhD journey and celebrate with you at the end. As an honorary mention- Dr. Phyu Thwe
has been the best graduate student mentor for me. I am forever indebted to you for your
guidance!
Lastly, thank you to my partner Nathan Horsfall, who has been a part of this
entire journey from applications to two cross-country moves. I am forever grateful for
you.

v

TABLE OF CONTENTS
CITATIONS ...................................................................................................................... ii
DEDICATION ................................................................................................................. iii
ACKNOWLEDGEMENTS ............................................................................................ iv
CHAPTER 1 ...................................................................................................................... 1
Comprehensive Literature Review .................................................................................. 1
1.1: Basic principles underlying genome organization .............................................. 2
1.1.1: The nucleosome as the fundamental subunit of DNA ...................................... 2
1.1.2: Gene expression ................................................................................................ 3
1.1.3: Foundational principles of epigenetics ............................................................. 4
1.2: Higher order chromatin organization ................................................................. 5
1.2.1: Fundamental principles of chromatin architecture ........................................... 6
1.2.2: Gene regulation mediated by higher order chromatin organization in
development ................................................................................................................ 9
1.2.3: Chromosome architecture in cancer programs ............................................... 11
1.3: Post translational histone modifications ............................................................ 12
1.3.1: The core histone proteins ................................................................................ 12
1.3.2: Modifications of the core histone proteins ..................................................... 13
1.3.3: Overview of histone acetylation and methylation .......................................... 13
1.3.4: Histone acetylation and methylation in cancer ............................................... 16
1.4: Next generation sequencing methods for studying chromatin-based
mechanisms .................................................................................................................. 18
1.4.1: Methods for studying 3D chromosome organization ..................................... 18
1.4.2: Methods for post translational histone modifications ..................................... 21
1.4.3: Measuring gene expression ............................................................................. 22
1.5: Dynamics of chromatin structure ...................................................................... 23
1.5.1: Chromatin-remodeling in response to hormone signaling .............................. 23
1.5.2: Chromatin-remodeling in response to small molecules .................................. 25
1.6: Scope of Dissertation: .......................................................................................... 26
References .................................................................................................................... 29
CHAPTER 2 .................................................................................................................... 44
vi

Three-dimensional analysis reveals altered chromatin interaction by enhancer
inhibitors harbors TCF7L2-regulated cancer gene signature .................................... 44
Abstract ..................................................................................................................... 23
Introduction ............................................................................................................... 24
Results ....................................................................................................................... 27
Discussion ................................................................................................................. 36
Methods..................................................................................................................... 39
Figures....................................................................................................................... 46
References:................................................................................................................ 56
CHAPTER 3 .................................................................................................................... 64
Disruption of broad epigenetic domains in PDAC cells by HAT inhibitors.............. 64
Abstract........................................................................................................................ 65
Background ............................................................................................................... 66
Results ....................................................................................................................... 67
Discussion ................................................................................................................. 74
Methods..................................................................................................................... 78
Figures....................................................................................................................... 82
References ............................................................................................................... 102
CHAPTER 4 .................................................................................................................. 111
Temporal dynamic reorganization of 3D chromatin architecture in hormoneinduced breast cancer and endocrine resistance ........................................................ 111
Abstract ....................................................................................................................... 112
Introduction ................................................................................................................. 113
Results ......................................................................................................................... 116
Discussion ................................................................................................................... 123
Methods....................................................................................................................... 127
Chromosome conformation capture coupled with qPCR (3C-qPCR) ........................ 136
Figures......................................................................................................................... 144
References ................................................................................................................... 162
CHAPTER 5 .............................................................................................................. 173
Discussion and Concluding Remarks ...................................................................... 173
COMPREHENSIVE BIBLIOGRAPHY .................................................................... 185
vii

Appendix A .................................................................................................................... 225
Altering cancer transcriptomes using epigenomic inhibitors ................................... 225
Abstract ................................................................................................................... 226
Background ............................................................................................................. 227
Results ..................................................................................................................... 230
Discussion ............................................................................................................... 237
Conclusions ............................................................................................................. 242
Methods................................................................................................................... 243
Figures..................................................................................................................... 247
References ............................................................................................................... 262
Appendix B .................................................................................................................... 268
Supplemental Materials for Chapter 2 ....................................................................... 268
Appendix C .................................................................................................................... 273
Supplemental Materials for Chapter 3 ....................................................................... 273
Appendix D .................................................................................................................... 289
Supplemental Figures for Chapter 4 ........................................................................... 289
Appendix E .................................................................................................................... 294
Transcriptomic Signatures of Tacaribe Virus-Infected Jamaican Fruit Bats ........ 294
Abstract ................................................................................................................... 295
Importance .............................................................................................................. 295
Introduction ............................................................................................................. 296
Results ..................................................................................................................... 298
Discussion ............................................................................................................... 304
Conclusion .............................................................................................................. 312
Materials and Methods ............................................................................................ 313
References ............................................................................................................... 321

viii

LIST OF FIGURES
Figure

Page

Figure 2.1: Characteristics of interacting chromatin regions in PANC1 cells .................. 46
Figure 2.2. Classification of PANC1 domains with epigenetic marks ............................. 48
Figure 2.3: The relationship between interaction peaks and sub‐domains ....................... 50
Figure 2.4: Effects of histone acetyltransferase inhibitors on chromatin loops and
gene expression in PANC1 cells ....................................................................................... 52
Figure 2.5: Effects of histone acetyltransferase inhibitors on TCF7L2‐mediated
looping in PANC1 cells .................................................................................................... 54
Figure 3.1: Determination of super-enhancers and broad H3K4me3 domains in
PDAC cell lines that correspond to different histological grades ..................................... 82
Figure 3.2: Broad domains mark distinctive pathways and are predictive of
poorer patient survival ...................................................................................................... 87
Figure 3.3: Inhibitors of histone acetyltransferases impact global H3K27ac levels ......... 91
Figure 3.4: HAT Inhibitors Influence the Acetylation levels at Super-Enhancers ........... 96
Figure 3.5: Broad domains are linked to topological associated domain boundaries ....... 99
Figure 4.1: Identification of E2-induced compartments in MCF7 cells at T1
versus T0 ......................................................................................................................... 144
Figure 4.2: Defining E2-induced temporal dynamic re-compartmentalization
(TDRC) in MCF7 cells ................................................................................................... 146
Figure 4.3: Identification of altered compartments in TamR cells ................................. 149
Figure 4.4: Epigenetic modifications on E2-induced TDRCs and TRACs .................... 151
Figure 4.5: A distribution of ERα and CTCF peaks in E2-induced TDRCs
and TRACs...................................................................................................................... 154
Figure 4.6. Gene expression and looping in E2-induced TDRCs and TRACs ............... 157
Figure 4.7: A proposed model for dynamic 3D chromatin architecture ......................... 160
ix

Appendix A-1: Targeting the WNT pathway using epigenetic inhibitors ...................... 247
Appendix A-2. The effects of epigenetic inhibitors on the transcriptome of
HCT116 and PANC1 cells .............................................................................................. 249
Appendix A-4. Effects of epigenetic inhibitors on gene expression in PANC1 cells .... 252
Appendix A-5. ICG-001 and C646 affect many of the same genes in HCT116
and PANC1 cells ............................................................................................................. 254
Appendix A-6. Epigenetic inhibitors can partially restore a normal expression
pattern to tumor cells ...................................................................................................... 256
Appendix A-8. In PANC1 cells, treatment with ICG-001 does not affect the same
genes as does reduction in levels of TCF7L2 ................................................................. 259
Appendix A-9: ICG-001 negatively regulates the cholesterol biosynthesis
network ........................................................................................................................... 261
Appendix B-1: Comparison of TCC and HiC TADs and boundaries ............................ 269
Appendix B-2: Visualization of Repeated HMM state S1/S7/S9 ................................... 270
Appendix B-3: Length distribution of topological domains in drug
treated PANC1 ................................................................................................................ 271
Appendix B-4: Pearson correlation between sub-domain and change of
sub-domain ...................................................................................................................... 272
Appendix C-1: Identification of super-enhancers in PANC1 cells ................................. 274
Appendix C-2: Identifying Broad H3K4me3 domains in PANC1 cells ......................... 277
Appendix C-3: Pathway analysis of super-enhancers and broad H3K4me3
domains in different PDAC grade groups ....................................................................... 279
Appendix C-4: Gene expression relative to broad domains ........................................... 281
Appendix C-5: The impact of ICG-001 treatment on broad H3K4me3 domains........... 283
Appendix C-6: Chromatin-interacting domains in PANC1 cells ................................... 286
Appendix C-7: Domains with increased ChIP-seq signal after HAT inhibitor
treatment are enriched in boundary regions .................................................................... 288

x

Appendix D-1: Identification of 24 patterns of dynamic compartments ........................ 290
Appendix D-2. Validation of 3C-qPCR for HOMER loops ........................................... 292
Appendix D-3. False Discovery Rate (FDR) and percentage of compartments ............. 293
Appendix E-1: Transcriptomic analysis of Jamaican fruit bats infected with
Tacaribe virus (TCRV) ................................................................................................... 316
Appendix E-2: De novo assembly of the Jamaican fruit bat transcriptome ................... 317
Appendix E-3: Differential gene expression analysis following TCRV infection
in Jamaican fruit bats ...................................................................................................... 318
Appendix E-4: Immune-specific expression analysis of TCRV-infected
Artibeus jamaicensis bats ................................................................................................ 319
Appendix E-5: Amino acid alignment of Jamaican fruit bat IgG V regions .................. 320

xi

CHAPTER 1
Comprehensive Literature Review

1

1.1: Basic principles underlying genome organization
Research over many decades has enhanced our knowledge concerning eukaryotic
genome organization. Genome organization refers to the structural orientation of
deoxyribonucleic acid (DNA) and is highly controlled. The discovery of the structure of
DNA in the 1950s [1] provided the platform for later investigations regarding its
mechanisms within genetic inheritance, determination of cellular fates and contributions
to disease phenotypes. Other studies in the 1950s-1960s elucidated significant aspects of
DNA structure including the ratio of bases [2] and the determination of DNA as the
‘backbone’ of chromatin structure [1, 3]. After the discovery of its involvement in
inheritance during the 19th century, its rediscovery inspired researchers to expand on this
fundamental knowledge and to further investigate DNA’s regulation and influences on
cellular mechanisms. This became possible as new revelations discovered the genome to
be densely organized inside of the approximate 10 μm nucleus [4]. In this section, I
provide an overview of key concepts governing genome organization including DNA
structure, epigenetics and gene expression.

1.1.1: The nucleosome as the fundamental subunit of DNA
Scientific investigations in the 1970s paved the way for succeeding chromatin
research. In the early 1970s, chromatin fibers were discovered to be approximately 100
angstroms thick [5, 6] and in 1975 the structure of this fiber was confirmed after earlier
propositions acknowledging that DNA was wrapped around eight histone proteins in
repeating units, comprising chromatin [7]. These units, called nucleosomes, were first
visualized by Oudet et al. with an electron microscope. They achieved these after
2

depleting lysine-rich histones, which allowed them to observe chromatin structure as a
replicating unit of spherical particles [7]. The molecular structure of the nucleosome was
subsequently solved [8, 9] and research began to reveal its significance in biological
outcomes including transcription, DNA repair and cell cycle processes [10-12].
Elucidating the organization of the tightly packed chromatin within the nucleus provided
the foundation needed to explore chromatin regulation in cellular mechanisms.

1.1.2: Gene expression
As the central dogma of molecular biology highlights, underlying information
contained within DNA has the potential to be transferred to RNA followed by protein
through successive steps (transcription and translation, respectively) [13]. The
complexity of how these processes are achieved and the particular outcomes as a result,
extends far beyond this basic fundamental principle. Underlying this complexity is
temporal and spatial control of genes relative to the rest of the genome. This determines
the accessibility of genes and the ability of regulatory protein complexes to bind those
regions in order to undergo transcription. RNA polymerase proteins are the core of
transcriptional machinery. There are many different types of RNA polymerases with
distinct roles regarding the types of genes they are able to transcribe [14]. While RNA
polymerases I and III transcribe ribosomal RNAs and transfer RNAs/small RNAs
respectively [15-17], RNA polymerase II regulates protein coding genes and long noncoding RNA via sophisticated control steps assuring correct structure at the site of
transcription and allows for correction of mismatched bases [18-20]. Additionally, RNA
polymerase II coordinates with core general transcription factors, which acts to help RNA
3

polymerase II localize to transcriptional initiation regions known as promoters to carry
out these activities [21].
A different type of transcription factor class contains proteins that are sequence
specific and have the ability to bind to DNA binding domains such as the High Mobility
Group-box (HMG) domain [22, 23]. This ubiquitous protein domain is found in many
transcription factors including the Sry-type HMG box (SOX) family of transcription
factors, which play transcriptional roles in development and differentiation [24].
Additionally, transcription factors have other effector domains allowing for various other
functions; for example, the recruitment of other regulatory complexes [25]. The spatial
and temporal control of the genome also contributes to the ability of these factors to
recognize their DNA binding sites and carry out their given roles. To this end, there are
far less transcription factors within the human genome than there are genes and so they
function via combinatorial mechanisms and make up transcriptional regulatory networks
[22]. The effector function of transcription factors can vary and dictate the regulatory
outcome. For instance, they have the capability of activating or repressing gene
expression programs through the recruitment of chromatin-modifying enzymes and other
cofactors that influence DNA accessibility directly impacting transcription [26].

1.1.3: Foundational principles of epigenetics
Epigenetic mechanisms play key roles in chromatin accessibility. In regard to the
term itself, ‘epigenetics’ was coined by C.H. Waddington around 1940-1950 [27]. While
the field of genetics encompasses research elucidating gene-based mechanisms regarding
heritability, epigenetics extends beyond this notion to not only include heritable changes
4

but rather concerns modifications occurring along the genome that do not include
alterations to DNA sequences themselves. Consequences of research efforts over many
years has revealed modifications influencing transcriptional control including DNA
methylation, post translational histone modifications, chromatin architecture and noncoding RNAs to be among these epigenetic aspects [28-32]. DNA methylation was
identified in the 1940s and refers to the transfer of methyl groups to CpG dinucleotides
by DNA methyltransferase enzymes [33]. Mechanistically, this modification can result in
gene silencing by blocking the binding of transcriptional regulators or by recruiting gene
repressive complexes [34-37]. Histone modifications incorporate different edits to amino
acid tails of histone proteins some of which include acetylation, methylation,
ubiquitination and phosphorylation. These modifications can either be transferred on or
removed and can further act as docking sites for chromatin regulatory proteins and
transcriptional complexes modulating chromatin accessibility and gene regulation [38].
Importantly, epigenetic regulation contributes to the heterogeneity of cellular functions as
a result of gene expression alterations, in part, due to these modifications.

1.2: Higher order chromatin organization
Aspects underlying chromatin architecture within the nucleus and its
contributions to cellular phenotypes are still largely unknown. After the identification of
3-dimensional chromatin structure within the nucleus, researchers over the last several
decades have desired to elucidate fundamental principles regarding the nuclear
organization of chromatin. Moreover, questions within these explorations have included:
(1) In the small nuclear environment, how is chromatin organized and why does it take on
5

this organization?; (2) What molecular consequences does chromatin organization play in
driving differentiation and development?; (3) Where are the genome-wide chromosome
contacts in different cell types and what implications do these have on gene expression
programs?; and (4) What are the implications of chromatin organization on diseased
outcomes? In this section, I highlight principles of chromatin architecture and its
importance in normal cellular phenotypes as well as cancer.

1.2.1: Fundamental principles of chromatin architecture
Chromatin regulation is a dynamic process by which fluctuations between
condensed and relaxed chromatin states have been recognized to impact various cellular
processes. Among these mechanisms are DNA repair [39], transcription [40] and cell
division [41]. Cells must maintain genomic structural integrity and functional identity
throughout successive generations to prevent transformations into an aberrant phenotype
[42, 43]. Unveiling 3-D chromosome organization within the nucleus is crucial for
understanding direct structural mechanisms underlying gene regulation and other celltype specification processes.
It was first proposed in 1885 by Carl Rabl that chromosomes exist in distinct
chromosome territories, which was later supported with experimental findings conducted
by Cremer et al. [44, 45]. How the chromosomes are oriented during interphase is
important for transcriptional regulatory targets and therefore directly influences cellular
phenotypic outcome. The radial positioning of chromosomes in the nucleus and the
relationship between these territories and gene density have been determined in the
interphase nucleus [46]. To this end, it is well accepted that these chromosome territories
6

are organized such that gene-dense chromosomes are positioned interiorly [45], allowing
for long-range interactions between genomic regions and can help dictate the phenotypic
outcome of the cell [47]. For example, a long range single nucleotide polymorphism
region was shown to interact with the oncogenic gene c-MYC through long-range
chromatin interaction in colorectal cancer cells, ultimately playing a role in the
upregulation of this cancer driver [48].
Further elucidation of structures contributing to chromosome architecture and
organization within the nucleus revealed additional components including: the nucleolus,
transcriptional complexes, histone locus bodies, heterochromatin and euchromatin [49].
These discoveries were products of combinatorial efforts involving traditional
microscopic techniques as well as newly developed molecular tools (discussed in Chapter
1.5). From here, the interest arose in focusing efforts to identify specific domains
associated with distinct territories in the nucleus.
Among the different types of associating contacts identified were lamina
associated domains, nucleolar associated domains and topologically associated domains
[50]. While nucleolar and lamina associated domains involve the interaction of
chromosomes with nuclear components, topological associated domains refer to DNADNA contacts. In addition to the identification of different interacting regions, genomic
compartments were discovered. These spatially segregated compartments along the
genome were defined at a 1 Mb resolution and are categorized into either compartment
types A or B [47]. These compartments were coordinated with epigenetic and gene
expression programs, allowing for further characterization of these regions. Type A
compartments were found to be enriched in genes and associated with open chromatin
7

regions; therefore, compartment A is commonly referred to as an open compartment. In
contrast, compartment B was determined to be more densely packed and is referred to as
a closed compartment. Understanding these compartments have revealed functional
relationships between chromatin structure and gene activity. The topologically associated
domains mentioned previously were identified within these compartments [51].
Moreover, topologically associated domains are genomic regions with self-interacting
chromatin regions. The frequency of interactions within 100 kb along the genome
revealed dense regions of self-interactions. Observations of these topological associated
domains also revealed regions along the chromatin where interaction density abruptly
ends. These regions, termed boundary regions, separate topologically associated domains
and contain high levels of the transcription factor CCCTC-binding factors (CTCF) [52] in
addition to other chromatin remodeling proteins, condensin and cohesin [53].
Long-range chromatin interactions are involved in cis gene regulatory programs
by facilitating enhancer-promoter interactions [54]. After the discovery of enhancer
regions, it was postulated that enhancer regions interact with promoter regions to regulate
gene expression. Their interaction is achieved through chromatin looping as these
regulatory regions are far apart from each other on a one-dimensional level [55, 56]. For
example, with the goal of defining mechanisms underlying a gene relevant to kidney
cancer, Moisan et al., identified enhancer elements that were localized to the promoter
region of the PKD2 gene via CTCF stabilization mediated by chromatin looping in renal
cancer cells [57].
Together the identification of compartments and topological associated domains
have laid the groundwork needed for understanding spatial organization of chromosomes
8

and its regulatory link to functional biological outcomes. The architecture of
chromosomes during interphase is important for mediating maintenance of cellular
genomes and gene expression regulation. Current efforts seek to further elucidate
mechanisms that these architectural elements play in normal and diseased processes.

1.2.2: Gene regulation mediated by higher order chromatin organization in development
While chromosome territories have been determined to display differences in cell
types through repositioning [57, 58], topologically associated domains are largely
conserved between species and have shown little variance during differentiation [59].
However, the interactions occurring with the topologically associated domains
themselves can vary. Therefore, the separation of chromosomes into topologically
associated domains provides a framework for distinct developmental-specific nuclear
positioning. As cells differentiate, they respond to many different signals and rely on
their underlying transcriptional machinery including protein complexes to respond to
these cues. Among these responses are that of transcriptional regulatory control [60, 61].
The gene expression programs are controlled by many different proteins including
transcription factors, co-regulatory proteins and chromatin regulators that bind to DNA at
regulatory regions. As chromosomes are arranged in their territories during interphase,
and within these territories, chromosomes contain regulatory interacting regions as
discussed earlier. It is evident that organization of the genome is directly important for
gene expression and therefore research has aimed to uncover their role in development
through differentiation and cell-type specificity.
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Among the hallmark studies investigating the role of chromatin organization and
gene expression in regard to development include studies investigating the inactivation of
the X chromosome [62-64]. A study seeking to characterize cis-regulatory mechanisms
involved in X inactivation using female mouse embryonic fibroblasts found that while
topologically associated domain organization remains largely the same for the X
inactivated chromosome compared to the activated, there were differences in internaltopological associated domain interactions [63]. Additionally, when interrogating gene
expression differences within these regions, they found a correlation between intratopologically associated domain alterations and differential gene expression throughout
differentiation. Lastly, they revealed that alterations of boundary regions resulted in the
mis-regulation of long-range gene-networks. A more recent study by Dixon et al.
mapped genome-wide chromatin interactions in H1 human embryonic stem cells and
human embryonic stem cell-derived lineages and ultimately uncovered reorganization of
chromatin architecture during stem cell differentiation [65]. This reorganization during
lineage specification was observed through switches between chromosome compartment
types (A and B) and changes in the frequency of local interactions within the topological
associated domains. They associated these regions with gene expression and identified
subsets of genes displaying alterations in gene expression patterns. Together these studies
serve as examples to the groundbreaking efforts implicating differential 3D-genomic
architecture within chromosome compartments and topologically associated domains,
their influence on gene regulation and moreover the implications of this molecular
network on cellular development.
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1.2.3: Chromosome architecture in cancer programs
Some of the first hypotheses regarding chromosomal abnormalities within cancer
were conceived in the late 1800s and early 1900s by the German scientists David Paul
von Hansemann and Theodore Boveri who proposed that cancer is a result of aberrant
chromosome regulation during the cell cycle [66,67]. For many years pathologists have
used changes in nuclear structure as a diagnostic framework to detect cancer [68].
Expanding from fundamental observations of abnormal nuclear morphology in addition
to the quantity of nuclei in cancer cells comes later observations, which have revealed
changes in higher-order chromatin organization. Despite the advancements in our
knowledge regarding abnormal gene expression programs within various cancers, the
specific roles these changes in 3D-chromatin structure plays in cancer phenotypes
remains to be further elucidated.
Changes in chromosome territories have been linked to differential gene
expression programs in cancer [69, 70]. Marella et al. investigated chromatin territory
organization in normal epithelial and breast cancer cell lines and observed alterations in
chromosome territories through an increase in associations between chromosome 4 and
chromosome 16 [71]. Another study investigating alterations in topologically associated
domains in cancer revealed changes within interacting regions where they also identified
differences in chromatin architecture surrounding genes that were differentially expressed
within these altered long-range chromatin interactions [72]. While there are other similar
observations in different cancers [73] and recent studies have produced large datasets for
studying 3-D chromatin alterations in cancer, much still remains to be elucidated.
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1.3: Post translational histone modifications
The structure of chromatin and gene expression has emerged as a key area of
research for uncovering mechanisms underlying cellular phenotypes. Modifications of the
core histone proteins influence gene expression programs in the way that some
modifications can dynamically alter how open or closed the chromatin is, thereby
affecting regulatory protein accessibility to genes during transcription. Research has
identified modifications that can occur to the free amino acid tails of the core histone
proteins at specific residues that are directly linked to a biological outcome; this is
referred to as the histone code hypothesis [74]. Histone tail acetylation and methylation
are the modifications that have been identified to primarily play the role in switching the
dynamics of chromatin accessibility. To this end, therapeutic agents targeting epigenetic
histone modifications have been developed to mitigate oncogenic development in the
cancer phenotype.

1.3.1: The core histone proteins
Post translational histone modifications have emerged as important regulatory
components of cellular processes influencing gene regulation. Histone proteins wrapped
in DNA assemble into nucleosomes and are the foundational building blocks of
eukaryotic chromatin. Early reports in the late 1880’s suggest the discovery of histone
proteins and work in the 1960s was the first to report a potential function for these
proteins in controlling gene regulation [75]. Evolutionary processes have resulted in the
four core histone proteins that make up the nucleosome and pack the DNA tightly. These
four core proteins that make up the octamer are H2A, H2B, H3 and H4 [76]. Each histone
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protein contains globular domains that modulate the interactions between the core histone
proteins. Additionally, each protein contains amino tails that contain approximately 30
amino acids that extend away from the nucleosome structure and are subject to different
modifications [77].

1.3.2: Modifications of the core histone proteins
Histone proteins have the potential to gain post translational covalent
modifications on their extended free amino acid tails. While on an individual level, these
modifications largely do not affect the structure of the nucleosomes themselves, higher
order chromatin structure containing many nucleosomes can be impacted by these
changes [78]. Modifications to the N-terminal tails of H2A, H2B, H3 and H4 were first
reported in the 1963 by Phillips et al. [79]. The variety of modifications that can occur to
the amino acid tails include methylation, acetylation, ubiquitylation, phosphorylation,
ribosylation and sumolyation and each modification has the ability to translate into
distinct biological outcomes [78]. The histone protein H3 is the most extensively
modified histone protein and has been studied to examine epigenetic post translational
histone modifications during normal cellular development as well as the progression and
maintenance of diseased states [80]. In this review, I highlight histone acetylation and
methylation of the core histone protein, H3.

1.3.3: Overview of histone acetylation and methylation
Histone acetylation and methylation was first described in 1964, when Allfrey et
al. suggested its potential role in the regulation of RNA synthesis [81]. Notably, these
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modifications have been extensively studied in regard to their contribution to closed and
permissive chromatin states ultimately impacting nucleosome positioning and orientation
of key regulatory sequences [82].
Histone acetylation is mediated by histone acetyltransferase (HAT) enzymes.
There are different HATs containing specific subunits that dictate the distinct acetylation
pattern it writes on the histone tail [83]. Human HATs can be grouped into five families,
comprising of approximately thirty different HATs and while the sequences in HAT
domains differ between families, they have high structural similarities within family
members [84]. These enzymes rely on accessory proteins along the chromatin for
localization to specific sites allowing the exchange for the acetyl group provided by
Acetyl-CoA to modify the lysine [77]. This results in a more permissive, open chromatin
state and allows the recruitment of proteins to these now accessible regions as the
nucleosomes typically act as a barrier for RNA polymerase during this process [26].
The HAT ability of CBP/p300, one of the five HAT family members, was
discovered in 1996 [85, 86]. These enzymes are the only HATs that are able to acetylate
all of the core histone proteins [86]. In terms of a functional example of this HAT,
CBP/p300 are recruited by the transcription factor DUX4 in myoblasts to globally mark
the underlying genome with the H3K27ac modification [87]. This transcription factor is
known to be involved in a form of muscular dystrophy; however, the mechanisms of
action remain poorly defined. In this study, Choi et al., highlights a new epigenetic
mechanism by which a HAT, recruited to the genome via a transcription factor, modifies
histones resulting in open chromatin surrounding genes relevant to muscular dystrophy.
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The dynamic exchange between HAT and histone deacetylase (HDAC) enzymes
results in changes between chromatin states as HDACs remove acetyl groups typically
resulting in a more closed chromatin arrangement [74]. In principle, the acetylation to the
lysine group serves two overall purposes: (1) it neutralizes some of the positive charge of
the histone protein and thus results in a weaker interaction of the DNA with the histone,
thereby resulting in a euchromatin state [81] and (2) it acts as a docking site for the
recruitment of other regulatory proteins that can come in and direct transcriptional
changes.
In contrast to histone acetylation, histone methylation results in condensed
chromatin. This modification to the histone tails can be acquired at the amino acids
arginine or lysine; however, the role of arginine in chromatin dynamics and
transcriptional regulation is not as well defined compared to those of lysine alterations
[88]. Lysine has the ability to gain either one, two or three methyl groups which are
mediated by the enzymes, histone methyltransferases (HMT), that recognize specific
lysine residues. HMTs that mediate the acquisition of methyl groups of lysine residues
are of two different broad classes, SET domain containing or non-SET domain
containing, each with different catalytic mechanisms [89].
Histone methylation does not change the charge of the histone and so it has the
ability to correlate with either transcriptional activation or transcriptional repression
depending on the location of the methylation [77]. These methylation patterns are also
dynamically regulated by demethylase enzymes and for the case of lysine demethylation,
these are referred to as lysine demethylases. The methyl groups replace the hydrogen
groups by exchanging with methyl groups provided by S-Adenosyl methionine to result
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in either mono, di or tri methylation [90]. Similar to that of acetylation, regulatory
proteins can recognize these methyl groups. Different chromodomains of HMTs prefer to
bind to specific methylated lysine residues and go on to perform their specific effector
function; this results in the outcome of either a more heterochromatin or euchromatin
state [91].
Foundational studies characterized the fundamental core histone proteins and
revealed their N-terminal tails are subject to different covalent post-translational histone
modifications. Later research identified factors writing and removing these modifications
from the tails, which was followed with advancements in our knowledge surrounding
regulatory proteins reading these modifications and carrying out the gene regulatory
programs influencing cellular phenotypes. The dynamic relationship within histone
acetylation and histone methylation programs allows for the switch between open and
closed chromatin states.

1.3.4: Histone acetylation and methylation in cancer
Cancer is a heterogeneous disease with underlying abnormalities in genomic and
epigenomic profiles [92]. Aberrant regulation of posttranslational histone modifications is
among these abnormalities, which has been shown to contribute to the cancer phenotype
by altering accessibility of key target genes [93]. In fact, histone modifications have
emerged as key regulators in this disease [94, 95]. This finding expanded on the prior
determination of DNA methylation in cancer that revealed the interaction of HDACs with
a chromatin-modifying factor that aids in methylating DNA within promoter regions of
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tumor suppressor genes [96, 97]. Furthermore, the association of DNA
methyltransferases (DNMTs) with HDACs was revealed [94, 95].
The dynamic mechanisms within histone acetylation and histone methylation
have since been discovered to regulate known oncogenes and tumor suppressors
ultimately influencing the progression and metastasis of cancers [98, 99]. These finding
have inspired the expansion of the histone code hypothesis to include the regulatory roles
of epigenetics in cancer transcriptional programs. Histone acetylation and methylation
patterns are controlled by the interchange of their enzyme activities, which ultimately
provide balance in a dynamic relationship between a euchromatin and heterochromatin
state. Since these processes impact active and inactive gene states, continuing to elucidate
these mechanisms in the development and maintenance in cancer cell models holds
relevant purpose in better understanding the mechanisms underlying the disease and has
also shown promise in therapeutic targets.
Histone acetylation landscapes that are altered in cancers can be attributed to the
recruitment of HDACs to tumor suppressor genes that are important for silencing
epigenetic programs. In contrast, increased HAT activity at oncogenes can contribute to
growth and proliferation of cancer cells. For example, abnormal HDAC regulation has
been identified in pancreatic cancer where HDAC1-3 and HDAC7 have been identified to
be overexpressed [100-103]. The cellular consequence of these alterations is dependent
on the specific enzyme involved. Notably, the aberrant expression of HDAC7 results in
the ability to distinguish between advanced pancreatic cancer from earlier neoplasms
[101] and HDAC1-3 enzymes have been shown to impact processes of p53, NFkB and
p65 programs, which have been correlated with cancer progression including pancreatic
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cancer [104, 105]. The HAT p300 has been shown to be influenced by the activity of
nuclear factor of activated T cells (NFAT) and glioma-associated oncogene family zinc
finger 3 (GLI3) in that these transcription factors recruit this active HAT and thereby
mechanistically results in loosening of the chromatin and allows for the transcription of
the c-MYC oncogene [106], a known regulator of many cancer phenotypes [107, 108].

1.4: Next generation sequencing methods for studying chromatin-based mechanisms
Early methods in determining DNA structure and the organization relied primarily
on microscopic and biochemical techniques. These techniques have led us to
groundbreaking findings that have since served as the foundation of normal and aberrant
cell phenotypes. Modern technologies have allowed us to study the epigenome and
transcriptome on a genome-wide scale. These technologies termed ‘Next Generation
Sequencing’ technologies have revolutionized the way we study genomic based
mechanisms and have notably provided great insight into cancer phenotypes. Here I
describe methodologies used to study the various layers of genomic regulation described
above including: (1) 3-dimensional chromosome architecture, (2) post translational
histone modifications and (3) gene expression.

1.4.1: Methods for studying 3D chromosome organization
Research investigating nuclear organization initially relied on microscopic
techniques. While on the fundamental level, light microscopy has allowed for the basic
observation of nuclear morphology, advancements in microscopic methods have allowed
for interrogation of nucleic acid sequences within the nucleus. Fluorescence in situ
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hybridization is a microscopic technique developed in the 1980’s that uses fluorescent
probes designed to bind to a complementary sequence along the genome. This technique
identified co-localization of distal genes during active transcription [109]. Fluorescence
in situ hybridization and its derivatives holds power when investigating single cells or
smaller cell populations. However, when inquiring about cell populations on a genomewide level, this and other microscopic techniques fall short.
While microscopy still holds importance and value in genomic and molecular
biology research, advancements in genome-wide methods have allowed for the
investigation of entire genomes within single or whole cell populations. Modern methods
for defining genome-wide landscapes of histone modifications uses Next Generation
Sequencing technologies to expand characterization past single loci. A groundbreaking
study in 2002 by Dekker et al. described the first chromosome conformation capture (3C)
based assay, which allows for the association of genome-wide contacts [110]. Some of
the derivatives of 3C technologies include 4C and 5C. While there are differences in the
number of targeted genomic regions, the fundamental principle of 3C is shared across the
other derivatives. In short, the chromatin is fixed using a fixative such as formaldehyde
which results in covalent linkage between DNA and protein interactions [111]. The
crosslinked chromatin is then digested typically using a 6 bp restriction endonuclease and
is followed by chromatin dilution and ligation, resulting in the ligation of intramolecular
fragments. The advancements of 3C into 4C (circularized chromosome conformation
capture) and 5C (chromosome conformation capture carbon copy) builds on the
limitations from the given predecessor. Whereas 3C interactions represent a ‘one vs. one’
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interaction, 4C allows for the detection of ‘one vs. all’ interactions and 5C expands to
‘many vs. many’.
The innovation of Next Generation Sequencing technologies permitted the
development of methods determining all genome-wide interactions for any given loci. In
2009, Lieberman et al. developed the first among these methods named Hi-C [47]. This
methodology does not require the identification of target loci and rather identifies all
chromosome interactions. The principles of Hi-C are shared with that of 3C and its
derivatives; however, modifications include filling the digested ends with a biotin and
generation of a Next Generation Sequencing library following ligation and isolation of
biotinylated fragments post dilution, ligation and linearization. Paired-end massive
parallel sequencing is then performed on the fragments to amplify and identify the
junctions. This method was modified in 2011 by Kalhor et al. with the aim of improving
the signal to noise ratio [112]. This method biotinylates the proteins after crosslinking
and solubilization of the chromatin. After enzyme digestion, the fragments are tethered to
magnetic streptavidin beads and selected through magnetization allowing for reduction of
inappropriate intermolecular interactions. The ends of the DNA are then filled in,
biotinylated, purified, exonuclease treated, sheared into smaller fragments and pulled
down by magnetic streptavidin beads. Lastly, the Next Generation Sequencing libraries
are prepared and sequenced as described for Hi-C. This technique is referred to as
Tethered Chromatin Conformation Capture. These technologies have advanced our
understanding of chromosome contacts due to the high resolution they provide at any
given interaction loci across the genome.
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1.4.2: Methods for post translational histone modifications
Next Generation Sequencing has also led to the development of novel methods for
identifying the genome-wide landscape of histone modifications. These technologies
have afforded an advantage for genome-wide analyses compared to prior methods that
limited investigations to specific loci. This method pairs the traditional chromatin
immunoprecipitation (ChIP) technique with massive parallel sequencing and is termed
ChIP-seq. ChIP allows for the investigation of protein-DNA interactions within the
nucleus [113, 114] and when paired with NGS, results in genome-wide binding sites of
the protein of interest [115]. To perform the ChIP, proteins are first crosslinked with
formaldehyde and the cells are lysed to release the DNA from the nuclei [116].
Sonication is then used to fragment the DNA into approximately 500 bp fragments,
which can then be used to isolate protein-DNA complexes. The complexes are
immunoprecipitated with an antibody against the protein target of interest and isolated
using protein A/G magnetic bead selection with a series of washes. The chromatin bound
to the protein is then eluted, the cross-links are reversed and the proteins are proteinase
digested. After the DNA is purified, enrichment can be detected using quantitative
polymerase chain reaction (qPCR) with primers designed against known target regions
for the protein of interest. For some studies this is the endpoint of the investigation;
however, when inquiring about whole genome targets either microarrays or highthroughput sequencing can be used. Microarrays utilize a hybridization technique that
allows for fluorescently labeled DNA fragments to hybridize to an array of genomic
targets, when paired with ChIP this is referred to as ChIP-on-chip. In contrast, Next
Generation Sequencing libraries can be built from the fragments and used in massive
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parallel sequencing by synthesis to yield high throughput results of the proteins’ targets
along the entire genome. The enrichment of these targets are determined when comparing
the ChIP-seq data for the protein of interest relative to an input control.

1.4.3: Evaluating gene expression
Many methods have been designed to quantify gene expression over the years.
Quantitative reverse transcriptase PCR (qRT-PCR) can be used to determine expression
of individual gene targets along the genome [117]. The development of two technologies,
the microarray and RNA-sequencing, have advanced our capability of studying gene
expression by allowing the investigation of thousands of genes. As mentioned above,
microarray is a hybridization technique that utilizes a fluorescent dye for later
quantification. The array is designed with fixed DNA probes against the RNAs of
interest. The prepared cDNAs from the given experiment are passed over the microarray
slide and any complementary sequences between the probes and cDNAs will have an
affinity for hybridization. The fluorescent dyes are ultimately used for optimal
measurements where relative amounts from each probe can be calculated, thereby
correlating with expression quantification [118]. Next Generation Sequencing, described
earlier, resulted in the development of RNA-sequencing. This technique was developed
to investigate the quantity and presence of RNA at a given time. This method utilizes
massive parallel sequencing to investigate the entire transcriptome.
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1.5: Dynamics of chromatin structure
Chromatin accessibility is a dynamic process mediated by external stimuli and
affects the capability of transcriptional regulators to bind their regulatory elements along
the genome. The switch between open and closed chromatin states is referred to as
chromatin-remodeling and is influenced by a variety of epigenetic mechanism. In
addition to DNA methylation [29], posttranslational histone modifications [30] and noncoding RNAs [31], environmental stimuli can also influence chromatin organization and
accessibility. For example, cigarette smoke has been shown to remodel chromatin by
altering histone acetylation patterns resulting in increased gene expression of proinflammatory genes [119] and has recently been implicated in lung cancer phenotypes
[120]. Moreover, chromatin-remodeling is a well-known facet underlying cancer
phenotypes [121] and because of the reversibility of chromatin-remodeling, efforts have
been made to target regulatory factors with the potential for therapeutic intervention.
Therefore, elucidating chromatin-remodeling mechanisms underlying disease phenotypes
is important for identifying agents capable of disease mitigation.

1.5.1: Chromatin-remodeling in response to hormone signaling
Nuclear receptors have been shown to mediate chromatin-remodeling by
recruiting regulatory proteins that alter downstream transcriptional programs [122]. These
nuclear receptors are transcription factors that are activated by their coordinated ligand
and contribute to epigenetic and gene expression changes in normal and disease
phenotypes.
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A clear example of this relationship is that of hormones and their corresponding
receptors. St. John et al. studied the hormone Vitamin D3 in the transition between
osteoblasts and osteocytes [123]. Through the integration of genome-wide histone
modifications and gene expression datasets in response to hormone-stimulation, they
identified temporal changes in chromatin-remodeling around osteocyte-relevant genes.
Since Vitamin D3 hormone is involved in bone remodeling, this provided mechanistic
context for this hormone in chromatin-remodeling during osteoblast differentiation.
Another study in mammary epithelium during different cellular states investigated
genome-wide H3K27me3 changes in response to two hormones, prolactin and progestin
[124]. Ultimately, they determined hormone-regulated histone methylation patterns to be
mediated by the chromatin remodeling complex EZH2 in mammary cell lineage
specification.
Aberrant nuclear hormone receptors are underlying phenotypes of several cancers
and furthermore can be used to further classify cancer subtypes of breast cancers [125].
Among these prevalent cancers is the estrogen receptor (ER) positive subtype [126].
Other receptors linked to breast cancer are the progesterone (PR), androgen, thyroid and
glucocorticoid receptors [127-129]. A study investigating chromatin-remodeling
signatures in ER/PR positive breast cancer in response to temporal stimulation revealed
structural transitions in topologically associated domains that coordinated with the
hormones estrogen and progestin [130]. Furthermore, changes in genome-wide histone
modification signatures were also observed that coordinated with hormone response and
suggested unique and concordant hormone chromatin reorganization. Furthermore,
changes in genome-wide compartments and histone modifications resulted in gene
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expression differences in response to either hormone. In another study, alterations in
long-range chromatin interactions and DNaseI hypersensitivity coordinated with changes
in gene expression in response to glucocorticoid steroid hormone pulsations in a murine
breast cancer model [131].
As nuclear receptors play a role in transcriptional processes and aberrant
expression of nuclear receptors has been associated with disease phenotypes, elucidating
mechanisms underlying their alterations in response to their given ligands is important.
While there are many nuclear receptors whose downstream mechanisms result in distinct
cellular phenotypes, among these are hormone nuclear receptors. Understanding the
dynamic mechanisms within chromatin remodeling in regard to genome-wide chromatin
architecture and histone modification alterations in cancer phenotypes will allow for
elucidation of chromatin-mediated etiology of cancer and may provide insight into
therapeutic targets. In Chapter 4 of this dissertation, I present high resolution chromatin
dynamics in response to temporal stimulation of an estrogen derivative in ER positive
breast cancer cell models.

1.5.2: Chromatin-remodeling in response to small molecules
Changes in chromatin structure are often mediated by enzymes that communicate
toward downstream transcriptional programs as discussed earlier. As research has
continuously supported epigenetic mechanisms governing chromatin-remodeling to be
reversible, there has been increased interest in modulating these processes in human
disease. To this end, small molecule inhibitors have emerged as promising for altering
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mechanisms involving chromatin-remodeling and a subset of the selective inhibitors have
advanced to clinical trials.
Some of the major overall classes of inhibitors that have been developed include:
histone acetyltransferase inhibitors and histone deacetylase modulators [132],
bromodomain inhibitors, DNA methyltransferase modulators and protein
methyltransferase inhibitors [133]. HDAC inhibitors have been widely developed for
cancer therapies [134]. Recently, an HDAC inhibitor was shown to increase expression of
a tumor antigen and resulted in a decrease in immune suppressive cell types in non-small
cell lung cancer cells [135].

1.6: Scope of Dissertation:
As discussed in the literature review portion of this chapter, aberrant chromatin
based processes including higher order chromatin organization and post translational
histone modifications are widely appreciated as contributing constituents to cancer
development and maintenance. Elucidating these processes is important not only for
gaining understanding regarding the molecular heterogeneity underlying this disease but
targeting these mechanisms has also shown therapeutic promise. Here, I describe our
work applying Next Generation Sequencing technologies to study functional genomics
within the 3-dimensional and epigenetic landscape of two prevalent cancers.
Chapter 2 of this thesis embodies integrative genomic analyses revealing
epigenetic plasticity in a pancreatic ductal adenocarcinoma cell-line model. The overall
goal of this chapter was to reveal chromatin-based mechanisms in pancreatic ductal
adenocarcinoma and to determine the effects of clinically relevant histone
26

acetyltransferase inhibitors on the cancer epigenome. This chapter builds on our study
identifying the impact of ICG-001 and C646 on gene expression in pancreatic ductal
adenocarcinoma and colorectal cancer cell-lines (highlighted in Appendix A). I define the
3-dimensional chromatin landscape of pancreatic ductal adenocarcinoma and
characterizes the distribution of post translational histone modifications within these
interacting regions and correlate these regions with gene regulatory programs. I then
determine the effects of histone acetyltransferase inhibitors on chromatin loops and gene
expression in the widely used pancreatic ductal adenocarcinoma cell-line, PANC1.
In Chapter 3, I characterize grade-specific broad H3K4me3 and H3K27ac regions
in pancreatic ductal adenocarcinoma cell-lines and furthermore determine the influence
of these histone acetyltransferase inhibitors on these broad epigenomic domains. Lastly, I
propose genome-wide mechanisms mediated by these inhibitors within these regulatory
regions.
In Chapter 4, I identified the dynamic reorganization of chromatin domains in
estrogen receptor positive breast cancer cell models. The overall goal of this chapter was
to elucidate chromatin-based mechanisms in response to temporal stimulation of the
estrogen derivative, 17-β estradiol, in an estrogen receptor positive breast cancer cell-line
and the tamoxifen resistant derivative of these cells. Furthermore, we aimed to establish
the role of estrogen receptor alpha in mediating these dynamics and further linked these
processes to gene expression.
This body of work focuses on the characterization of higher-order chromatin
organization and histone-modification mechanisms of two deadly cancers. Furthermore,
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we investigate the plasticity of these mechanisms in response to external stimuli to
determine the dynamics of these mechanisms in regard to transcriptional outcomes.
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CHAPTER 2

Three-dimensional analysis reveals altered chromatin interaction by enhancer
inhibitors harbors TCF7L2-regulated cancer gene signature

44

Abstract
Distal regulatory elements influence the activity of gene promoters through
chromatin looping. Chromosome conformation capture (3C) methods permit
identification of chromatin contacts across different regions of the genome. However, due
to limitations in the resolution of these methods, the detection of functional chromatin
interactions remains a challenge. In the current study, we employ an integrated approach
to define and characterize the functional chromatin contacts of human pancreatic cancer
cells. We applied Tethered Chromatin Capture (TCC) to define classes of chromatin
domains on a genome-wide scale. We identified three types of structural domains (TAD,
boundary and gap) and investigated the functional relationships of these domains with
respect to chromatin state and gene expression. We uncovered six distinct sub-domains
associated with epigenetic states. Interestingly, specific epigenetically active domains are
sensitive to treatment with histone acetyltransferase (HAT) inhibitors and decrease in
H3K27 acetylation levels. To examine whether the subdomains that change upon drug
treatment are functionally linked to transcription factor regulation, we compared TCF7L2
chromatin binding and gene regulation to HAT inhibition. We identified a subset of
coding RNA genes that together can stratify pancreatic cancer patients into distinct
survival groups. Overall, this study describes a process to evaluate the functional features
of chromosome architecture and reveals the impact of epigenetic inhibitors on
chromosome architecture and identifies genes that may provide insight into disease
outcome.
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Introduction
The compartmentalization of the eukaryotic genome into highly organized
chromatin domains is central to the regulation of gene expression and to cellular
homeostasis (Dekker & Mirny, 2016). Until recently, the genome and its structural
organization has largely been studied as a unidimensional entity where local chromatin
structure is regulated by epigenetic mechanisms such as post-translational histone
modifications, DNA methylation and chromatin-binding proteins. However, advances in
genome-wide chromatin conformation capture (3C) methods have enabled the study of
the three-dimensional (3D) organization of the genome. Studies employing various 3Cbased methods, including 4C, 5C, ChIA-PET and Hi-C, have been developed to map
long-range chromatin interactions, and have provided experimental evidence to explore
the principles of 3D genomic architecture (Ramani, Shendure, & Duan, 2016).
Collectively, these approaches support a model that interphase chromosomes occupy
distinct chromosome territories and provide insight into how chromosomes fold within
these territories (Duan et al., 2010; Heidari et al., 2014; Lieberman-Aiden et al., 2009;
Sexton et al., 2012). However, the mechanisms that underlie the partitioning of the
genome into these domains and their functional importance remains poorly defined.
Analysis of Hi-C data has revealed characteristic structural features of the
genome, including chromatin compartments, topologically associated domains (TADs),
and chromatin loops (Dixon et al., 2012; Lieberman-Aiden et al., 2009; Rao et al., 2014;
van Steensel & Dekker, 2010). These distinctive higher order chromatin structures are
believed to frame long-range enhancer-promoter interactions for epigenetic gene
regulation (de Laat & Duboule, 2013; Dekker, Marti-Renom, & Mirny, 2013; G. Li et al.,
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2012; Sanyal, Lajoie, Jain, & Dekker, 2012). However, large-scale structural studies
generally provide little mechanistic detail regarding the functional relationships between
higher order chromatin structure and cell-specific gene regulation. Recent computational
and statistical approaches demonstrate that Hi-C data can be used to identify interacting
genomic loci at a resolution of 8-20 kb (Ay, Bailey, & Noble, 2014; Jin et al., 2013; Lan
et al., 2012), providing sufficient resolution to integrate higher order chromatin
organization and gene expression data.
In cancer, altered regulation of epigenetic networks plays a central role in
tumorigenesis and metastasis. While DNA methylation and histone modification patterns
are frequently associated with both solid and hematological malignancies, it remains to
be determined if 3D chromatin states are characteristic to specific cancer types and their
gene expression programs (de Laat & Duboule, 2013; Dowen et al., 2014; Gondor &
Ohlsson, 2009). The reversibility of histone modifications makes them an attractive target
for cancer therapy and thus defining the epigenetic landscape of specific cancer types
may provide important insight into the development of new therapeutic targets. Small
molecule inhibitors that target histone modifying enzymes to disrupt the cancer cell
epigenome are being developed for the treatment of cancer (Perri et al., 2017). In
particular, histone acetyltransferases (HATs) are emerging targets in drug discovery with
potential applications in cancer and other disease models (Wapenaar & Dekker, 2016).
HATs catalyze the acetylation of lysine residues on histones during the epigenetic
regulation of gene transcription (Grunstein, 1997). In addition to histones, HATs mediate
the lysine acetylation of transcription factors, which is important for their function
(Farnham, 2009; Singh et al., 2010; Vaquerizas et al., 2009). However, currently the role
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that HATs, histone acetylation and HDACs play in regulating higher order chromatin
structure remains unknown.
In this study, we investigate the relationship of higher order chromatin structure,
histone modification and gene expression using the human pancreatic cancer cell line
PANC1. We conducted Tethered Chromatin Capture (TCC), a modified Hi-C protocol
(Kalhor et al., 2011), to identify and characterize chromosome interactions and domains
in PANC1 cells. We integrated the interacting regions with chromatin state information
(histone modifications, DNase hypersensitivity, and RNA Polymerase II binding) to
uncover distinct types of subdomains associated with specific epigenetic states. We then
determined the impact of two epigenetic inhibitors that target the histone
acetyltransferases CBP (ICG-001) and EP300 (C646) on chromatin architecture (Bowers
et al., 2010; Eguchi, Nguyen, Lee, & Kahn, 2005). Finally, we incorporated chromatin
binding and gene expression data for the transcription factor TCF7L2 to examine the
association of chromosome architecture and TF-mediated gene regulation. Overall, our
analysis highlights (1) a process for evaluating chromosome architecture and epigenetic
states (2) the impact of two histone acetyltransferase inhibitors on chromosome
architecture and (3) chromatin architecture associated with TCF7L2-mediated gene
regulation.
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Results
Identification of chromosomal interacting regions in PANC1
We conducted our studies of higher order chromatin structure in the human
pancreatic ductal adenocarcinoma (PDAC) cell-line PANC1, which is a model used for a
variety of mechanistic and functional studies of pancreatic cancer. We identified the
interacting regions of chromatin via tethered conformation capture (TCC) using 2
biological replicates (Kalhor et al., 2011). The TCC protocol decreases random
intermolecular ligations between DNA fragments, particularly from interchromosomal
interactions. We assessed the TCC data quality by comparison to available Encyclopedia
of DNA Elements (ENCODE) HiC datasets for PANC1. Figure 2.1-A compares the
genome-wide and chromosome 17 contacts for the TCC and HiC datasets binned at 1 Mb
resolution, respectively, where the heatmap color indicates the contact frequency. Both
interaction maps exhibit comparable patterns of the regional enrichment of long-range
interactions. However, the TCC dataset has a notable depletion of interchromosomal
interactions compared to the HiC dataset with a similar percentage of cis interactions
greater than 20 kb (cis and trans interactions, respectively; Fig. 2.1-B). Pairwise
comparison of TCC and Hi-C interaction matrices binned at 1 Mb have Pearson
correlation coefficients greater than 0.9 (Fig. 2.1-C). The correlation of the TCC
replicates for each chromosome binned at different resolutions (200 kb, 500 kb and 1
Mb) also correlate well, except for chromosome 9. Poor correlation for chromosome 9
has been found in other cell types (Rao et al., 2014). Further, the PANC1 TCC and HiC
datasets have a comparable number of corresponding topological associated domains
(TADs) and TAD boundaries (Appendix B-1). Overall, these results indicate a high
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degree of similarity between the TCC and HiC datasets. Thus, TCC replicates were
combined for downstream analyses of PANC1 chromatin structure.
Using the merged TCC replicates, we defined a total of 1,371 TADs, 709
boundary and 71 gap domains. Boundaries are interaction-sparse regions that lack interdomain chromosomal interactions with neighboring TAD regions, whereas gaps are
regions that lack interactions and are located between two identified domains. Gaps
occurred in gene deserts or centromeres and few boundaries or gaps were found between
two adjacent TADs. This is consistent with other studies showing that the genome is
partitioned into Mb-sized local chromatin interaction domains (Dekker et al., 2013;
Dixon et al., 2012; Rao et al., 2014). 60% of genes are contained within TADs whereas
boundaries and gaps contain 38% and 2% of genes, respectively.

Classification of epigenetic marks
We next characterized the epigenetic states associated with the different types of
PANC1 structural domains (TADs, boundaries, and gaps). We applied a Hidden Markov
Model (HMM) to segment the genome based on combinatorial epigenetic states using
histone ChIP-seq data (Bonneville & Jin, 2013). A12-state HMM with a 1 kb bin size and
an optimized emission probability matrix using the best Bayesian Information Criterion
(BIC) scores was used (Fig. 2.2-A). The resulting 12 epigenetic states are referred to as
S1-S12, and can be categorized by regulatory potential by the emission probability
values. In particular, values greater than 0.1 are considered valid marks for that state and
values larger than 0.5 represent dominant marks. S1 and S7 are one-mark states enriched
with the repressive mark H3K27me3, whereas S9 is a two-mark state having both
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H3K27me3 and H3K9me3. Both S2 and S11 represent regions that are depleted of any
epigenetic marks (emission probabilities less than 0.015), thus are termed depleted states.
We determined the proximity of the epigenetic states by evaluating their transition
probabilities (Fig. 2.2-B). Three states (S1, S7, and S9) also have relatively high
transition probabilities to each other, indicating a strong neighborhood of interspersed
H3K36me3 and H3K9me3 repressive marks. The S6 state is a one-mark state enriched
only with the repressive H3K9me3 and the S8 state enriched with both H3K36me3 and
POLR2A. S3 and S4 are enriched with H3K27ac/H3K9ac/H3K4me1 and
DNase/POLR2A. S10 is an intermediate active state, with a pattern similar to S3 and S4,
but only enriched with H3K4me1. S5 and S12 are two mixture states showing enrichment
of both active and repressed marks, as well as high POLR2A.
We categorized genomic regions into 8 different categories and determined the
distribution of epigenetic states within each region (Fig. 2.2-C). Non-promoter regions,
including 5’ and 3’ distal and gene body (intragenic) categories are enriched in repressive
states (S1, S7 and S9). Active states are enriched in 5’ TSS and 3’ Proximal regions
(states S4 and S5). Figure 2.2-D shows a region that contains a gap, boundary and TAD,
with the corresponding epigenetic state. The bulk of gaps are S2 domains and are
depleted of any epigenetic mark (Fig. 2.2-E). Interestingly, there are subgroups of
boundaries and TADs that have varied patterns of histone modifications. We therefore
further divided these into different categories; S1/S7 dominant (repressive marks),
S4/S5/S10 dominant (active marks, near a TSS), or a mixture (mixed percentage of active
and repressive states). This characterization indicates distinct epigenetic states are
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physically connected and certain domains contain interspersed repressive epigenetic
patterns (Appendix B-2).
Based on the association of epigenetic states, we classified adjacent or intradomain states by defining subdomains. These combinations of states resulted in six
subdomains referred to as SD1 to SD6 (Fig. 2.2-F). The subdomains are on average 60
kb. SD1 is a depleted subdomain (comprised of S2 and S11) and lacks marks, SD2 and
SD3 are repressed subdomains (S6/S7 and S1/S7/S9, respectively) and SD4 is a gene
body subdomain (S5/S8/S12). SD5 is an active enhancer subdomain (S4/S5/S10/S11 or
only S10/S11), and SD6 is an active promoter subdomain (S3/S4/S5 states), which are
centered by a promoter (S4) and extend up/downstream of the 5’ TSS (S3).

Correlation of sub-domains and interacting peaks
To explore the relationships between chromosomal loops epigenetic states and
domains, the loci of interacting chromatin regions were determined at a 10 kb resolution
in 40 kb overlapping windows (interaction peaks (IPs). We identified 30,297 significant
IPs (FDR <0.1 with a peak pair distance >20 kb). 90% of IPs are intra-domain
interactions, whereby the two different loci are located within the same domain. Nearly
80% of the IPs are within a TAD, 19% of the IPs are in a boundary, and very few IPs are
in gap regions. Since cancer cell-lines typically harbor chromosomal abnormalities,
including chromosomal amplification, we investigated whether amplified regions
contribute to the set of IPs. Only 0.72% of the IPs for PANC1 are in amplified regions of
PANC1 cells, confirming that amplified regions are not enriched in the set of identified
long-range interactions (Lan, Farnham, & Jin, 2012). Since the small number of IPs in the
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amplified regions of PANC1 cells may play important roles in gene regulation, we
included them in downstream analyses, which has been done previously (Fullwood et al.,
2009).
The heatmap in Figure 2.3-A demonstrates that the specific subdomains of
interacting loci tend to be the same on either end. For instance, an IP having SD4 at one
end usually has a matched SD4 at the other end. This result is consistent with the
hypothesis that the two ends of an IP are indeed physically close to or interacting with
each other and thus have similar epigenetic states. We also found that many IPs have at
least one locus in a depleted or repressed subdomain (SD1, SD2, or SD3) (summarized in
Fig. 2.3-A, right panel).
We annotated the IPs according to gene regions and defined six promotercentered and one non-promoter interaction groups (Fig. 2.3-B); Promoter (P; -5 to +1 kb
of a TSS), Distal (D; 100 kb upstream or downstream of a TSS), and Far (F) regions
(greater than 100 kb from a TSS). We defined promoters that interact with each other.
Because the distance between two loci was calculated using the center of each locus (as
opposed to the boundary), in certain cases, the two loci of one IP could actually overlap
with each other. If this occurs, then it is possible that the same promoter is identified by
both loci; these are designated PP1. There are also promoter-promoter (PP) IPs, where
different promoters are at each loci (PP2). If one end of an IP is in the promoter region of
one gene and the other end in the distal region of the same gene, this IP is categorized as
PD1. PD2 is an IP that has one end in promoter region of Gene1 and the other end in
distal region of Gene2. Similarly, if one end is in the promoter region of one gene and the
other end in the far region of the same gene, this IP is categorized as PF1. PF2 is an IP
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that has one end in the promoter region of Gene1 and the other end in far region of
Gene2. If neither end is in the promoter region of any gene, that IP is classified as nonpromoter-related and given the designation O-O (total number is 19,035).
In total, we obtained 11,262 IPs associated with at least one promoter, and thus
referred them as P-centered IPs or looping. We found that approximately 26% of looping
events represent promoter-promoter interactions with 951 PP1 and 2,059 PP2
(interactions between the promoters of different genes), respectively. Further, 24%
promoter IPs (2,724) occur with distal regions of the same gene (PD1; 2,898 genes),
whereas 27% of IPs (3,045) are between the promoter and distal regions of different
genes (PD2). The expression level of genes in PANC1 cells linked to each IP categories
was determined (Fig. 2.3-C) (Gaddis et al., 2015). Interestingly, promoter-centered loops
either contain genes that are in the repressed states (low expression and in SD1-3) or
genes that are in the active states (higher expression and in SD4-6). Genes in IPs
corresponding to SD5 and SD6 are more highly expressed as compared to any other types
of subdomains. Overall, these results indicate that connecting epigenetic states to
topological structure can identify epigenetic subdomains that have distinct patterns of
gene expression.

HAT inhibitors affect chromosomal organization in PANC1 cells
We previously reported the impact of the histone acetyltransferase (HAT)
inhibitors ICG-001 and C646 on global gene expression in PANC1 cells (Gaddis et al.,
2015). To examine whether PANC1 sub-domains are functionally linked to changes in
gene expression, we treated cells with ICG-001 and C646 for 24 hours and performed
32

TCC on control and treated cells. The total number of TADs within each chromosome is
equivalent between drug-treated and control-treated PANC1 cells (Appendix B-3). While
a large proportion of the TADs, boundaries and gaps do not change with treatment (50%,
40%, and 80%), we identified some of the chromatin domains to be sensitive to HAT
inhibitor treatment. We therefore classified the domain changes (Fig. 2.4-A). The most
frequent type of change occurred within TADs, whereby treatment increases the TAD
length by a maximum of 300 kb (Fig. 2.4-B; conserved-expand category, yellow bar). In
contrast, a TAD in treated cells that overlaps with a TAD in untreated cells but the
position shifts by more than 300 kb occurs much less frequently (Fig. 2.4-B; the shift
category, blue bar). The boundaries were most sensitive to treatment and were more
prone to change than either gap or TADs (Fig. 2.4-B, purple bar). Pearson correlation
showed that domain type changes are associated with boundaries and represent the active
subdomains (SD4-6; Appendix B-4). This suggests that changes of a domain type,
especially the transition of boundary to TADs are linked to epigenetically active regions.
To examine how the HAT inhibition impacts histone acetylation within chromatin
domains, we conducted ChIP-seq for H3K27ac in ICG001- and C646-treated PANC1
cells. We calculated the log2 Fold Change (log2FC) of normalized and averaged
H3K27ac read signals in 100 bp bins in drug-treated versus untreated PANC1 cells for
each domain and sub-domain. We observed a minor decrease of H3K27ac at altered
categorical domains (Shift/Split/Type-Change) and a slight increase of H3K27ac in the
No Change category (Fig. 2.4-C, left panel). While we did not observe major alterations
in these domain categories, there were significant differences in the sub-domains.
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Specifically, all of the active subdomains (SD4-6) showed loss of H3K27ac signal
in the treated cells (Fig. 2.4-C, right panel). H3K27ac is enriched at promoter and at
distal regions. We found that the loss of H3K27ac is more profound at the promoter
active subdomain SD6 than at the enhancer active subdomain SD5, suggesting that these
inhibitors may affect HAT activity at promoters more than at enhancers. To assess how
IPs are altered in drug-treated cells, we performed an Interaction Peak (IP) analysis
(described above) and identified 10,787 IPs in ICG001-treated and 13,773 IPs in C646treated PANC1 cells. This represents an approximate 50% reduction in total IPs in treated
PANC1 cells compared to the untreated control. Additionally, we identified that only
approximately 50% of IPs in drug-treated cells were concordant with the control. Thus,
treatment with ICG001 and C646 results in a decline in total IPs and also generation of
new IPs (Fig. 2.4-D).
We previously identified 2,029 differentially expressed genes (DEGs) in ICG001treated and 1,740 DEGs in C646-treated cells compared to control cells treated with
DMSO (using a log2FC cutoff of 0.5 and a detection p-value < 0.05), with an overlap of
754 DEGs common to both drugs (Gaddis et al., 2015). We integrated expression data
with domains and found that approximately 70% of the genes that respond to drug
treatment are located in conserved domains. Strikingly, the subdomains SD5 and SD6
contain a large number of DEGs, regardless of the type of domain or domain change they
are associated with (Fig. 2.4-E). After further associating DEGs with regions of
differential H3K27ac enrichment and with looping events, we derived a list of 784 genes
for ICG001-treated cells and 380 genes for C646-treated cells, for a combined total of
992 DEGs that have altered chromatin domains.
34

TCF7L2-regulated genes are involved in altered chromatin interactions
ICG001 and C646 inhibit the activity of CBP and P300 HATs and likely alter key
signaling pathways. ICG001 was developed to be a specific inhibitor of the Wnt signaling
pathway, which is important for developmental and disease processes (Eguchi et al.,
2005; Emami et al., 2004). A key transcription factor involved in this pathway is
TCF7L2, which recruits CBP/P300 to its target gene regulatory elements. Our previous
study assessed the impact of TCF7L2 and HAT inhibitors in PANC1 cells; however, the
relationship between these processes and chromatin interactions and their epigenetic
states remains unknown. TCF7L2 has been linked to a variety of human diseases such as
type II diabetes and cancer (Blahnik et al., 2010; Cauchi & Froguel, 2008). In a previous
study exploring cell type-specific binding patterns of TCF7L2, we showed that the
majority of TCF7L2 sites co-localize with H3K4me1 and H3K27ac (Frietze et al., 2012).
Given the relationship between TCF7L2 and H3K27ac marked distal regulatory
elements, we hypothesized that drug treatment would affect TCF7L2-associated
chromatin loops in PANC1 cells. We therefore identified promoter-distal (PD) IPs that
were bound by TCF7L2 in PANC1 cells that are no longer classified as IPs in the drugtreated cells. We isolated the genes associated with these IPs and compared them to genes
differentially expressed upon drug treatment or upon TCF7L2 knockdown in PANC1
cells, which we identified in a previous study (Fig. 2.5-A) (Gaddis et al., 2015). We
found that the highest fraction of these IPs were those containing interactions between
promoter and distal regions of different genes (PD2-D). We derived a list of 39 genes that
are differentially expressed in drug-treated PANC1 cells and are also regulated by
TCF7L2. Pathway analysis using Gene Set Enrichment Analysis (GSEA) (Fig. 2.5-B)
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(Subramanian et al., 2005) reveals enrichment in several cancer-related pathways,
including Wnt signaling. We used SurvExpress (Aguirre-Gamboa et al., 2013) to
determine if these genes can stratify survival risk of pancreatic cancer patients and found
that this geneset predicts a significant survival correlation (Fig. 2.5-C, left panel, p-value
2.5e-07), with high-risk patients displaying a probability of an overall worse survival rate
(Aguirre-Gamboa et al., 2013). Specifically, 25 of the candidate genes showed
differential gene expression between the high- versus low-risk patient groups (Fig. 2.5-C,
right panel). Thus, our results demonstrate that the HAT inhibitors not only alter
chromatin interactions but also distinguish TCF7L2-regulated genes for potentially useful
clinical signatures.

Discussion
Despite advances in 3C-based chromatin interaction mapping (Dekker, Rippe,
Dekker, & Kleckner, 2002; Libbrecht et al., 2015), there is a lack of understanding of
how nuclear architecture affects gene expression and cellular function. In particular, our
knowledge of how the 3D chromatin architecture of cancer cells contributes to cancer
cell-specific gene expression programs is limited. Due to the limitation of sequencing
depth and the use of 6-mer cut sites of restriction enzymes, most studies of 3D chromatin
architecture thus far have focused on characterizing very large 0.7-2Mb TADs. Although
such studies provide important insights into chromosomal architecture (Deng et al., 2014;
Lan, Farnham, et al., 2012), studies of large domains do not address the challenge of
associating chromosomal interactions with transcriptional control at the individual gene
level. Recent advances in both the experimental and computational aspects of
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chromosomal interaction analyses now enable the exploration of the 3D chromatin
architecture of the human genome at a much higher resolution than previously possible,
allowing for the construction of a detailed genome-wide interaction map (Ay et al., 2014;
Jin et al., 2013; Lan, Farnham, et al., 2012). A recent study used an in situ Hi-C protocol
to achieve 1-5 kb resolution of interacting genomic segments and linked chromatin loops
with promoters, enhancers, and CTCF sites (Rao et al., 2014); however, it did not address
the relationship between gene loops and gene regulation.
In this study, we demonstrated that the method of TCC can partition the PANC1
genome into three types of structural domains termed gap, boundary and TAD. Our
results are similar to previous studies of other cell types that used different experimental
chromatin interaction methods (Dixon et al., 2012; Nora et al., 2012). Interestingly, we
observed that both TAD and boundary domains (which are 1-5 Mb in length) were
embedded with approximately 170,000 intra-domain chromatin interactions or interaction
peaks. We found that these domains could be further categorized into six types of subdomains, each with distinct epigenetic characteristics. We note that similar types of subcompartments were defined in a previous study (Rao et al., 2014). However, there are
notable differences between the method we present here and that of which was described
in the previous study. The previous method divided each of two compartments with
histone marks based on underlying interaction intensity and patterns. In contrast, we first
used an unbiased training process in which we trained epigenetic states on the whole
genome. We then associated the states with gene structure, expression, and other features
resulting in the derivation of the six sub-domains. Using this approach, we found that
promoter-centered looping genes within the three active subdomains (SD4-6) showed
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much higher expression than those in the two repressed subdomains (SD2-3) (Fig. 2.3C), suggesting these newly defined subdomains have functional distinctions.
We further examined the relationship of histone acetylation in chromatin
architecture. Although two histone acetyltransferase inhibitors, ICG001 and C646, have
been previously shown to alter gene expression in cancer cells (Emami et al., 2004;
Gaddis et al., 2015; Oike et al., 2014), their impact on the 3D genome and epigenome
structure has not been studied. Therefore, we conducted TCC and ChIP-seq of H3K27ac
in ICG001- and C646-treated PANC1 cells. Interestingly, we uncovered five major types
of domain changes that occur upon treatment of PANC1 cells with ICG001 or C646 (Fig.
2.4-A). In regards to Type-Change domains, we found that TADs are largely conserved
and stable with drug treatment whereas boundary domains tend to switch to TADs. We
also found that the drugs altered chromatin structures associated with positive regulatory
elements. The H3K27ac enrichment is reduced predominantly within the active enhancer
subdomains (SD6; Fig. 2.4-C) and the most significant gene expression changes occurred
in the active-promoter subdomains (SD6; Fig. 2.4-E). We were able to link loops that are
lost upon drug treatment with a list of 39 coding genes regulated by TCF7L2, a
transcription factor important for developmental processes and implicated in human
disease. This subset of genes is associated with cancer-related pathways and could
separate pancreatic cancer patients into distinct survival groups.
In summary, we have developed a computational analytical approach for analysis
of HiC/TCC data that can identify domains and subdomains and can classify chromatin
looping events. Through the use of epigenetic inhibitors, our work also provides insights
into the interdependence of 3D chromatin looping and transcriptional control. We
38

recognize that our current studies cannot determine if the enhancers that are affected by
the epigenetic drugs are the same enhancers as identified by the chromosomal looping
method. Future work using CRISPR/Cas9 to delete the TCF7L2-associated enhancers
within the identified promoter-enhancer loops is needed to fully elucidate the mechanistic
involvement of enhancer-mediated looping events in the regulation of drug-responsive
genes. Nevertheless, our work provides genome-wide evidence that a strong association
exists between a subset of enhancer-associated loops and enhancer-regulated genes.

Methods
Tethered Chromatin Capture (TCC)
TCC was performed as described (Kalhor et al., 2011). Briefly, approximately
5x107 PANC1 cells were crosslinked with 1% formaldehyde for 10 minutes at room
temperature, crosslinking was quenched with 0.125M glycine for 5 minutes at room
temperature and cell pellets were collected and stored at -80C. Nuclei were digested
with 2000U HindIII prior to dilute solid-surface ligation reactions and TCC library
preparation as described (Kalhor et al., 2011). For drug treatments, PANC1 cells were
grown to 60% confluency before a 48-hour treatment with 10 μM ICG-001 (Tocris), 10
μM C646 (Sigma-Aldrich) or DMSO and fixed and harvested as described above.

Frequency contact matrix of TCC data
Paired raw reads of TCC data for the PANC1 cell line were aligned to the human
reference genome (hg19) by BWA (H. Li & Durbin, 2009) with default parameters.
Reads were trimmed by 5 bp until 25 bp and aligned iteratively. Multiple aligned reads
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and reads with a MAPQ less than 30 were removed. After performing fragment filtering
(such as removing self-circles, error-pairs, and PCR duplicate reads), the reads were
binned into either 500 kb or 1 Mb size bins, where the sum of interaction pairs within the
bins was used for all bin-bin interactions. The construction of a frequency contact matrix
was done as described previously (Bau et al., 2011; Wang et al., 2013). Briefly, binned
data was first subjected to normalization and transformation into Z-scores, the
distribution of chromosomal interaction frequencies of both cell lines was then examined
using a 500 kb or 1 Mb resolution for intra-chromosomal and a 1 Mb resolution for
whole-genome contact matrices. More specifically, for every 500 kb or 1 Mb bin of
chromosome regions, the number of interactions (i.e., Z-scores not equal to zero) between
each chromosome region and the rest of the chromosome regions was counted. The
chromosomal interaction frequency of the region was then calculated as the counted
number of interactions in the region divided by the total number of chromosome regions
(e.g. with a 1 Mb resolution there are 3,029 chromosome regions in the human genome,
and with a 500 kb resolution there are 498 chromosome regions in chr1). Z-scores of
intra- or inter-chromosomal interaction matrices were then constructed as either a
genome-wide contact heat map or a chromosome-specific intra-chromosomal contact
heat map.

Topological domains of TCC data
A raw interaction contact matrix of each chromosome at 100 kb resolution was
normalized using Hi-Corrector (W. Li, Gong, Li, Alber, & Zhou, 2015), which
implements a set of scalable algorithms adapted from the original IC algorithm (Imakaev
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et al., 2012) for parallel computing. Domains were detected using TopDom (Shin et al.,
2016) based on the local minima of normalized contact matrix. For two consecutive local
minima, if any bin does not show a significant difference between the contact frequencies
of within interactions and between interactions, they are defined as being within a
topological domain (TAD); otherwise, they are either a boundary or a gap. The boundary
and gap regions represent TAD-free chromatin at the given sequencing resolution and
current parameter settings. We note that a boundary does not refer to the left or right side
of a TAD, but is a specific region that has low interactions within itself and also between
neighboring regions. Thus, based on this definition, there is not always a boundary
between two TADs. A Gap is a region depleted of interactions.

HMM epigenetic states and subdomains
Histone modification marks (H3K27ac, H3K4me1, H3K4me3, H3K36me3,
H3K27me3, H3K9me3), RNA Polymerase II, DNase-seq and TCF7L2 datasets in
PANC1 cell lines were obtained from the ENCODE Project (Consortium, 2012; Frietze
et al., 2012).
The data was trained by a univariate first-order Hidden Markov Model (HMM)
(Heinz et al., 2010) to identify combinatorial epigenetic states. For each bin on the
genome, the reads of each epigenetic mark were evaluated to determine if that mark is
enriched in that bin (1) or not (0). We then used this binarized information of all
epigenetic marks to train the HMM model for the default 300 iterations. For each
combination of bin size (1 kb) and number of states (8, 10, 12, and 20), 5 trainings of the
HMM model were performed and the best model was selected based on the Bayesian
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information criterion (BIC). The outputs of emission and transition matrices or states
were visualized using the commercial MATLAB program. Consecutive bins of the same
HMM states were merged into a single region, given that the bins were within the same
domain defined by TopDom.
The emission probability of the HMM represents the distribution of the epigenetic
marks in that particular bin, whereas the transition probability represents the possibility
that a certain state should be assigned to a specific bin given the known state of the
previous bin. If in a given state there were marks with an emission probability greater
than 0.5, only these marks are considered as dominant marks for that state. For states
without dominant marks, we used an emission probability cutoff of 0.1 for a mark to be
considered as valid to identify a corresponding state.
The transition matrix indicates which states are frequently neighbors. In addition,
states that have very low values in the emission matrix, such as S2 and S11 in Figure
2.2-A, may represent epigenetic mark-depleted states. Therefore, based on the transition
and emission matrix, as well as the other genomic features, certain epigenetic states were
merged together to a single region and biologically defined as a subdomain. These
subdomains reflect the epigenetic modification context over a chromatin structural
domain.

TCC data modeling using HOMER
We use HOMER (Heinz et al., 2010) to find significant interactions or interaction
peaks (IPs) in our TCC data. HOMER can search for pairs of loci that have a greater
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number of reads in interaction data than would be expected by chance using a
background model. HOMER defines the expected number of reads as
𝒇(𝒊 − 𝒋)(𝒏∗𝒊 )(𝒏∗𝒋 )
𝒆𝒊𝒋 =
𝑵∗
where f is the expected frequency of reads, N* is estimated total number of reads, and n*
is the estimated total number of interaction reads at each region. HOMER uses the actual
number of interaction reads at each region as the initial value and then iteratively
calculates the expected number of reads using the above model until the error between
expected and observed reads totals per region is near zero. We examined genomic regions
at 40 kb resolution to find significant interactions, using a minimum distance of 10 kb to
consider an interaction between regions. The peaks were then further filtered using an
FDR cutoff of 0.1 and distance cutoff of 20 kb between loci centers.
In addition to the genomic location of the two interacting regions, HOMER also
outputs a binomial p-value and FDR based on Benjamini correction. We further filtered
the peaks using FDR<=0.1 and loci distance greater than 20 kb to isolate a more stringent
set of IPs.

Associating chromatin interactions with epigenetic subdomains
For each IP, the subdomain overlaps (1 bp) with the two loci of the peaks were
extracted. The average sizes of interaction peaks are longer than that of subdomains, so
one peak locus may cover multiple subdomains. Changes in histone modifications in
treated PANC1 cells were calculated by first extracting and averaging reads in the
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subdomains in 100 bp bin, then dividing the averaged reads in drug-treated PANC1 cells
by control PANC1 cells.

Associating chromatin interactions with annotated genes
For all annotated human RefSeq genes, we defined 5 genomic regions (Fig. 2.3B) relevant to transcription start sites (TSS), which are Promoter (-5 kb to +1 kb), Distal
(±100 kb), and Far (beyond 100 kb). Then, we defined the following seven categories of
IPs: 1) PP1—any IPs with both ends within the same Promoter; 2) PP2-- any IPs having
two ends located in two different Promoters; 3) PD1-- any IPs between a Promoter and a
Distal region, with the closest TSS to the Distal region being the same gene as for the
Promoter end; 4) PD2-- any IPs between a Promoter and a Distal region, with the closest
TSS to the Distal region NOT being the same gene as for the Promoter end; 5). PF1-- any
IPs between a Promoter and a Far region, with the closest TSS to the Far region being the
same gene as for the Promoter end; 6) PF2-- any IPs between a Promoter and a Far
region, with the closest TSS to the Far region NOT being the same gene as for the
Promoter end; and 7) Other-- any IPs that do not involve a Promoter.

Integrating gene expression datasets
All of our expression datasets were obtained from our previous study (Gaddis et
al., 2015). Further details for each component of our analysis are described. For assessing
the differential expression analysis for IP alterations within untreated and HAT-inhibitor
treated PANC1 cells, total RNA was collected for untreated PANC1 cells and cells
treated with either epigenetic inhibitor for 96 hours. Total RNA was collected using
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Trizol (Life Technologies). Ultimately, these RNAs were labeled, hybridized and
analyzed with Illumina HT-12 v4 Expression BeadChips (catalog#: BD-103-0204) with
the Direct Hybridization Assay and then scanned on an Illumina HiScan (catalog#: BD103-0604). We analyzed the data as described. For this analysis we used a log2FC cutoff
of 0.5 and p-value <0.05 for further analyses.
To incorporate TCF7L2 regulation we utilized our knockdown RNA-seq data.
Total RNA after knockdown with 40nM siRNA targeting TCF7L2 or an siControl. We
then performed RNA-sequencing on the polyA+ RNA selected True-Seq libraries using
the Illumina HiSeq2000 platform and differential expression was determined as described
(Gaddis et al., 2015). For this analysis we used a log2FC cutoff of 0.5 and p-value <0.05
for further analyses. Lastly, for determining the expression levels of PANC1 genes within
promoter-centeric IPs we used our control dataset from the RNAseq experiment.
Ontology analyses were performed using GSEA (Subramanian et al., 2005) with
default settings and survival analysis was done using SurvExpress (Aguirre-Gamboa et
al., 2013).
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Figures
Figure 2.1: Characteristics of interacting chromatin regions in PANC1 cells
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Figure 2.1: Characteristics of interacting chromatin regions in PANC1 cells. A,
Genome-wide and chromosome 17 interaction matrices for PANC1 HiC (top) and TCC
(bottom) datasets. The color intensity represents the normalized number of contacts
between a pair of loci and the chromosome numbers are indicated on the outside of the
matrix. B, The observed proportions of intra- and interchromosomal interactions in the
valid HiC pairs using HiC or TCC (cis and trans, respectively). C, Histogram displaying
the size distribution of TADs within each individual chromosome. TCC, tethered
chromatin capture; TADs, topological associated domains
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Figure 2.2. Classification of PANC1 domains with epigenetic marks
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Figure 2.2. Classification of PANC1 domains with epigenetic marks. A, Emission
probabilities of 12 epigenetic states trained by an HMM model on seven histone
modifications, DNase and POLR2A. Marks containing emission probability values
greater than 0.1 for a given state are considered to be valid and values greater than 0.5 are
considered valid marks for that state and values larger than 0.5 represent dominant marks.
B, Transition probabilities of the 12 epigenetic states mentioned in (A) with a high
transition indicating a higher probability that a state is assigned to a given bin due to the
state of the previous bin. C, Genome‐wide location analysis of the 12 epigenetic states
defined in (A). D, Illustration of one genomic region along chromosome 7 displaying a
TAD, boundary and gap domain with the corresponding IGV snapshots of 7 histone
modifications, DNase and POLR2A. E, Heatmap displaying clustering of the 12
epigenetic states within the corresponding domains. Each row corresponds to one domain
and each column represents the percentage of each epigenetic state in each domain.
Columns are clustered based on the TAD domains. F, We then categorized the
12 epigenetic states based on their regulatory potential, these new categorizations are
referred to as “sub‐domains.” We identified six sub‐domains (SD1‐6). The epigenetic
mark‐depleted states S2 and S11 are merged into SD1, the interspersed S6‐S7 transition
regions are merged into a repressed SD2, the interspersed S1‐S7‐S9 regions are merged
into a repressed SD3, and the regions having active states are merged into a genebody
SD4 and two active enhancer/active promoter SD5 and SD6. TADs, topological
associated domains; HMM, Hidden Markov Model.
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Figure 2.3: The relationship between interaction peaks and sub‐domains
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Figure 2.3: The relationship between interaction peaks and sub‐domains. A,
Subdomains at each locus of interaction peaks (IPs) (left). ‘Peak Loci 1′ and ‘Peak
Loci 2′ represent the two ends of an IP. The table on the right summarizes the sub‐
domains identified in (Figure 2). B, Classification of promoter‐centric IPs based on
nearest genes. We defined a promoter region (P) to include 5 kb upstream to 1 kb
downstream of a TSS, a distal region (D) as 100 kb upstream or downstream of a TSS,
and any region beyond 100 kb from a TSS as a far (F) region. IPs for which the same
gene is the nearest gene to both ends are defined as PP1, PD1, and PF1 whereas loops in
which the nearest gene is different for each end are denoted as PP2, PD2, and PF2. C,
Boxplots of expression for genes associated with promoter‐centric IPs in PANC1 cells.
For PD1 genes, only one gene is involved and that data is plotted in the PD1 panel, for
PD2 genes, the expression of the gene at the promoter end is plotted in the PD2‐P panel
and the expression of the gene at the other end is plotted in the PD2‐D panel. P‐P is PP1
and PP2 combined. The expression of all other genes that are not involved in IPs in
PANC1 cells are plotted in the Non‐IP panel. The genes are grouped by the type of
subdomain where the promoter is located. PP, promoter‐promoter; TSS, transcription
start sites.
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Figure 2.4: Effects of histone acetyltransferase inhibitors on chromatin loops and gene
expression in PANC1 cells
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Figure 2.4: Effects of histone acetyltransferase inhibitors on chromatin loops and
gene expression in PANC1 cells. A, Diagram of observed types of domain alterations
after HAT inhibitor treatment. (1) No change – regions which match exactly between
control and treated cells, (2) conserve‐expand – regions identified as a TAD in both
control and treated cells, with the length of the TAD increasing by at most 300 kb in
treated cells, (3) conserve‐shrink – regions identified as a TAD in both control and treated
cells, with the length of the TAD decreasing by at most 300 kb in treated cells, (4) shift –
a region identified as a TAD in treated cells that overlaps with a TAD in control cells,
with the position shifting by more than 300 kb, (5) split – a region identified as one TAD
in control cells but covers multiple TADs in treated cells, and (6) type‐change – a region
identified as a TAD in control cells but has switched to a gap or boundary in treated cells.
B, Percentage of domain changes after treatment for 96 hours with ICG001 (left) and
C646 (right). C, Log2 fold change of H3K27ac levels after treatment, separated by type
of domain changes described in (A) (left panels) and type of sub‐domains (right panels).
D, Overlap between IPs identified in untreated and ICG001 treated (left) or C646 treated
(right) PANC1. E, Number of differentially expressed genes after ICG001 (left) or C646
(right) treatment, separated by type of domain change or sub‐domain. HAT, histone
acetyltransferase; TADs, topological associated domains.
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Figure 2.5: Effects of histone acetyltransferase inhibitors on TCF7L2‐mediated looping
in PANC1 cells
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Figure 2.5: Effects of histone acetyltransferase inhibitors on TCF7L2‐mediated
looping in PANC1 cells. A, Number of differentially expressed genes within promoter‐
centric IPs that were bound by TCF7L2 in untreated PANC1 cells that are no longer
classified as IPs in the drug treated cells. These differentially expressed genes were
altered in siTCF7L2 knockdown cells as well as drug treated cells. PP2‐P1 and PP2‐P2
are genes of which the promoters are associated with a PP2 IP, PP1 is the gene of which
the promoter is associated with a PP1 IP, PP2‐D is the distal gene, while PP2‐P is the
promoter gene that are associated with a PD2 IP and PD1 is the gene that is associated
with PD1 IP. B, KEGG pathway analysis of the genes (n = 39) that are associated with
promoter‐distal interactions and that are differentially expressed in drug treated PANC1
cells that are regulated by TCF7L2. C, Survival analysis of 176 TCGA pancreatic
adenocarcinoma patients of the 39 genes identified in (A). The red line is the survival of
the High Risk group, and green line is the survival of the low risk group patients. “+” in
the legend stands for the censored patients in each risk group (left). Boxplots displaying
the expression of the 39 genes in the two risk groups (right). CI, confidence interval; HR,
hazard ratio; P, P value
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CHAPTER 3
Disruption of broad epigenetic domains in PDAC cells by HAT inhibitors
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Abstract
The spreading of epigenetic domains has emerged as a distinguishing epigenomic
phenotype for diverse cell types. In particular, clusters of H3K27ac- and H3K4me3marked elements, referred to as super-enhancers and broad H3K4me3 domains,
respectively, have been linked to cell identity and disease states. Here, we characterized
the broad domains from different pancreatic ductal adenocarcinoma (PDAC) cell lines
that represent distinct histological grades. We find that distinct PDAC grades exhibit
characteristic broad epigenetic features that are predictive of patient prognosis and
provide insight into pancreatic cancer cell identity. In particular, we find that genes
marked by overlapping Low-Grade broad domains correspond to epithelial phenotype
and hold potential as a marker for patient stratification. We further used ChIP-seq to
compare the effects of histone acetyltransferase (HAT) inhibitors to detect global changes
in histone acetylation and methylation levels at broad domains. HAT inhibitors treatment
influence subclasses of broad domains in pancreatic cancer cells, which are potentially
reflective of therapeutic responses. Thus revealing imperative insight into nuclear signals.
The results reveal potential roles for broad domains in cells from distinct PDAC grades
and demonstrates domain-specific responses to epigenetic inhibition.
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Background
Cancer is a complex disease arising from both genetic and epigenetic alterations
that impact changes in gene expression to drive and maintain the malignant phenotype. In
recent years, epigenomic profiling has revealed that cancer progression involves a global
reprogramming of networks of functional DNA regulatory elements including enhancers
[1]. Enhancers are cis-acting elements that positively control the transcription of target
genes and play central roles in regulating cell-type or tissue-type specific genes during
development and differentiation [2]. Enhancer sequences are comprised of DNA
sequence motifs that allow transcription factors to bind in a sequence-specific manner,
and to recruit various histone writers to regulate transcriptional regulation. Recently,
clusters of enhancer elements, referred to as super-enhancers have been linked to cell
identity and disease states [3-7]. In addition, regions with widespread H3K4me3
modification called broad H3K4me3 domains have also emerged as important domains
linked to the expression of tumor suppressor and cell identity genes [8, 9]. Understanding
the functional roles of these epigenomic domains in different cancer types has the
potential to uncover new strategies for the development of new cancer therapies [10].
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of
pancreatic cancer and ranks as one of the deadliest diseases with a five-year survival rate
of less than 5% [11, 12]. PDAC is associated with a number of genetic and epigenetic
alterations, leading to the activation of growth promoting and cell survival pathways and
the inactivation of apoptotic and tumor suppressor pathways [13]. Recent reports have
demonstrated the PDAC enhancer landscape and have classified enhancers associated
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with PDAC progression [14-16]. However, the genes regulated by broad epigenomic
domains in PDAC cells remains unanswered.
To increase our understanding of broad epigenomic domains and their association
with PDAC gene regulation in cancer progression, we classified super-enhancer and broad
H3K4me3 domains in human PDAC cell lines. We specifically defined groups of
epigenomic domains that correspond to distinct histological grades and compared their
enriched pathways and linked gene expression levels. We show that broad domains
correlate with clinical features and hold potential as markers for patient stratification. As
epigenetic inhibitors are promising avenues for cancer treatment, we also explored the
ability of these compounds to target PDAC epigenomic domains.

Results
Classifying the broad domains of different PDAC cell lines
We analyzed ChIP-seq data from different human PDAC cell lines to identify
super-enhancer and broad H3K4me3 domains, respectively [14]. This data was derived
from a panel of human PDAC cell lines that are representative of both Low and High PDAC
tumor grades, based on genotypic and phenotypic characteristics [17-19]. For example, the
‘High-Grade’ PANC1, MiaPaCa2 and PT45P1 cell lines all express mesenchymal genes
[14, 19], show mesenchymal spindle-shaped cell morphology [20], and are considered to
be poorly differentiated [17, 21, 22]. In contrast, the ‘Low-Grade’ PDAC cell lines
CAPAN1, CAPAN2, CFPAC1 and HFPAC1 display epithelial-like features and are
considered to be well-differentiated [23-26]. To determine the super-enhancer domains
using these different PDAC datasets, we essentially followed the same procedures used in
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Hnisz et al. [3] with some slight modifications. Briefly, H3K27ac peaks were called from
ChIP-seq data against input and enriched peaks that clustered within 5 kb were stitched
together. These stitched regions were then ranked to determine super-enhancers. Broad
H3K4me3 domains were determined from enriched peaks identified from ChIP-seq, where
the top 5% of peaks based on domain size were used to call broad H3K4me3 domains [27].
In total, we identified between 457 to 1,346 super-enhancers and 1,214 to 2,559 broad
H3K4me3 domains in seven different PDAC cell lines that correspond to Low- and HighGrade groups, respectively (Figure 3.1-A). We observed that many genes were
differentially marked by broad domains according to the assigned PDAC Grade group. As
an example, the VIM gene encoding VIMENTIN, which is central to metastasis and is
highly expressed in poorly differentiated High-Grade cells, is bound by both types of broad
epigenetic domains only in High-Grade cells (Figure 3.1-B). We inspected the profiles of
other regulatory histone modifications within the broad epigenetic domains using
ENCODE data from PANC1 cells [28, 29]. The PANC1 super-enhancers exhibit higher
H3K4me3 and H3K4me1 signal compared to typical enhancers (Appendix C-1). Both
typical and broad H3K4me3 domains display low H3K4me1 enrichment, whereas broad
H3K4me3 domains display higher H3K27ac than typical H3K4me3 regions (Appendix C2). Comparison of the ChIP-seq signal of the different domains between cell lines reveals
that the majority of super-enhancers and broad H3K4me3 domains are uniquely enriched
in a given cell line (Figure 3.1-C and D).
We hypothesized that cells in separate differentiation states exhibit characteristic
broad epigenetic patterns. We therefore compared the regions between different PDAC cell
lines to define Grade-specific broad domains. Altogether, 38 super-enhancers were
68

common to all PDAC cell lines, and 61 and 224 super-enhancers were unique to HighGrade and unique to Low-Grade groups (HGU and LGU, respectively) (Figure 3.2-A).
Similarly, we identified 228 common and 177 HGU and 302 LGU broad H3K4me3
domains (Figure 3.2-B). We further compared the overlap of both types of broad domains
for the different PDAC groups by clustering these regions. There were 87 overlapping
super-enhancer and broad H3K4me3 domains for LGU, compared to the 34 overlapping
HGU (Figure 3.2-C). In general, Low-Grade PDAC cells had an increased number of
super-enhancer domains compared to High-Grade PDAC cells, whereas both groups have
a similar number of broad H3K4me3 domains. Overall, this analysis revealed that
distinctive PDAC Grades exhibit characteristic broad epigenomic domains.

Broad epigenomic domains mark distinctive PDAC pathways
Prior studies have demonstrated that broad domains are associated with
developmental and cell identity genes and broad H3K4me3 domains in particular have
been shown to mark tumor suppressor genes [8, 9, 30]. To explore the gene pathways
associated with super-enhancers and broad H3K4me3 domains, we annotated genes
marked by each type of domain and determined their functional classifications (Appendix
C-3 and Figure 3.2-D). Interestingly, pathway enrichment analysis showed that the genes
marked by overlapping domains are involved with a variety of signaling pathways that
were either specific to LGU, HGU, or common to all PDAC cells. For example, pathways
that enriched common to all PDAC cells included TGFB, microRNAs in cancer and cell
cycle. Pathways specific to HGU included VEGF and Ras signaling pathways, whereas
pathways specific to LGU were tight junction and Hippo signaling (Figure 3.2-D).
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Broad regions predict poorer survival in PDAC patients
Super-enhancers and broad H3K4me3 domains have been linked to increased gene
expression in a variety of tissue types [31, 32]. We therefore inspected the relative
expression levels of genes marked by different broad domains across PDAC Grades using
available RNA-seq data from the corresponding cell lines [14]. As expected, both superenhancer and broad H3K4me3 domains unique to each Grade group (LGU and HGU)
showed appreciably elevated expression in the corresponding group compared to the
contrasting group (Figure 3.2-E, Appendix C-4). For example, genes marked by HGU
super-enhancers had significantly higher expression levels in High-Grade cells compared
to Low-Grade cells.
We next explored the clinical association of the gene expression for genes uniquely
marked by different broad domains relative to patients’ overall survival using the TCGA
PDAC dataset [33]. Kaplan-Meier survival analysis showed that gene expression marked
by HGU super-enhancers as well as HGU broad H3K4me3 domains are strong predictors
of poor survival (Figure 3.2-F). In contrast, gene expression linked to LGU domains do
not predict a poorer survival rate. However, the expression levels of genes bound by both
LGU super-enhancers and broad H3K4me3 domains are significantly associated with a
worse overall survival in PDAC patients (Figure 3.2-F). Overall, these results reveal that
genes uniquely bound by different domains are predictive of PDAC patient outcome.
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Histone acetyltransferase inhibitors alter global H3K27ac and H3K4me3 levels
Epigenetic modulation via small molecule inhibitors has been proposed as an
approach for treating various malignancies, including pancreatic cancer [34, 35]. We have
previously shown that the two HAT inhibitors ICG-001 and C646 differentially impair the
global gene expression levels in human pancreatic and colorectal cancer cell lines [36].
However, the impact of HAT inhibitor treatment on histone acetylation remains unknown.
To determine the effect of HAT inhibitors on genome-wide H3K27ac enrichment, we
treated PANC1 cells with ICG-001, C646 or a vehicle control and performed H3K27ac
ChIP-seq, each with biological replicates. As expected, HAT inhibitor treatment caused
significant changes in genome-wide H3K27ac patterns compared to vehicle treatment
(Figure 3.3-A). Differential H3K27ac analysis showed that 4,675 and 5,362 regions with
reduced H3K27ac levels in ICG-001 and C646 treated cells, respectively (FDR <0.1).
There were also 2,391 and 4,383 sites with elevated H3K27ac levels in ICG-001 or C646
treated cells, respectively (Figure 3.3-B). Interestingly, for either treatment the majority of
higher H3K27ac enrichment clustered within the gene body (intragenic regions), whereas
the bulk of reduced H3K27ac enrichment corresponded to distal intergenic regions (Figure
3.3-C). Examples of genes that display altered H3K27ac patterns for each treatment are
shown in Figure 3.3-D. Pathway enrichment analysis indicated that HAT inhibitor
treatments influence H3K27ac enrichment at genes that map to a variety of pathways
(Figure 3.3-E). For example, both treatments decreased H3K27ac levels at genes that
belong to pancreatic, glioma, breast and gastric cancers, whereas C646 decreased the
H3K27ac at HIF-1 and phosphatidylinositol signaling gene pathways.
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We further investigated the impact of ICG-001 treatment on global H3K4me3
levels in PANC1 cells. ChIP-seq for H3K4me3 showed global H3K4me3 enrichment
alterations in ICG-001 treated PANC1 cells. In total there were 6,847 increased and 3,219
decreased regions (Appendix C-5). PPP2R2C, a tumor suppressor gene [37], exhibited
elevated H3K4me3 signal with ICG-001 treatment compared to control. In contrast
NKIRAS1, encoding a RAS-like protein exhibited decreased H3K4me3 signal with ICG001 treatment (Appendix C-5).

HAT inhibitors alter PDAC broad epigenomic domains
We next determined the impact of HAT inhibitor treatment on H3K27ac signal at
super-enhancers and found that both treatments specifically impact H3K27ac enrichment
levels at many super-enhancers (Figure 3.4-A). In total, there were 136 and 128 superenhancers with reduced H3K27ac levels, whereas 121 and 117 super-enhancers showed
significant gains in H3K27ac levels after ICG-001 and C646 treatments, respectively (FDR
< 0.1). Notably, the majority of super-enhancers with decreased H3K27ac are the same
between either treatment (~90%), whereas only ~50% of the domains with increased
H3K27ac are the same between either treatment (Figure 3.4-B). Increases in H3K27ac
signal at super-enhancers was associated with elevated gene expression levels and similarly
decreased enrichment at super-enhancers corresponded to a reduced gene expression
levels, but only with ICG-001 treatment (Figure 3.4-C). Pathway enrichment analysis
showed that different pathways are linked to the super-enhancers targeted by HAT
inhibitors (Figure 3.4-D). ICG-001 treatment targets super-enhancers that correspond to
genes involved with AGE-RAGE signaling complications in diabetes. In addition to super72

enhancers, ICG-001 treatment resulted in 4 decreased and 113 increased broad H3K4me3
domains. A comparison of both domains targeted by ICG-001 treatment reveals an increase
of H3K27ac and H3K4me3 enrichment at 24 distinct genomic regions (Appendix C-5).
Overall, these results delineate the broad epigenomic domains that are sensitive to HAT
inhibitor treatment in PANC1 cells.

HAT inhibitor treatment targets broad domains that are enriched at TAD boundary regions
Recently, super-enhancer domains that overlap with broad H3K4me3 domains
were shown to be linked to higher-order chromatin interactions, signifying a unique spatial
organization of chromatin around cell-specific epigenetic domains [8, 38]. We therefore
examined the relationship between higher-order chromatin organization and broad
epigenetic domains in PANC1 cells. Genome-wide chromatin contacts were determined
by analyzing tethered-chromatin conformation capture (TCC) data in PANC1 [39].
Chromatin contacts were partitioned into topologically associated domains (TADs) and
TAD boundary regions using a resolution of 40 kb (Figure 3.5-A and Appendix C-6). We
examined TADs in relation to CTCF and PANC1 broad domains. As expected, CTCF was
significantly enriched at TAD boundaries (Figure 3.5-B). Similarly, broad H3K4me3
domains were significantly linked to TAD boundaries, however super-enhancers were not
found to be enriched at TAD boundaries (Figures 3.5-C and 3.5-D). To study if HAT
inhibitor-sensitive domains are linked to higher-order chromatin structures, we
investigated the significance of association of both types of broad domains that are
impacted by ICG-001 treatment with TAD boundaries. We found that the domains with
increased H3K4me3 and H3K27ac enrichment were significantly associated with TAD
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boundaries, whereas domains with decreased enrichment were not associated with TAD
boundaries (Appendix C-7). Thus, these results show that broad domains that gain
enrichment of either active histone modification are linked to TAD boundaries. Overall,
this analysis demonstrates a global impact of drug treatment on the epigenome and shows
that certain classes of broad domains within TAD boundaries are sensitive to epigenetic
inhibitors.

Discussion
An improved understanding of PDAC tumor biology and tumor grading should
leverage available therapies and data. Here we extend prior data that indicated HAT
inhibitors elicit distinctive effects on cancer cell transcriptomes by exploring the
susceptibility of broad domains to HAT inhibitor treatment [36]. While drugs that target
epigenetic mediators are currently in development [40, 41], the downstream effects on the
epigenome of existing drugs has not yet been thoroughly examined. In particular,
epigenome-wide studies of their effects remains largely undetermined. In this study, we
utilize ChIP-seq to compare the effects of treatment with C646, which is a competitive
inhibitor of both p300 and CBP [42] to the effects of ICG-001, which prevents CBP
interaction with the co-activator β-catenin [43, 44]. Indeed, following treatment with either
drug we detect global changes in histone acetylation levels. Our results suggest that, in
general, these two drugs have similar effects on the epigenome of PDAC cells; however,
we were able to identify cell-specific and drug-specific responses after treatment.
We observed dramatic effects on the epigenome upon treatment with either ICG001 or C646, with hundreds of regions showing differential enrichment of H3K27ac or
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H3K4me3. Interestingly, both drugs targeted similar super-enhancers, causing a reduction
in histone acetylation levels near genes involved in pancreatic cancer and other solid
cancers (Figure 3.4). Since it is of current interest to target super-enhancers, we find that
both super-enhancers and broad H3K4me3 domains are sensitive to epigenetic modulation.
Thus, our results provide insight into the plasticity of these domains in response to
epigenetic modulation. Future work could tailor these therapeutics to target such domains;
thereby impacting specific cellular pathways involved with PDAC tumorigenesis.
The extension of epigenetic regulatory domains has emerged as a diagnostic marker
that can serve to distinguish cancer cell identity and disease state. Accordingly, we
characterized the broad domains in several different cell lines that represent distinct PDAC
histological grades. By clustering the domains from 7 different PDAC cell lines into Highand Low-Grade groups, we find that different PDAC grades exhibit characteristic
epigenetic features that are predictive of PDAC prognosis and provide insight into
pancreatic cancer cell identity. Of particular interest are the genes marked by both superenhancer and broad H3K4me3 domains in Low-Grade groups. Low-Grade groups
demonstrate an enrichment for a greater number of unique gene pathways, which include
several pathways significant to PDAC progression. Such pathways include tight junction,
glycerophospholipid and Rap1 signaling pathways. We also provide evidence that genes
marked by overlapping Low-Grade broad domains correspond to epithelial phenotype and
hold potential as a marker for patient stratification (Figure 3.2). Thus, different PDAC
grades exhibit characteristic pathways marked by broad epigenomic domains that provide
insight into pancreatic cancer cell identity in the context of PDAC progression.
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Pancreatic Ductal Adenocarcinoma (PDAC) broad domains span numerous
distinctive loci including the HOX, SMAD, and FOX family of genes, proteins that have
known roles in cell-type specific functions and are known factors in PDAC tumor cell
biology [45-47]. After annotating the genes marked by different broad domains, we
identified known PDAC signaling pathways including the TGFβ and MAPK pathways,
which are downstream effectors of oncogenic KRAS. Oncogenic KRAS is an established
driver of pancreatic cancer and several pathways that are known downstream effectors of
KRAS signaling and play central roles in PDAC cancer cell growth and survival [48-50],
were found to be marked by broad domains in domains common to all PDAC cells. Superenhancers common to all PDAC cell lines were significantly enriched with a variety of
cancer signaling pathways including focal adhesion, PI3K-AKT, microRNAs and Hippo
signaling. LGU super-enhancers were uniquely associated with several pathways that
include tight junction, Rap1 signaling and glycerophospholipid metabolism. Aberrant lipid
synthesis and the reprogramming of lipid metabolism has been associated with the
development and progression of pancreatic cancer [51] and several phospholipids have
been identified as potential biomarkers in different types of pancreatic cancers [52, 53].
MAPK signaling was the singular KEGG pathway enriched in HGU super-enhancers
(Appendix C-3). Similarly, the broad H3K4me3 domains common to all PDAC groups
were associated with distinctive pathways including transcription corepressor, protein
kinase, cadherin binding and RNA binding pathways (Appendix C-3). Several enriched
pathways linked to LGU broad H3K4me3 domains include SMAD, protein kinase C, TGF
beta, and beta-catenin pathways, whereas the HGU broad H3K4me3 domains solely mark
genes enriched in transcriptional corepressor pathways. Examples of broad PDAC
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epigenomic domains encompassing disease-associated genes include SMADs and FOXC2
for super-enhancer regions and MYC and CCND1 for broad H3K4me3 domains (Appendix
C-1 and 2).
Interestingly, our analysis indicates that Low-Grade unique broad H3K4me3
domains are enriched for TGFβ signaling pathways. TGFβ acts as a tumor suppressor with
growth-inhibitory activity in epithelial cells during early pancreatic tumorigenesis.
However, TGFβ appears to promote tumor progression in advanced disease [54]. We also
found broad epigenomic domains mark several others pathways with less wellcharacterized roles in PDAC tumor biology, including microRNAs and proteoglycans in
cancer.
The histone modifications H3K4me3 has been widely recognized as a mark of
active promoter regions [55]. Recent studies have correlated broad H3K4me3 domains
with enhancer activity at tumor suppressor genes in normal and cancer cells to provide
mutation-independent insight into tumor suppressor pathways of disease states [9]. Here,
we found broad H3K4me3 domains span a number of genes including HOX, MYC and
CCND1 genes. As super-enhancers and broad H3K4me3 domains have been shown to
function coordinately through chromatin interactions [8, 38], we identified regions
containing both domains in both High- and Low-Grade cells. As mentioned previously, the
expression of genes marked by both domains is significantly associated with poor
prognosis in pancreatic cancer patients.
In summary, our data provides new perspective on the effect of HAT inhibitors on
the epigenome and provides knowledge of the broad domains unique to different
histological grades of pancreatic cancer. Our data show that epigenomic domains that
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correlate with clinical features, that they are plastic and hold potential as markers for patient
stratification.

Methods
Cell culture and epigenetic inhibitor experiments
The human cell line PANC1 (ATCC #CRL-1469) was obtained from the American
Type Culture Collection. The cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. We obtained
ICG-001 from Michael Kahn (University of Southern California) and C646 from VWR
(catalog# 102516-240). Cells were grown to 70% confluency followed by treatment with
10μM ICG-001 or 10μM C646 and were collected after 12hrs.

ChIP-sequencing
After 12-hour incubation with either ICG-001 or C646, cells were crosslinked with
1% formaldehyde (Thermo Scientific #28908) for 10 minutes and quenched with 0.125M
Glycine. The ChIP-seq experiments were further performed as described by O’Geen et al.
[56] and the antibodies used for the given targets were as follows: H3K27ac (Abcam,
Cambridge, MA, USA; Ab4729 lot#GR16377-1) and H3K4me3 (Abcam, Cambridge, MA,
USA; Ab8580). We performed duplicate ChIP-seq experiments for each histone. For each
histone ChIP-seq assay, 10μg of chromatin was incubated with (2.5-5μg) of antibody. To
confirm enrichment of target sequences, we performed qPCR in ChIP versus input samples.
DNA was quantified using Qubit (Invitrogen) and libraries were prepared using the
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NEBNext ChIP-seq Illumina Sequencing library preparation kit (New England Biolabs,
Ipswich, MA, USA).

Tethered Chromatin Capture (TCC)
Tethered chromatin capture (TCC) was performed as detailed by Kalhor et al. [57].
Briefly, approximately 5 x 107 PANC1 cells were crosslinked as described above for ChIPseq experiments and cell pellets were collected and stored at -80C. Nuclei were digested
with 2000U HindIII prior to dilute solid-surface ligation reactions and TCC library
preparation was performed as described [57].

ChIP-sequencing analysis
For all datasets raw sequencing reads were aligned to the human reference genome
hg19 using bowtie2 with default parameters [58]. ENCODE ChIP-seq datasets were
obtained from GSE31755. We determined binding sites of each ChIP-seq experiment using
MACS2 with default parameters with the exception of using the flag ‘-broad’ for
determining broad H3K4me3 binding sites [59]. Super-enhancer regions were identified
over typical-enhancer regions using the Ranked Ordering of Super Enhancer (ROSE) tool
[5, 60]. Briefly, peaks were called from the H3K27ac ChIP-seq data and stitched together
in 12.5 kb windows, which were further used to identify super-enhancers (ranked cutoff
score of 19701.68). Broad H3K4me3 regions were obtained via filtering for the top 5% of
peaks (largest by domain size). Enrichment of signal within regions was plotted with the
functions ‘plotProfile’ and ‘plotHeatmap’ within deepTools [61]. Overlapping binding
regions were determined using peak interesectR. To determine peak locations relative to
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gene

regions,

we

utilized

the

‘annotatePeaks.pl’

function

within

HOMER

[62]. Visualization snapshots of ChIP-seq regions were obtained by building a signal track
via

the

‘bdgcompare’

utility

in

MACS

[59].

Bigwigs

were

obtained

by

‘bedGraphToBigWig’ via UCSC tools [63] and further visualized using Integrated
Genomic Viewer [64, 65].

Coordination of Grade-Specific Broad Domains
H3K4me3, H3K27ac and control ChIP-seq datasets for PDAC cell lines were
obtained from GSE64557 and processed as described above. We utilized the Bioconductor
package ‘seqsetvis’ [66] to visualize the distribution and overlap of genomic regions.

Differential Binding Analysis of ChIP-seq datasets
To determine differential typical and broad H3K27ac and H3K4me3 regions we
used the DIffBind R package [67, 68] with an FDR cutoff of <0.1.

Pathway Enrichment Analysis
Annotation of enriched gene pathways was performed using either ClusterProfiler
or the Stanford GREAT tool [69, 70].

Integration of Gene Expression Datasets
For integrating High- and Low-Grade gene expression for the different cell lines,
we retrieved the corresponding RNA-sequencing expression datasets (GSE64558). We
mapped these datasets to the human genome reference, hg19 and gene counts were
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nomalized using DESeq2 [71]. The mean of the normalized counts between replicates of
each cell line was used to generate expression heatmaps. ICG-001 and C646 Illumina
beadchip expression datasets were obtained from our previous study (GSE64038). We
overlapped these differentially expressed genes within treatments with our genes annotated
within drug altered broad regions to demonstrate expression changes at these genes.

Topological domains from TCC data
Paired raw reads of TCC data for the PANC1 cell line was processed using the HiCPro pipeline [72]. Briefly, these reads were aligned to the human reference genome hg19
using bowtie2 with default parameters [58]. 25bp of the reads were trimmed and the reads
were then aligned iteratively. Reads with a MAPQ score less than 30 were removed and
the fragments were filtered for self-ligated fragments, duplicated reads from PCR and
error-pairs. Domains were detected using TopDom based on the local minima of
normalized contact matrix [73, 74]. To visualize the relationship between broad domains
and TADs, we used HiCPlotter [75].

Feature Enrichment Analysis within TAD Boundary Regions
To determine enrichment of broad domains within +/- 20 kb of the Boundary
regions, we iteratively determined the expected distribution either CTCF, broad H3K4me3
or super-enhancer regions within our TAD boundary domains within 8,354 randomly
selected bins and iteratively repeated this 1,000 times. We then calculated our observed
estimation of the given regions (either for CTCF, broad H3K4me3 or super-enhancers)
within TAD Boundaries.
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Figures
Figure 3.1: Determination of super-enhancers and broad H3K4me3 domains in PDAC
cell lines that correspond to different histological grades
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Figure 3.1. Determination of super-enhancers and broad H3K4me3 domains in
PDAC cell lines that correspond to different histological grades. A. The total number
of super-enhancers and broad H3K4me3 domains found in different human PDAC cell
lines that represent either High-Grade (purple) or Low-Grade (green) PDAC groups. B.
Genome browser representation of the H3K27ac and H3K4me3 ChIP-seq signal, as well
as the RNA-seq signal over an approximate 14 kb region surrounding the VIM locus. C.
Heatmap displaying the classification of super-enhancer domains across 7 human PDAC
cell lines. The color scale reflects the density of H3K27ac signal at super-enhancer regions.
D. Heatmap displaying the classification of broad H3K4me3 domains across 7 human
PDAC cell lines. The color scale reflects the density of H3K4me3 signal at broad
H3K4me3 domains.
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Figure 3.2: Broad domains mark distinctive pathways and are predictive of poorer
patient survival
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Figure 3.2: Broad domains mark distinctive pathways and are predictive of poorer
PDAC patient survival. A. Clustering of genomic regions encompassing super-enhancers
across seven human PDAC cell lines to define common, High- and Low-Grade unique
super-enhancers. B. A similar analysis was performed on broad H3K4me3 domains to
define common, High- and Low-Grade unique (HGU and LGU, respectively) broad
H3K4me3 domains. C. A similar analysis was performed to look at overlapping domains,
where ‘B’ represents Broad H3K4me3 domains and ‘S’ represents super-enhancers. D.
Gene Ontology pathway enrichment profiles of genes marked by both domains that are
common, HGU or LGU domains. E. Comparison of expression levels of genes marked by
the indicated domains in High-Grade and Low-Grade PDAC cells. Data is derived from
mean normalized expression counts of genes. F. Kaplan-Meier survival analysis of highand low-risk groups (red and black, respectively) for genes marked High-Grade unique
(HGU) and Low-Grade unique (LGU) domains for the indicated domain type.
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Figure 3.3: Inhibitors of histone acetyltransferases impact global H3K27ac levels
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Figure 3.3: Inhibitors of histone acetyltransferases impact global H3K27ac levels. A.
Differential H3K27ac enrichment analysis reveals significantly altered genome-wide
H3K27ac sites in response to ICG-001 (Top) or C646 (bottom) treatment (FDR <0.1),
signal is represented as log2 normalized read count for the indicated condition. B. Signal
heatmaps representing the H3K27ac within altered regions after ICG-001 or C646
treatment identified from the differential analysis. C. Location analysis of increased or
decreased H3K27ac signal after treatment relative to gene regions. D. Example of genes
with increased or decreased H3K27ac signal after ICG-001 treatment, signal is represented
as fold enrichment over input. E. KEGG pathway enrichment analysis of genes within
altered regions after HAT inhibitor treatment.
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Figure 3.4: HAT inhibitors influence the acetylation levels at super-enhancers
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Figure 3.4. HAT inhibitors influence the acetylation levels at super-enhancers.
A. Scatterplot displaying the differential enrichment of H3K27ac (log2 ChIP-seq read
count) for ICG-001 (left) and C646 (right) compared to control, the blue diagonal line
separates those of increasing or decreasing signal with the colored dots corresponding to
regions with significant changes in treatment compared to control (FDR <0.1). B. Overlap
analysis of regions comparing the increased or decreased H3K27ac regions after ICG-001
and C646 treatment. C. Boxplots displaying log2 fold change of genes (treatment vs
control) within the given differential domains identified in A. D. Pathway enrichment
analysis of genes within altered super-enhancers after ICG-001 or C646 treatment.
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Figure 3.5: Broad domains are linked to topological associated domain boundaries
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Figure 3.5. Broad domains are linked to topological associated domain boundaries.
A. Chromatin interaction matrix at 40 kb resolution showing broad domains contained
within TAD regions. Statistical associations of TAD boundaries were performed for B.
CTCF, C. super-enhancers and D. Broad H3K4me3 domains.
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CHAPTER 4

Temporal dynamic reorganization of 3D chromatin architecture in hormoneinduced breast cancer and endocrine resistance

111

Abstract
Recent studies have demonstrated that chromatin architecture is linked to the
progression of cancers. However, the roles of 3D structure and its dynamics in hormonedependent breast cancer and endocrine resistance are largely unknown. Here we report
the dynamics of 3D chromatin structure across a time course of estradiol (E2) stimulation
in human estrogen receptor α (ERα) positive breast cancer cells. We identified subsets of
temporally highly dynamic compartments predominantly associated with active open
chromatin and found that these highly dynamic compartments showed higher alteration in
tamoxifen resistant breast cancer cells. Remarkably, these compartments are
characterized by active chromatin states, and enhanced ERα binding but decreased
transcription factor CCCTC-binding factor (CTCF) binding. Lastly, we identified a set of
ERα-bound promoter-enhancer looping genes enclosed within altered domains that are
enriched with cancer invasion, aggressiveness or metabolism signaling pathways. This
large-scale analysis expands our understanding of higher order temporal chromatin
reorganization underlying hormone-dependent breast cancer.
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Introduction
Numerous efforts have been devoted to revealing the basic principle of three
dimensional (3D) chromatin architecture and genome organization inside the cell nucleus
of various mammalian genomes1-8. One prominent structural feature of genome
organization is the formation of various types of chromosomal domains 9 defined as
spatial compartments1,10, topologically association domains (TAD)3 or lamina-associated
domains (LAD)11. The discrete TADs ranging from several hundreds of kilobases (kb) to
several megabases (Mb) are usually stable in diverse cell types and are highly conserved
across different mammalian species, suggesting that they are inherent and important
functional units of mammalian genomes12,13. By contrast, spatial compartments
comprised of two types, compartment A or B, form an alternating pattern of active and
inactive domains along chromosomes. Their sizes usually range around 5 Mb and are
characterized by genomic features associated with transcriptional activity, such as
chromatin accessibility, active or repressive histone marks, gene density, GC content and
repetitive regions14,15. Furthermore, A and B compartments show tissue- or cell-type
specificity that are correlated with cell-type specific gene expression patterns16,17.
However, a recent study found A or B compartments may be much smaller in size at a
couple of hundred kb when using improved Hi-C protocols in higher resolution maps18.
These maps are similar in size to the topologically constrained domains 19. It is also
increasingly recognized that spatial compartments and TADs are fundamentally two
independent chromosomal organization modes20,21, thus disputing the common notion of
a hierarchical folding principle that TADs are the building blocks of larger compartment
domains.
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Recent efforts have focused on understanding the relationship between higherorder structures and human development and disease.22-24. For instance, new studies
demonstrated that the reprogramming of high-order structures of both the paternal and
maternal genomes gradually occurs during early mammalian development23,24. Another
study showed that disorganization of prostate cancer 3D genome architecture occurs
coincident with long-range epigenetically activated or silenced regions, which
coordinated with gene transcription25. Despite the advances in our knowledge of 3D
genome regulation, several critical questions remain to be answered in the field. For
example: (1) how stable or dynamic are chromosome domains upon signaling stimuli as
cells respond to external cues? (2) To what extent do these changes affect establishing or
re-establishing the compartmentalized architecture? (3) What degree of impact do the
master or key transcription factors in a particular cell system have on chromatin
reorganization? (4) What are the roles of chromatin architecture in governing the
progression of human diseases, such as cancers?
Estrogen (E2) signaling plays a crucial role in driving estrogen receptor α positive
(ERα+) breast cancer cell growth and proliferation26,27. The cellular response to E2
induction is characterized by timed and coordinated transcriptional regulation primarily
mediated by ERα. Thus, it has been frequently used as a model system to illustrate the
mechanisms underlying transcriptional controls in cancer development and progression
as well as in fundamental biological process 28-32. Using genome-wide approaches, we and
others demonstrated very little coincidence between ERα targeted genes in breast cancer
cells versus acquired endocrine resistant breast cancer cells indicating distinct
transcriptional regulatory mechanisms underlying endocrine resistance 33-37. In a recent
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study, we used a 3C-based high throughput protocol to identify two densely mapped
distant estrogen response element (DERE) regions which were frequently amplified in
ERα+ breast cancer38,39. Interestingly, these aberrantly amplified DEREs deregulated
target gene expression linked to cancer development and tamoxifen resistance. However,
the roles of 3D structure and its dynamics in hormone-dependent breast cancer and
endocrine resistance are largely unknown.
To establish a basis for data-driven learning and modeling of the temporal
dynamics and 3D chromatin reorganization, we applied tethered chromatin conformation
(TCC), a modified Hi-C protocol40 for high depth sequencing. We performed TCC in a
time-series of E2-induction in the ERα+ breast cancer cell line, MCF7 as well as the
tamoxifen resistant MCF7 (TamR) cell line. Here, we present a time-series of genomewide maps of chromatin contacts, identify the temporal dynamic patterns of chromatin
compartments, compare the patterns between MCF7 and TamR cells and examine the
enrichment of ERα and CTCF binding as well as five active and repressive histone marks
in the patterns. We further identify ERα-bound promoter-enhancer (ERα-PE) looping
genes enclosed within TamR altered dynamic compartments. This large 3D-scale of
chromatin data provides a rich resource for studying the basic characteristics of hormonedependent breast cancers and provides further insight into the mechanisms of tamoxifen
resistance.
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Results
Re-compartmentalization of chromatin at early E2 treatment
Despite many studies demonstrating that E2 induces the highest levels of ERα
binding and gene activity around 45min to 1hr28,30, little has been done to
comprehensively characterize the changes of chromatin architecture in MCF7 cells in a
genome-wide manner. In this study, we conducted TCC analysis in hormone-starved
MCF7 cells (T0) and compared this to MCF7 cells treated with 1hr of E2 (T1). The
Pearson correlation of chromatin interactions showed that biological replicates are largely
correlated for each treatment at different resolutions (Figure 4.1-A), illustrating good
quality TCC data. We thus combined two replicates at either time point to identify
chromosome compartments with HiCLib10 (Figure 4.1-B). With a sequencing depth of
around 200 million (75 million uniquely mapped) paired-end reads for each data set, we
expect the resolution of compartments around 40-50kb41. Surprisingly, the genomic size
of a majority of compartments is either smaller than 1Mb or between 1-2Mb, and very
few are larger than 5Mb (Figure 4.1-C and D). Our data seems to contradict earlier
studies that determine compartment sizes to be larger than 2Mb 1,10; however, it is
consistent with newly reported studies using improved Hi-C protocols in conjuction with
a higher sequencing depth18. We found a similar number of compartments, 2,067 and
2,039, in the untreated and E2-treated cells respectively, where approximately half
consisted of compartment A (active chromosome domains) and half were compartment B
(inactive chromosome domains) at each time point (Figure 4.1-E). We then compared
the compartments between untreated and E2-treated cells, and found that the type of
compartments drastically changes following E2 treatment. The number of common or
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conserved compartments between treatments increases from 28%, 55%, 74% to 78%
using different bin sizes of 100kb, 250kb, 500kb and 1Mb, respectively (Figure 4.1-F).
Our results at lower resolution (500kb or 1Mb) are in-line with many other studies that
report approximately 80% conserved domains among different conditions or cell
types3,12. However, at a higher resolution of 100kb, we identified 576 Common
compartments between untreated and E2-treated cells and 1,463 Transit compartments
sensitive to E2 treatment that shifted in size or flipped between A/B compartments. Of
Transit compartments, 743 (51%) of them shift only 100kb and 247 (17%) shift more
than 400kb while 116 (8%) flipped between A/B compartments (Figure 4.1-G). These
data demonstrate a re-compartmentalization of higher-order chromatin domains following
1 hour of E2 treatment.

Temporal dynamic chromatin along prolonged E2 treatments
Several studies found that transcriptional responses to longer E2 treatments were
dramatically different than responses to shorter treatments30,31. In order to understand the
dynamics of chromatin structure in longer E2 treatment periods in MCF7 cells, we further
conducted TCC analysis in three more time points, 4hr (T4), 16hr (T16) and 24hr (T24),
each with biological replicates. In order to capture the dynamic patterns following a
prolonged E2 treatment, we determined compartments at 100kb and compared the
compartments among the five time points. As expected, the number of compartments was
very similar among the five time points. We used the Common and Transit compartments
obtained from the comparison of T1 vs. T0 and compared them to T4, T16 and T24
respectively. We also separated the comparison of active open chromatin compartment A
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(Figure 4.2-A, upper panel) from inactive closed chromatin compartment B (Figure 4.2A, lower panel). When re-examining these sets of Common or Transit compartments, we
identified 15 patterns of changed compartments from 16 sets (Appendix D-1) and 9
additional patterns from the last set (labeled X in Appendix D-1) based on the converted
bins. We were able to categorize these 24 patterns of chromatin into six types of
temporally dynamic re-compartmentalization (TDRC): Highly Common Compartments
(HCC, patterns 1-4 with a FDR of 0.268), Early Transit Compartments (ETC, patterns 58 with a FDR of 0.230), Late Transit Compartments (LTC, patterns 9-12 with a FDR of
0.192), Lowly Dynamic Compartments (LDC, patterns 13-16 with a FDR of 0.178),
Moderately Dynamic Compartments (MDC, patterns 17-20 with a FDR of 0.161), and
Highly Dynamic Compartments (HDC, patterns 21-24 with a FDR of 0.201) (Figure 4.2B). There is also a statistically significant difference (p=7.6x10-11, Wilcoxon rank-sum
test) between highly dynamic compartments (MDC and HDC) and lowly dynamic
compartments (HCC, ETC, LTC and LDC) (Figure 4.2-C). Interestingly, the MDC and
HDC are predominantly composed of compartment A mainly from Transit to Transit
compartments along the time courses of E2 treatment (Figure 4.2-D and E), while the
LDC has the most changed compartment B. This data suggests that active chromatin
domains are more susceptible to change in response to E2 stimulation over time.

Altered chromatin compartmentalization in resistant cells
Increasing evidence suggests that ERα-mediated gene deregulation or epigenetic
alterations may be key mechanisms underlying acquired tamoxifen resistant breast
cancer42,43. However, the knowledge of endocrine resistant associated 3D regulation is
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still limited. To delineate the altered 3D architectures, we further conducted TCC analysis
in a tamoxifen resistant MCF7 cell line, MCF7-TamR44. At a resolution of 100kb, we
identified 2,103 compartments including both A and B (Figure 4.3-A). We further
defined a compartment to be a tamoxifen resistant altered compartment (TRAC) if it was
a Transit compartment and if there was at least one converted bin between TDRC and a
TamR compartment. As such, we obtained six corresponding types of TRACs: TA-HCC
(FDR of 0.154), TA-ETC (FDR of 0.250), TA-LTC (FDR of 0.154), TA-LDC (FDR of
0.165), TA-MDC (FDR of 0.139) and TA-HDC (FDR of 0.226). Patterns 17, 19, 21, 23,
and 24 in TA-MDC and TA-HDC types showed higher alteration than other patterns,
suggesting that the higher dynamics of the compartments in E2-induced MCF7 cells, the
stronger alterations of the compartments in TamR cells (Figure 4.3-B). Further, we
observed that the average size of TA-HDC and TA-ETC types were longer than those in
unaltered compartments, while the size of TamR unaltered compartments (TRUCs) were
longer than TA-HCC (Figure 4.3-C). Att a bird’s-eye-view, we identified three
interesting types of TRACs: Shrunk, Expanded and Flipped (Figure 4.3-D-F). Our data
suggest that a group of genes within the same domain may be concordantly regulated
during acquired tamoxifen resistance.

Epigenetic states in dynamic re-compartmentalization
Epigenetic marks have been shown to classify genomic compartments and
chromosomal domains into subcompartments or subdomains in diverse cell types18.
There is little known about the structural roles of one-dimensional (1D) epigenetic states
in E2-induced 3D chromatin structure. We performed ChIP-seq of three active marks,
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H3K27ac, H3K4me1, and H3K4me3, and two repressive marks, H3K9me3 and
H3K27me3 in a time course of E2 treatment in MCF7 cells as well as in asynchronous
TamR cells, each with biological replicates. We first trained a total of 30 histone
modification data by ChromHMM at various parameters 45, and obtained ten HMM states
(Figure 4.4-A and B). Through interpreting both HMM emission and transition
probabilities, we inferred seven biologically meaningful epigenetic states, including two
active states (S9 and S10), two bivalent states (S3 and S8) and three repressive states (S1,
S4 and S6) (Figure 4.4-C). We were also able to map these states back into each of six
types of E2-induced dynamic compartments and TamR altered compartments. Overall,
we observed that more active states were distributed in compartment A and more
repressive states in compartment B, while three types of dynamic changed compartments,
i.e., LDC, MDC and HDC, have a higher percentage of active states than HCC does
(Figure 4.4-D-G). Surprisingly, S1 showed a high percentage of distribution in
compartment A despite that it is a repressive state.

ERα and CTCF binding in dynamic re-compartmentalization
Since ERα is a master transcription factor mainly in response to E2 stimulation in
MCF7 cells and CTCF is a chromatin organizer known to regulate the 3D architecture,
we wanted to understand their regulatory roles in mediating these 3D structural
dynamics. We performed ChIP-seq of ERα and CTCF at five time points of E2stimulated MCF7 cells and in TamR cells, each with biological replicates. We used
MACS46 to call ERα binding sites (peaks) in each of the 12 data sets and obtained 7,553
peaks in untreated MCF7 cells (T0), and between 13,000-20,000 ERα peaks in E2-treated
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MCF7 cells at four time points and untreated TamR cells respectively (Figure 4.5-A).
Interestingly, we found Patterns 18 and 20 of MDC and Pattern 24 of HDC had the
highest number of ERα binding sites in compartment A but not in compartment B in E2induced MCF7 cells as well as in TamR cells (Figure 4.5-B), illustrating that there are
more ERα binding sites in higher dynamic active chromatin.
Furthermore, we identified approximately 50,000 CTCF peaks in each of the five
time points of E2-induced MCF7 cells and in TamR cells (Figure 4.5-C). On the
switched domain boundary between two compartments, we observed generally lower
averages of CTCF binding sites in three types of TDRCs (LDC, MDC, HDC), and three
types of TRACs (TA-LDC, TA-MDC, TA-HDC) than other three types (Figure 4.5-D).
When testing the correlation of ERα binding within the compartments vs CTCF binding
on the boundary regions, Pattern 24 of HDC or TA-HDC was the only pattern having
more than 80% ERα peaks and less than 0.4 CTCF peaks per compartment in E2-induced
MCF7 cells (Figure 4.5-E—left panel) or in TamR cells (Figure 4.5-E—right panel).
Collectively, our results indicate a reciprocal relationship to ERα binding and CTCF
binding at highly dynamic changed compartments during the temporal response to E2
stimulation which is also observed in cells with acquired tamoxifen resistance.

Differentially expressed genes and putative loops
We next examined the gene expression and loops within these TDRCs and
TRACs. We utilized a publicly available time-series RNA-seq dataset47, profiled at 10
time points of E2-treated MCF7 cells, to identify differentially expressed genes. By
picking 5 time points close to this study (T0 = 0 min, T1 = 40 min, T4 = 160 min, T16 =
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640 min, T24 = 1280 min), we identified 4,106 dynamic differentially expressed genes
(DDEGs) across all time points. As expected, a majority of such genes were located in
dynamically changed compartment A with most in the MDC and HDC types (Figure 4.6A). There seems to be minimal difference in the average of gene expression levels within
each of the six types of TDRCs. However, the variance of DDEGs in LDC, MDC and
HDC is higher than HCC, ETC and LTC (Figure 4.6-B). GSEA analysis48 showed
ribosome, tight junction, endocytosis, lysosome, cell cycle, WNT signaling pathway,
insulin signaling pathway, focal adhesion, and MAPK signaling pathway were among the
top functional categories for the 1,396 DDEGs in MDC and HDC types (Figure 4.6-C).
We further performed RNA-seq in parental MCF7 and TamR cells, each with three
biological replicates and identified a total of 2,097 TamR-specific differentially
expressed genes (TDEGs). More than half of them (1,188) were in the combined TAM&HDC types (Figure 4.6-D). We then identified 42,390 TamR-specific significant
interaction pairs or putative loops from TamR TCC data by HOMER 49 and using our T0
TCC dataset as the contrast. 3C-qPCR validations further confirmed the differential
looping intensity of seven randomly selected pairs between parental MCF7 and TamR
cells (Appendix D-2). Of the 42,390 identified loops, 16,807 were overlapped with a
promoter (-5kb/+1kb around the 5’TSS), 9,638 of them had either H3K27ac or H3K4me1
peaks in the distal loci, 4,122 of them had at least one ERα binding site at either loci of
the loop and were thus considered as ERα regulated promoter-enhancer (ERα-PE) loops
(Figure 4.6-E). Finally, 396 TDEGs within 599 ERα-PE loops in the combined TAM&HDC types were identified as ERα dysregulated dynamic looping genes in resistant
cells. Functional annotation and gene pathway analysis with GSEA showed these genes
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were mapped to nine KEGG signaling pathways related to cancer invasion and
aggressiveness, as well as glycolysis and metabolism (Figure 4.6-F). Taken together, our
results demonstrate that these ERα-associated dynamically reorganized active domains
regulating gene looping events may result in higher susceptibility to alterations in
tamoxifen resistant cells. This prompts us to speculate that these genome domains and
looping genes may be responsible for driving the acquired tamoxifen resistance.

Discussion
Despite the increasing developments of various 3C-derived high throughput
sequencing techniques in which it advances our understanding of the principles of 3D
genome architecture, several important questions remain to be answered in the field. One
of the many aspects is to elucidate how stable or dynamic chromosome domains are in
response to signaling stimuli and to what extent these changes affect establishing or reestablishing the compartmentalized architecture. Our main goal of this study is to
establish a basis for data-driven modeling of temporal dynamics and 3D chromatin
reorganization given that such studies are very limited. While mega-sized TADs are
conserved among different cell types and mammalian species 3,5,12, 100-500kb size of
subTADs or compartments are considered to be dynamic where the boundaries are nonconserved18,50. Though our data showed the total number of compartment domains are
quite similar among different time points, the changes in size (of at least 100kb) of
compartments are very pronounced, particularly in these E2-induced highly dynamic
compartments. With a very loose definition of dynamic changes requiring a minimum of
100kb, we were able to unveil 24 temporal dynamic patterns upon E2-induction which
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were further categorized into six major types. Indeed, the MDCs and HDCs were not only
predominately of active compartment A but also contained dynamic differentially
expressed genes enriched with biological process terms ribosome, tight junction, cell
cycle and others (Figure 4.6-C). Many of them characterize known effects of estrogen on
the MCF7 cell phenotype51. In contrast, there were no significant differences between E2induced early and late changed compartments in which both types were comprised of
very few compartments. Our data implied that these moderate to high dynamic
compartments may play an essential role in governing hormone-mediated luminal breast
cancer development.
Many studies including ours have demonstrated that E2 instructed dynamic
transcriptional programs rewired or altered transcription regulatory networks in
tamoxifen resistant breast cancer cells36,52,53; however, very few focused on examining
3D regulatory roles in tamoxifen resistance. Our previous studies utilized a 3C-seq
technique to identify two densely mapped DERE regions located on chromosomes 17q23
and 20q13 frequently amplified in MCF7 cells and found their aberrantly amplified
DEREs deregulated target genes were potentially linked to cancer development and
tamoxifen resistance38. However, this study containd many limitations including the
technique itself, smaller data volumes and fewer computational tools available for a
thorough analysis. Our current work has significantly improved in the following aspects:
1) we generated high quality TCC datasets with increased sequencing depth allowing for
the detection at 40kb resolution; 2) we produced TCC datasets in an E2-induced time
series in MCF7 cells and then compared it to TamR cells; and 3) we utilized many stateof-art computational tools to process TCC and ChIP-seq datasets. Remarkably, our
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integrative analyses uncovered many temporal dynamic patterns characterizing the 3D
chromatin reorganization upon E2-induction. Interestingly, two types of temporal
dynamic re-compartmentalization (TDRC), i.e., moderately and highly dynamic
compartments (MDCs and HDCs), showed higher alteration in TamR cells (Figure 4.3B). Furthermore, the looping gene signatures enclosed in these two altered dynamic
domains were highly enriched with GO terms cancer invasion and aggressiveness or
metabolism. All of these biological processes captured the nature of acquired resistant
breast cancer cells54.
Our definition of 24 patterns or six types of dynamic changed compartments were
based upon how re-compartmentalization in MCF7 cells respond to E2 induction.
Interestingly, the resulted six types are identical to the analysis based on a mathematical
calculation resulting in a total of 256 combinations of E2-induced time-dependent
compartments (Appendix D-3) when using T0 as a contrast. Furthermore, we observed
the same trends of E2-induced time-dependent compartments in both MCF7 and T47D
cell lines, where the major trend are miscellaneous dynamic compartments in both MCF7
and T47D cell lines. Moreover, the altered compartments of both MCF7-TamR and
T47D-TamR have higher percentage of miscellaneous compartments. Our results suggest
that our analytical strategy and observations are generalizable in various cell lines.
Our findings further illustrated an anti-correlative trend of binding enrichments
between intradomain ERα sites and boundary CTCF sites (Figure 4.4-D and E).
Interestingly, the average of CTCF sites is generally lower regardless of its distance from
the boundary in these highly dynamic changed domains. Although our result is not so
surprising, it nevertheless implicates an underlying molecular event that ERα regulated
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high re-compartmentalization may be required to loosen CTCF insulator at the domain
boundary4,55. Furthermore, our data may support the higher-order chromatin architectural
role of ERα signaling in mediating hormonal activity, expanding our current
understanding of the molecular mechanism underlying the E2-induced breast
carcinogenesis through ERα regulation.
Collectively, our observations suggest a possible molecular mechanistic model
(Figure 4.7-A-D). A constitutive estrogen stimulation in breast cancer cells enhances
stronger ERα activity and further recruits its distal regulatory machinery including
different co-regulators, mediators, cohesions and chromatin remodelers, and then
mobilizes highly dynamic gene looping events which essentially expand to render a 3D
genome re-compartmentalization accompanying with lower CTCF binding at the
compartment boundary. In contrast, in breast cancer cells with the acquired resistance,
increased crosstalk between ERα and other signal transduction pathways such as
EGFR/HER256, IGF-IR53, and AKT/PTEN57 or altered expression of some key coregulators particularly reshuffle these highly dynamic gene looping resulting in altered
chromatin reorganization. To substantiate this model, we propose further functional or
mechanistic experiments in our follow up studies: 1) establishing genome-edited TamR
sublines by editing out a handful ERα sites selected from 599 gene loops using the
CRISPR/Cas9 technique58; in these sublines, examining the changes of ERα regulated
looping using ChIP-3C-qPCR and determining if resistant cells are re-sensitized; and 2)
establishing an in vivo model of TamR xenografts44; in this model, examining selected
ERα regulated loops using ChIP-3C-qPCR by comparing untreated vs. treated Gefitinib,
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an inhibitor to EGFR/HER2. With these results, we might expect to elucidate the detailed
3D ERα regulatory role in mediating tamoxifen resistance.
In summary, the high quality and large 3D chromatin data along with many ChIPseq and RNA-seq data provided a comprehensive resource for understanding how
estrogen exposure drives genome-wide 3D chromatin reorganization in ERα positive
breast cancer cells as well as how their alterations occur in hormone resistant cells. Our
integrative analysis reveals temporal dynamic patterning and 3D chromatin
reorganization of the breast cancer genome that occurs in response to E2 stimulation over
time. Our work may give further insight into the effective treatment strategies to
overcome tamoxifen resistance and discovery of novel epigenetic therapeutic targets.

Methods
Cell lines and reagents
The human parental MCF7, T47D and Tamoxifen Resistant (TamR) cell lines
were derived from Osborne et al. 199444. MCF7 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
2mM L-glutamine and 1% penicillin/streptomycin (pen/strep) until 90% confluent. For
temporal estrogen responsiveness, MCF7 cells were hormone-starved for 72hrs followed
by the addition of 100nM β-Estradiol (MP Biomedicals, Inc.) at 1hr, 4hr, 16hr and 24hr.
To hormone starve MCF7 or T47D cells, these cells were grown to 80% confluency as
described above. Once the desired confluency was reached, the cells were washed one
time with Phosphate Buffered Saline and the media was replaced with phenol-red free
DMEM supplemented with 5% charcoal-stripped FBS, 2mM (L-glutamine) and 1%
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(pen/strep). For the 0hr time point, cells were immediately crosslinked following 72hrs of
hormone starvation.
TamR cells were cultured in phenol red free DMEM supplemented with 10%
charcoal-stripped FBS, 2mM L-glutamine, 1% pen/strep, and 100nM Tamoxifen (SigmaAldrich). Tamoxifen was replenished every 48hrs and cells were crosslinked at 90%
confluency.

Tethered chromatin capture (TCC)
TCC was performed as Kalhor et al. described40. Approximately 50 million
MCF7 or T47D cells (either parental hormone starved with temporal addition of βEstradiol (E2) or TamR cells as described above) were crosslinked with 1%
formaldehyde for 10 minutes at room temperature, crosslinking was quenched with 0.125
M glycine for 5 minutes at room temperature and cell pellets were collected and stored at
-80oC. The crosslinked cells were lysed with 550μL of Cell Lysis Buffer (10mM HEPES
pH 8.0, 10mM NaCl, 0.2% Igepal CA-630, containing 1X protease inhibitor cocktail
(Thermo Scientific #88665) and 1X PMSF (Acros Organics #215740050). The cells were
homogenized with a dounce homogenizer for 20 strokes with pestle A after incubation on
ice for 15 minutes. The lysate was then centrifuged at 2,500 rcf for 5 minutes at room
temperature. The supernatant was discarded and the remaining pellet containing the
nuclei was washed twice with ice-cold wash buffer #1 (50mM Tris-HCl pH8, 50mM
NaCl, 1mM EDTA) and resuspended in 250μL of wash buffer #1. The chromatin was
then solubilized by the addition of 95μL of 2% SDS followed by an incubation at 65 oC
for 10 minutes. The cysteine residues were biotinylated by the addition of 105μL of
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25mM EZlink Iodoacetyl-PEG2-Biotin (IPB) (Thermo Scientific #21334) and incubated
at room temperature for 1 hour while rocking. The SDS was neutralized with 1300μL of
1X NEBuffer 2 (NEB #B7002S) on ice for 5 minutes, followed by the addition of 225μL
of 10% Triton X-100, which was then incubated on ice for 10 minutes followed by a final
incubation at 37oC for 10 minutes. DNA was digested overnight at 37oC with the
following reagents: 100μL of 10X NEBuffer 2, 5μL of 1M DTT, 430μL of water, and
2000U of HindIII (100U μL-1; NEB #R0104M). To remove remaining IPB, the samples
were then dialyzed for 4 hours at room temperature using a Slide-A-Lyzer Dialysis
Cassette with a 20kD cutoff (Thermo Scientific #87735) in 1L of dialysis buffer (10mM
Tris-HCl, pH 8.0 and 1mM EDTA). The biotinylated chromatin was then tethered using
400μL of MyOne Streptavidin T1 beads (Invitrogen #65601) after washing the beads
three times with PBST (1X PBS containing 0.01% Tween20) and re-suspending in 2mL
of PBST. 400μL of washed Streptavidin T1 beads was then added into each of five equal
aliquots of dialyzed sample. Binding occurred at room temperature for 30 minutes
followed by the addition of 150μL of 25mM IPB neutralized with 25mM 2mercaptoethanol, which was then incubated at room temperature for 15 minutes. Noncrosslinked DNA and non-biotinylated chromatin was removed by washing the beads
once with 600μL PBST followed by one wash with 600μL wash buffer #2 (10mM TrisHCl, pH 8.0, 50mM NaCl, 0.4% Triton X-100). To wash the beads, we utilized a
magnetic rack and ensured beads bound to the magnet before aspirating the buffer out.
The beads were then resuspended in 100μL of wash buffer #2. The 5’ overhangs were
filled with 63μL water, 1μL 1M MgCl2, 10μL 10X NEBuffer 2, 0.7μL 10mM dATP
(NEB #N0440S), 0.7μL 10mM dTTP (NEB #N0443S), 0.7μL 10mM 2’129

Deoxyguanosine-5’-O(1-thiotriphosphate) sodium salt (dGTPαS) (Biolog Life Science
Institute #D031-05), 15μL of 0.4mM Biotin-14-dCTP (Invitrogen #19518-018), 4μL of
10% Triton X-100, and 25U Klenow-large fragment (NEB #M0210L) and rocked at
room temperature for 40 minutes. 5μL of 0.5M EDTA was added to stop the reaction and
the beads were washed twice with wash buffer #3 (50mM Tris-HCl pH7.4, 0.4% Triton
X-100, 0.1mM EDTA) and resuspended in 500μL of wash buffer #3. The crosslinks were
reversed with 400μL of extraction buffer (50mM Tris-HCl pH8, 0.2% SDS, 1mM EDTA,
100mM NaCl) followed by the addition of 400μg of proteinase K (NEB #P8107S) and
incubation for two hours at 65oC. The initial conformation capture library (the
supernatant) was extracted twice with an equal volume of phenol:chloroform:isoamyl
alcohol (25:24:1 v/v) and once with an equal volume of chloroform. NaCl was then
added to a final concentration of 20mM and glycogen to 2ug μL-1 followed by
precipitation of the DNA with the addition of 900μL of ethanol (200 proof) and
incubation at -20oC overnight. The DNA was pelleted via centrifugation at 20,000 rcf at
4oC for 20 minutes. The pellet was then immersed in 500μL of 80% ethanol and
centrifuged at 20,000 rcf for 10 minutes. The ethanol was removed and the pellet was air
dried until approximately 90% dry and resuspended in 20μL of 10mM Tris-HCl pH8.
The five aliquots were combined and the RNA was removed via RNAseA digestion
(10μg RNAseA) for 30 minutes at 37oC. The DNA was purified using the Invitrogen
Purelink Quick PCR purification kit (Invitrogen #K310001). Biotin from non-ligated
DNA was removed from 5μg of purified DNA using 300U EXOIII (NEB #M0206S),
adjusting the total volume to 90μL with 10X NEBuffer 1 (NEB #B7001S). This reaction
was incubated at 37oC for 1 hour. The reaction was stopped with 2μL of 0.5M EDTA and
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2μL of 5M NaCl followed by incubation at 70oC for 20 minutes. A Covaris Focusedultrasonicator (Covaris S220) was used to shear the DNA, with a duty factor of 5%, peak
power of 175W, and 200 cycles per burst. Each sample was sonicated for 180 seconds
and purified using the Purelink Quick PCR purification kit and eluted in 50μL of elution
buffer. Libraries were generated with the NEBNext Ultra II DNA Library Prep Kit for
Illumina (NEB #E7645L). First, end-repair was performed after sonication. 1μg of DNA
was used and the total volume of sample was brought up to 50μL with 0.1X TE. The end
repair was carried out as outlined in the manufacturer’s protocol. After end repair, the
biotinylated DNA was pulled down using 10μL of MyOne Streptavidin C1 beads
(Invitrogen #65001). The beads were first washed twice with 500μL of 1X Binding and
Wash buffer (for 2X Binding and Wash buffer: 10mM Tris-HCl pH7.5, 1mM EDTA, and
2M NaCl) and resuspended in 2X Binding and Wash buffer, which was then added to the
end-repaired DNA. Lo-bind tubes (Eppendorf #022431021) were used to prevent sticking
of beads to the sides of the tubes. The samples were rocked for 30 minutes at room
temperature. The beads were washed one time with 1X Binding and Wash buffer
containing 0.1% Triton-X100 followed by one wash with 10mM Tris-HCl, pH8 and the
beads were collected in 60μL of 10mM Tris-HCl, pH8. Next, adaptor ligation was
performed as described in the NEBNext Ultra II DNA Library Prep protocol, following
the instructions for 1μg of input DNA. After ligation of Illumina adaptors on the beads,
the beads were washed twice with 1X Binding and Wash buffer and twice with 0.1X TE.
The beads were resuspended in 30μL of 10mM Tris-HCl pH8. 15μL of the beads
containing adaptor-ligated DNA was transferred to a new tube and we continued on to
PCR enrichment of adaptor-ligated DNA on the beads. The remaining 15µL was saved
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and stored it at 4oC. The PCR was carried out as outlined in the NEBNext Ultra II
protocol, NEBNext Multiplex oligos for Illumina (NEB #E7335S and #E7500S) were
used for the individual barcodes and the enrichment was performed using 10 cycles.
45μL of the supernatant containing the PCR products was transferred to a new tube and
were cleaned using a 0.8X bead cleanup of the PCR reaction with Agencourt AMPure XP
beads (Beckman Coulter #A63881). The AMPure XP beads were brought to room
temperature and resuspended. 36μL of the resuspended beads were added to the libraries
and mixed by pipetting. The beads were incubated at room temperature for 5 minutes and
the supernatant was discarded. The beads were washed twice while on the magnet with
200μL of 80% 200 proof ethanol. After air-drying the beads, the library was eluted off
the beads with 23μL of 0.1X TE and transferred to a new tube. The final library was
quantified using a Qubit fluorometer (Applied Biosystems) and analyzed using a
Bioanalyzer (Agilent Technologies).

Chromatin immunoprecipitation sequencing (ChIP-seq)
The antibodies used for ChIP-seq were: H3K27ac (Abcam, Cambridge, MA,
USA; Ab4729 lot #GR238071-1), H3K27me3 (Abcam, Cambridge, MA, USA; Ab6002
lot #GR137554-5), H3K4me3 (Abcam, Cambridge, MA, USA; Ab8580 lot #GR2402141), H3K4me1 (Abcam, Cambridge, MA, USA; Ab8895 lot #GR114265-2), H3K9me3
(Abcam, Cambridge, MA, USA; Ab8898 lot #GR216368-1), ERα (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; sc-543X lot #J0313) and CTCF (Cell Signaling
Technology, Danvers, MA, USA; D31H2 lot#1). We performed duplicate ChIP-seq
experiments for each histone or factor using chromatin collected on different cell culture
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dates. For each histone ChIP-seq assay, 10μg of chromatin was incubated with (2.5-5μg)
of antibody. 150μg of chromatin was used for CTCF ChIP-seq (with 20μL of antibody)
and 250μg of chromatin was used for ERα ChIP-seq (with 12 μg of antibody). ChIP-seq
samples were prepared as O’Geen et al. described59 with minor adjustments. The cells
were crosslinked as described above for TCC experiments. The crosslinked cell pellets
were washed twice with ice-cold 1X PBS and stored at -80oC until sonication.
Crosslinked cell pellets were thawed on ice and resuspended in 1mL ice-cold cell lysis
buffer (5mM PIPES pH8, 85mM KCl, Igepal 10μL mL-1) containing 1X protease
inhibitor cocktail and 1X PMSF. After incubation on ice for 15 minutes the samples were
then homogenized using a 2mL dounce homogenizer fitted with pestle ‘B’, using 20
strokes. The samples were then centrifuged at 430 rcf for 5 minutes at 4 oC. The
supernatant was removed and the pelleted nuclei were lysed with 1mL ice-cold nuclei
lysis buffer (50mM Tris-HCl pH8.1, 10mM EDTA, 1% SDS) containing protease
inhibitors (1X protease inhibitor cocktail and 1X PMSF). The nuclei were lysed while
incubating on ice for 30 minutes. Sonication was performed for 12 minutes using a
Covaris Focused-ultrasonicator (Covaris S220) with a peak power of 140W, duty factor
of 10%, and 200 cycles per burst. The sonicated material was then centrifuged at 20,000
rcf for 15 minutes at 4oC and transferred to a new tube. To quantify the chromatin, 20μL
of the sonicated chromatin was added to 80μL of ChIP elution buffer (50mM NaHCO 3
and 1%SDS) followed by the addition of 12μL of 5M NaCl. The samples were boiled at
97oC for 15 minutes and 10μg of RNAseA was added to the tubes once the sample was
cooled to room temperature. The sample was incubated at 37oC for 10 minutes to allow
for RNA digestion. The reverse-crosslinked chromatin was then purified using the
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Purelink Quick PCR purification kit and eluted in 20μL of nuclease free water. After
quantification via a nanodrop (Thermo Scientific) the total chromatin yield in our
sonicated material was calculated. To visualize the fragment sizes of the sonicated
chromatin, we ran 1μg of purified chromatin on a 1.5% agarose gel. If the chromatin
fragments were concentrated around the 300-500bp range, we continued onto
immunoprecipitation. If under-sonicated, additional sonication was performed as needed.
500ng of purified chromatin sample was saved as our input samples, these samples were
brought to a total volume of 150μL with ChIP elution buffer and stored at -20oC. ChIP
for each target was carried out using the quantities of chromatin and antibody abovementioned. The chromatin for each target was diluted with 5 times the volume of ice-cold
1X IP dilution buffer (50mM Tris pH7.4, 150mM NaCl, 1% Igepal (v/v), 0.25%
Deoxycholic acid, 1mM EDTA pH 8.0) containing protease inhibitors. The appropriate
amount of antibody for each reaction was added and rotated overnight at 4 oC. The
antibody/chromatin complexes were captured by the addition of 150μL of protein A/G
beads (Pierce #88803), which were first washed twice with 1X IP dilution buffer, for the
transcription factor ChIPs and 15μL of protein A/G beads for the histone ChIPs. These
complexes were rotated at 4oC for 2 hours. Following incubation, the beads were
captured using a magnetic rack and washed twice with IP wash buffer #1 (50mM TrisHCl pH 7.4, 150mM NaCl, 1% Igepal (v/v) 0.25% Deoxycholic acid and 1mM EDTA,
pH8). The beads were resuspended in the wash buffer for each wash and the supernatant
was removed between each wash. The beads were washed three times with IP wash
buffer #2 (100mM Tris-Cl pH9, 500mM LiCl, 1% Igepal, and 1% Deoxycholic acid).
The beads were transferred to a new tube on the third wash. The complexes were then
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eluted off of the beads by the addition of 75μL of ChIP elution buffer while vortexing at
room-temperature for 30 minutes. The supernatant was transferred to a new tube and the
elution step was repeated. The ChIP input samples were thawed and 20μL of 5M NaCl
was added to the 150μL of final eluted complexes and to the input samples. Crosslinks
were reversed overnight at 65oC and the ChIPs were purified using the Purelink Quick
PCR purification kit and the samples were eluted in 35μL of elution buffer. We
performed qPCR against targets enriched for each of the ChIPs. The ChIPs were diluted
1:5 and the input samples were diluted to 1ng μL-1. 2μL of DNA was used for each PCR
and 1ng was used for the input sample. Primers against GAPDH were positive for CTCF
and H3K4me3; STX16 for CTCF; GREB1 for H3K4me1 and H3K27ac; TFF1 for
H3K4me1, H3K4me3 and H3K27ac; ZNF180 and ZNF333 for H3K9me3; HOXB2 for
H3K27me3; and HES3 for H3K27me3. ZNF333 and ZNF180 were negative targets for
CTCF, ER-α, H3K4me1, H3K4me3, H3K27ac, and H3K27me3. TFF1 and SHISA5 were
used as negative targets for H3K9me3.
ChIP-seq libraries were generated using the NEBNext ChIP-seq Library Prep
Master Mix Set for Illumina (NEB#E6240L) as per manufacturer’s protocol with size
selection for the insert size of 300bp. Half of adaptor-ligated DNA was saved at 4oC
before PCR enrichment of adaptor ligated DNA. PCR enrichment was done using 10
cycles and cleaned with AMPure XP beads at 0.9X as outlined in the protocol. The final
library was eluted off of the beads using 30μL of 0.1X TE and the quality was analyzed
with a bioanalyzer (Agilent Technologies).
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Chromosome conformation capture coupled with qPCR (3C-qPCR)
Experiments using 3C-qPCR experiment were conducted as Hagège et al.
described60. Ten million cells (MCF7 or TamR) were harvested and then fixed with 1%
formaldehyde for 10 min at room temperature followed by 0.2M glycine to quench the
reaction. Cells were lysed with 0.2% Igepal CA630 for 1hr on ice, then the pelleted
nuclei were solubilized with 0.3% sodium dodecyl sulfate (SDS) for 1hr at 37oC and
diluted with 2% Triton X-100 for 1 h at 37oC. The genomic DNA was digested with 400
U HindIII overnight at 37 oC and the digestion was stopped with 1.6% SDS for 20 min at
65oC. The digested nuclei were diluted with 1:1 volume of ligation buffer and then
ligated with 100U T4 DNA ligase. The ligated DNA was de-crosslinked with 300µg
proteinase K overnight at 65oC and purified by phenol–chloroform extraction. The 3C
template was dissolved in 10mM Tris-HCl and analyzed with the quantitative PCR.

Parental and TamR RNA sequencing (RNA-seq) sample preparation and processing
Total RNA were extracted using the ZYMO Research Quick-RNA MiniPrep kit.
Ten million MCF7 or MCF7-TamR cells were lysed in RNA Lysis Buffer followed by
removing the majority of gDNA with a Spin-Away Filter. The mixture of RNA and
ethanol were then loaded onto Zymo-Spin IIICG Column. Trace DNA was removed by
DNase I on the column followed by washing twice with RNA Wash Buffer. The total
RNA was eluted with 50 μl DNase/RNase-Free Water. RNA-seq libraries were prepared
with Illumina TruSeq stranded mRNA kit. 4µg of total RNA of either parental MCF7 or
MCF7-TamR cells was incubated with RNA purification beads and then washed with
bead washing buffer. The mRNA was eluted with elution buffer and then reverse
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transcribed with Superscript III reverse transcriptase. The first strand cDNA was
synthesized with first strand synthesis act D mix and the second strand cDNA was
synthesized with second strand marking master mix. After cDNA was synthesized, a
single adenylate was added to the 3’ end with A-tailing mix and adapters were ligated
with ligation mix. DNA fragments were enriched with PCR master mix and then purified
to build the DNA library. The library was sequenced with Illumina HiSeq 2000. The
differentially expressed genes were identified with CuffDiff61. The 50bp single end
sequencing reads were aligned with the Tophat module, and then transcripts were
assembled with Cufflinks. The transcript assemblies were compared to annotation using
the Cuffcompare and two or more transcript assemblies were merged with Cuffmerge.
Lastly, the differentially expressed genes and transcripts were found with Cuffdiff.

Identification of compartment patterns and types
All TCC data were analyzed with HiCLib python package10 to identify chromatin
compartment A or B. Paired-end reads of TCC data were iteratively aligned to the human
reference genome (hg19) by bowtie262 with the minimal sequencing length of 20bp and
the length step of 5bp in the module of HiCLib mapping. The following reads were
removed from the dataset in the HiCLib HiCdataset object: beginning with the 5bp range
from the restriction enzyme cut site; the duplicate molecules; the fragment pairs separated
by less than 2 restriction sites within the same chromosome; extremely large restriction
fragments (more than 10,000bp) and extremely small restriction fragments (smaller than
100 bp); both ends of the pairs starting at exactly the same positions; the top 0.5% most
frequently identified restriction fragments. At this stage the self-circles, dangling ends
137

and PCR duplicate reads were removed and a maximum molecule length of 500bp was
specified at the initiation of the object. The correlation of two replicates was computed as
the following: the counts of mapped reads pairs were accumulated at the 1Mb bin, and
then the correlation of these counts for each chromosome were calculated separately.
After filtering the reads, the frequency contact matrices were constructed at a bin size of
100kb with the HiCLib fragmentHiC module. The contacts between loci located within
the same bin were then removed from the raw heatmap. The bins with less than half of a
bin sequenced and the 1% of regions with low coverage were also removed. The top
0.05% of interchromosomal counts as the possible PCR blowouts were truncated
followed by iterative correction to get the ICE heatmap using the HiCLib binnedData
module. All bins of the ICE heatmap on a diagonal were removed with the HiCLib
binnedData module. The bins with less than half of a bin sequenced were also removed.
All cis contacts were set to zero to obtain only the trans contacts. The cis contacts were
forged in an interative way. After removing the bins with zero counts the eigenvector
expansion was performed with the HiCLib binnedData module to get the first
eigenvectors of compartments. The continuous genomic regions of positive first
eigenvectors were defined as compartment A (active chromatin), and the continuous
genomic regions of negative first eigenvectors were defined as compartment B (inactive
chromatin) individually at the 100kb scale. The compartments of five time points (T0,
T1, T4, T16, T24) were compared to identify the dynamic patterns (Appendix D-1).
First, two kinds of compartments: T0 vs. T1 Common and T0 vs. T1 Transit were
identified by comparing compartments of T0/T1. The Common compartments are the
overlapping compartments and the Transit compartments are differential compartments,
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which will be used in the following steps as well. Next, T0 vs. T1 Common and T0 vs.
T1 transit were compared with T4, T16, T24 independently to generate the (a) T0 vs. T1
Common vs. T4/T16/T24 Common, (b) T0 vs. T1 Common vs T4/T16/T24 Transit, (c)
T0 vs. T1 transit vs T4/T16/T24 Common, (d) T0 vs. T1 transit vs T4/T16/T24 Transit.
Thirdly the pattern 1-15 were produced by comparing the various time points (T4, T16
and T24) of last step subsets a, b, c, and d, which are vs. T4, vs. T16, vs. T24. The rest
subsets were divided into pattern 16-24 according to the numbers of converted bins.
Finally, 24 patterns were identified from the intersection and difference among subsets a,
b, c, and d. According to their biological meanings, these patterns were able to categorize
into six types of dynamic changed compartments (DCCs): HCC (patterns 1-4), ETC
(patterns 5-8), LTC (patterns 9-12), LDC (patterns 13-16), MDC (patterns 17-20), HDC
(patterns 21-24).

Computation of differential compartments
The variance of first eigenvector values of compartments identified in T0, T1, T4,
T16, T24 was computed at the 100kb scale. The difference of HCC/ETC/LTC/LDC with
MDC/HDC was determined by two-sided Wilcoxon rank-sum test for their averaged
variance of first eigenvector values. The estimate of False Discover Rate (FDR) of the
differential compartment between any two compartments was conducted by a
permutation-based test. In brief, the difference in Means of Eigenvector Values of each of
two compartments: Compartment 1 and Compartment 2, was first calculated as the
Observed Value. The Eigenvector Values of two compartments were then pooled
together and randomly selected one half as randomized Compartment 1 and the other half
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as randomized Compartment 2. This was done for a total of 1,000 rounds of permutation.
In each round, the difference in means of Eigenvector Values of each of two randomized
compartments was calculated as a Permutated Value. All permutated values were
combined into a null distribution. The FDR is estimated based on how many permutated
values are above the observed value and the permutated null.

Epigenetic states
ChIP-seq of H3K4me3, H3K27ac, H3K4me1, H3K27me3, and H3K9me3 data
sets from five time points of E2-induced MCF7 cells and TamR cells were aligned to the
human reference genome hg19. We then utilized the Java program ChromHMM v1.1745
to characterize chromatin epigenetic states by integrating the histone modification ChIPseq datasets to identify de novo major re-occuring combinatorial and spatial patterns
based on a multivariate Hidden Markov Model. The results of the model were then used
to systematically annotate genome-wide maps of chromatin states. After the ChIP-seq
data were mapped to the human genome, the BinarizeBam module was used to binarize
uniquely mapped reads into 1kb bins for model learning. The binarized data were then
trained with LearnModel and ten epigenetic states were finally identified with a minimum
p-value after averaging five training rounds. The emission and transition matrices were
visualized using R. The ten ChromHMM states were classified into three kinds of
epigenetic states according to the combination of histone marks with the p-value cutoff of
0.3 for emission matrices. The active states were defined by H3K4me3, H3K27ac and
H3K4me1, repressive states defined by H3K27me3, H3K9me3 and bivalent states
including both active and repressive states.
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Identification of ERα and CTCF binding sites
ChIP-seq data for ERα and CTCF were aligned to the human reference genome,
hg19. We then determined binding sites by peaks calling with MACS v1.4.246. The
identified peaks were coordinated to the various compartments and boundary regions to
obtain the coincident sites. The peak summits generated by MACS were defined as
binding sites for the subsequent analyses.

Differential binding analysis of ERα
We identified ERα differential peaks (DPs) with the R Bioconductor package
DiffBind v2.6.663,64 using TamR vs. T0/T1/T4/T16/T24 as the contrast. Within the
anlaysis, peaks were first enriched for genomic loci from ChIP-seq data and then read by
DiffBind. Next, overlaps of peaks were examined to determine how well similar samples
cluster together with the function dba.count. Then, overlapped reads in each interval for
each unique sample were counted with the function dba.contrast. Lastly, a contrast was
established and then the core analysis of DiffBind was executed by default using
DESeq265 with the function dba.analyze. Finally, the results were reported and plotted
with the function dba.report.

Time-series RNA-seq data analysis
Time-series RNA-seq data of E2-treated MCF7 cells 47 were acquired from
GSE62789. Five time points close to this study (T0 = 0 min, T1 = 40 min, T4 = 160 min,
T16 = 640 min, T24 = 1280 min) were selected and mapped to the human genome using
Tophat and gene expression was analyzed with Cuffdiff61. After gene expression values
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were normalized with log2 transformation, the variances were calculated between the five
time points. The normalized gene expression values of genes located at each
compartment types in five time points were visualized with the R program.

Significant Interaction Loops
The uniquely mapped paired-end reads were inputted into HOMER v4.749 to
generate the significant interaction loops. In brief, HOMER was originally developed for
a de novo motif discovery program and is now able to identify significant loops. The
HOMER analyzeHiC module was used to make interaction matrices, normalize
interaction counts and identify the significant interaction loops. The loops were further
filtered with a LogP cutoff of -6 and distance cutoff 20kb between loci centers.
Tamoxifen resistant differential loops of MCF7-TamR were obtained via the analyeHiC
module of HOMER using MCF7 T0 as the contrast with the cutoff of FDR<=0.1 and the
distance of loci pair center at 40kb to 5Mb.

Enrichment of KEGG pathway
Differentially expressed genes in various compartments were analyzed using
Gene Set Enrichment Analysis (GSEA) v3.048. Kyoto Encyclopedia of Genes and
Genomes (KEGG) were selected as the geneset database. Gene ranking was determined
by the ratio of log2 fold change to p-value of differential expression.
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Data availability
Raw and processed TCC, ChIP-seq and RNA-seq data for MCF7 and TamR cells
is deposited in GEO under the accession number GSE108787, and raw and processed
TCC data for T47D and TamR cells is deposited in GEO under accession number
GSE119890. The RNA-seq data of E2-treatment time series MCF7 is available at GEO
accession number GSE62789.
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Figures
Figure 4.1: Identification of E2-induced compartments in MCF7 cells at T1 versus T0
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Figure 4.1: Identification of E2-induced compartments in MCF7 cells at T1 versus T0.
(A) Pearson correlation of two biological replicates with the bin size of 1Mb, 500kb and
200kb on individual chromosomes at T0 (Top) and T1 (Bottom). (B) Contact matrices of
compartment A (Black) and B (Red) at T0 (Top) and T1 (Bottom) respectively. (C,D)
Histograms of compartments with different sizes at T0 and T1 respectively. (E)
Distribution of compartments A and B in T0 and T1 respectively. (F) The percentage of
common and transit compartments at T1 vs T0 with various bin sizes. (G) The number of
compartments of T1 vs. T0 with various shifted length when bin size is 100kb.
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Figure 4.2: Defining E2-induced temporal dynamic re-compartmentalization (TDRC) in
MCF7 cells
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Figure 4.2: Defining E2-induced temporal dynamic re-compartmentalization (TDRC) in
MCF7 cells. (A) An instructive tree displaying the comparisons of compartments A (Top)
and B (Bottom) at E2-induced five time-points. T0: control, T1: 1 hour; T4: 4 hours; T16:
16 hours; and T24: 24 hours. (B) Number of compartments at each of the 24 individual
patterns categorized into six types of altered compartments: HCC including patterns 1-4;
ETC including patterns 5-8; LTC including patterns 9-12; LDC including patterns 13-16;
MDC including patterns 17-20; HDC including patterns 21-24. (C) The variance of first
eigenvectors of compartment types in T0, T1, T4, T16, T24. The p value was determined
by the Wilcoxon rank-sum test. (D,E) Snapshots displaying examples of compartment
changes, MDC (D) and HDC (E) along five time-points of E2-induction. The
compartment of interest is indicated between the green dashed lines. The blue dashed
ovals highlight the dynamic region.
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Figure 4.3: Identification of altered compartments in TamR cells
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Figure 4.3: Identification of altered compartments in TamR cells. (A) The number of
tamoxifen resistant compartments along chromosomes in MCF7 TamR cells. (B) The
percentage of tamoxifen resistant altered compartments (TRACs), A (Top panel) and B
(Bottom panel) in TamR cells. The x axis displays the identified compartments after
comparison with the 24 states identified in responsive cells. (C) Genomic size of six
types of TRACs and tamoxifen resistant unaltered compartments (TRUCs). (D-F) UCSC
genome browser snapshots of TRACs and the enclosed genes within their loci. Dark:
Compartment A; Gray: Compartment B. (D) contracted compartment. Blue lines
represent the compartment boundary. (E) Expanded compartment. (F) Flipped
compartment.
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Figure 4.4: Epigenetic modifications within E2-induced TDRCs and TRACs
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Figure 4.4: Epigenetic modifications on E2-induced TDRCs and TRACs. (A) Emission
probabilities of ten epigenetic states trained by a HMM model on five histones. The
enrichment of the corresponding mark is indicated by higher values and corresponds with
a darker pink color. (B) Transition probabilities of ten epigenetic states trained by a HMM
model on five histones. The enrichment of the corresponding mark is indicated by higher
values and with a darker pink color. (C) The summary of the corresponding histone marks
and each of the defined epigenetic states. (D) The percentage of epigenetic states on
dynamic E2-induced compartment A. (E) The percentage of epigenetic states on altered
TamR compartment A. (F) The percentage of epigenetic states on dynamic E2-induced
compartment B. (G) The percentage of epigenetic states on altered TamR compartment B.
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Figure 4.5: A distribution of ERα and CTCF peaks in E2-induced TDRCs and TRACs
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Figure 4.5: A distribution of ERα and CTCF peaks in E2-induced TDRCs and TRACs.
(A) The number of ERα (Left) and CTCF (Right) peaks within altered and unaltered TamR
compartments. (B) Heatmap showing the percentage of altered TamR compartments A
(Left) and B (Right) with ERα peaks. (C) The average number of CTCF peaks on altered
TamR compartment boundary in E2-induced five time-points and TamR MCF7 cell lines.
(D) The distribution of each of the 24 patterns (circled) of ERα peaks within compartments
and CTCF peaks on compartment boundary.
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Figure 4.6. Gene expression and looping in E2-induced TDRCs and TRACs
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Figure 4.6. Gene expression and looping in E2-induced TDRCs and TRACs. (A) The
number of dynamic DEGs located in each of six types of TDRCs-A. (B) A plot of gene
expression values along five time-points in each of the six types of TDRCs-A. Each
green line represents one gene, and blue line represents the average gene expression
value. (C) The enrichment of KEGG pathways of 1,396 genes in MDC/HDCs-A. (D) The
heatmap of DEGs of TamR versus MCF7 in each of six types of TRACs-A. (E) The
number of loops defined by HOMER. Putative: putative loops identified by HOMER.
Promoter: one locus of putative loops within -5kb/+1kb of TSS. Enhancer: one locus of
putative loops within -5kb/+1kb of TSS and the other with either H3K27ac/H3K4me1
peaks. ERα: at least one locus of loops with an ERα peak located within a promoterenhancer region. Gene: genes associated with ERα-PE loops showing differentially
expressed genes at TA-MDCs-A and TA-HDCs-A. (F) The enrichment of KEGG
pathways of 396 genes associated 599 ERα-PE loops.
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Figure 4.7: A proposed model for dynamic 3D chromatin architecture
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Figure 4.7. A proposed model for dynamic 3D chromatin architecture. (A-C).
Constitutive estrogen stimulation in breast cancer cells enhances stronger ERα activity
and further recruits its distal regulatory machinery and then mobilizes highly dynamic
gene looping which essentially expand to render a 3D genome re-compartmentalization
meanwhile force CTCF eviction resulting in reduced insulation activity at the
compartment boundary. (D). In acquired resistant breast cancer cells, increased crosstalk
between ERα and other signal transduction pathways such as EGFR/HER2, IGF-IR, and
AKT/PTEN or altered expression of some key co-regulators particularly reshuffle these
highly dynamic gene looping resulting in altered chromatin reorganization.
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Chapter 5.1: Summary
Chromatin based-mechanisms involved in the establishment and maintenance of
cellular phenotypes are mediated by higher-order chromatin organization and post
translational histone modifications. These regulatory processes coordinate the recruitment
of protein complexes to specific genomic targets that result in gene expression
alterations. This dissertation seeks to employ integrative high-throughput methodologies
to investigate dynamic epigenetic changes in cancer cell models. Presented here are new
contributions to the field of cancer genomics where I investigate the effects of external
stimuli on higher-order chromatin structure, post translational histone modifications and
gene expression. In Chapters 2 and 3 I reveal dynamic epigenetic mechanisms in
pancreatic cancer cell models in response to epigenetic inhibitors. In Chapter 4, I present
my work in ER positive breast cancer cells where plasticity was observed during
temporal estrogen stimulation in cell models sensitive or resistant to tamoxifen. Taken
together, this dissertation reveals novel insight into dynamic epigenomic alterations that
occur with external stimuli and provides insight into mechanisms underlying the
therapeutic responses in cancer cells.

Chapter 5.2: Implications of epigenetic plasticity in pancreatic cancer cell models

5.2.1: Overall outlook and contributions to the field
The work presented in Chapters 2 and 3 ultimately present an analysis framework
for investigating genome-wide histone modification landscapes in relation to 3Dchromatin topology. Additionally, I provide characterization of broad epigenetic domains
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corresponding to histological grade and give insight into genome-wide domain targets of
epigenetic inhibitors. Lastly, this work provides datasets in pancreatic cancer cell-lines
that are now available for public use for studies desiring to investigate: (1) chromatin
contacts and (2) epigenomic (histone modifications and 3D chromatin architecture) and
transcriptomic alterations in response to ICG001 and C646. In section 5.2.4, I propose
future directions that can build on the studies presented here.

5.2.2: Defining chromatin contacts and chromatin states in PDAC cells
The goal underlying the first part of this dissertation seeks to characterize
genome-wide patterns of chromatin structure in pancreatic cancer cell-lines and to
investigate the effects of two epigenomic inhibitors on these regions (Appendix A,
Chapters 2 and 3). This work provides an important basis for future studies regarding
epigenomic regulation and the effects of epigenomic inhibitors on the cancer genome.
In Chapter 2 of this dissertation, I present the genome-wide interactions within a
widely used pancreatic cancer cell-line and functionally characterize these regions by: (1)
defining genome-wide chromatin contacts; (2) classifying the surrounding domains in
relation to histone modifications; (3) determining how histone acetyltransferase inhibitors
impact chromosomal organization; and (4) investigating these interactions in regard to
chromatin regulation mediated by transcription factor binding. This chapter demonstrates
a computational analytical approach to investigating higher-order chromatin regulation
data relating to histone modifications and gene expression to classify chromatin looping
events. For the first time in the literature, we present a genome-wide view of chromatin
domains in the extensively studied pancreatic cancer cell-line, PANC1. After classifying
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these domains with epigenetic histone modifications, annotating these defined states to
gene regions and correlating PANC1 gene expression with these classified domains, we
found that domains coordinating with active epigenetic states contained increased gene
expression patterns. Repressed epigenetic states corresponded with decreased expression,
providing confidence in our domain classification pipeline as these epigenetic states are
correlative of gene expression [1]. Modifications such as H3K4me1 are known to play a
role in gene repression [2] but when co-marked with H3K27ac this signature typically
corresponds to active enhancers [3]. While there are general trends between histone
modifications and chromatin state, it is imperative to further investigate chromatin
machinery within these mechanisms to gain further insight about underlying regulation.
In the next part of Chapter 2, I investigated changes in interaction domain loci in
response to two epigenetic inhibitors and associate these altered regions with gene
expression. In our initial study (Appendix A), we investigated the effect of two histone
acetyltransferase (HAT) inhibitors on the pancreatic cancer transcriptome and found
shared and independent targets of ICG-001 and C646. Recent reports have identified
C646 to help sensitize pancreatic cancer cell-lines to the canonical therapeutic agent used
to treat pancreatic cancer [4] and has shown efficacy in other cancers [5, 6]. Additionally,
the efficacy of ICG-001 has shown similar effect [7, 8] and has furthermore been
promoted its advancement to clinical trials (NCT01764477; NCT01606579;
NCT01302405). With the potential in reverting the cancer phenotype, little is known
about the impact of these inhibitors genome-wide. Our study highlighted in Appendix A
was the first study to characterize the effects of these inhibitors on the cancer
transcriptome. Chapter 2 builds on this study by investigating potential chromatin-based
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mechanisms that may be influencing the transcriptional targets of these inhibitors. While
changes in 3D chromatin topology has been observed in response to temperature stress
[9], the impact of epigenetic inhibitors on genome-wide contacts was not known. Our
characterization identified shifts in domains that were correlated with transcription factormediated regulation using TCF7L2. Ultimately, I suggest a potential mechanism by
which transcription factor associated chromosome interactions containing an active
epigenetic signature surrounding these regions are altered by epigenomic inhibition.

5.2.3: HAT inhibitors on broad epigenomic domains in PDAC cells
In Chapter 3, I further investigate the active histone modification landscape by
defining typical and broad H3K4me3 and H3K27ac domains in pancreatic cancer cell
models corresponding to histological grade. I then determine the impact of histone
acetyltransferase inhibitors on these histone modification domains in the high-grade
PDAC cell-line, PANC1, the model in which we explore their impact on the
transcriptome (Appendix A) and chromatin architecture (Chapter 2). Broad epigenomic
domains have recently been linked to cancer-related genes programs [10, 11]. Our
comprehensive analysis of super-enhancers and broad H3K4me3 domains in high- and
low-grade pancreatic ductal adenocarcinoma cell-lines revealed, for the first time, that
both of genome wide landscapes of these broad epigenomic domains have the ability to
correspond to distinct high and low histological grades. When correlating annotated
genes within the broad domains with gene expression in the given cell-lines, we find that
gene expression correlates with predicted patient prognosis. We observed global
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acetylation and methylation changes after histone acetyltransferase inhibitor treatment
and furthermore, alteration in broad domains.

5.2.4: Future Directions
Cell-lines are important tools for investigating multiple facets of cellular
mechanisms. However; performing these analyses in low-grade and additional high-grade
samples would provide additional insight into the aggressive phenotype of PDAC and
could also allow us to investigate potential mechanisms underlying the different cellular
phenotype of the individual cell-lines. Recent reports have characterized the PDAC
transcriptome, genome and epigenome in primary and metastatic PDAC samples as well
as patient derived xenografts of PDAC of the classical and basal subtypes [12, 13].
Integrating the domain characterizations and gene targets from our studies could narrow
down specific targets and candidates for further investigations. We examine the role of
TCF7L2 and for the first time, correlate this transcription factor with chromatin
architecture. However, its direct involvement in the aggressive phenotype in PDAC is not
well understood. TCF7L2 is a downstream transcription factor of this pathway, there are
other TCF/LEF family members that could be of importance. Furthermore, future studies
could incorporate additional transcription factor regulation to determine other regulatory
mechanisms and moreover the biology of PDAC. These could functionally be tested
through perturbation experiments of the given transcription factor or chromatin regulator
and the described experiments could be repeated and integrated with the current datasets
to infer direct regulatory roles. Future studies modulating target regions within specific
chromatin states would provide further insight into the functional significance of our
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associations. For example, the advancements in CRISPR/Cas9 technologies provides
tools for which we can edit the genome in order to explore molecular consequences. A
future study could utilize this technology to create a double strand break at a superenhancer or broad H3K4me3 region containing a gene potentially contributing to the
PDAC phenotype using a high- and low-grade cell model to determine the role these
epigenetic regions are playing on gene expression of the gene of interest. Additionally,
chromatin architecture data could be used to determine how the absence of this region
alters chromatin interactions nearby and further phenotypic studies could be carried out to
determine if targeting the broad region of interest provides clinical potential in reverting
the cancer phenotype. Ultimately, exploring the relevance would be best determined by
using human PDAC samples to interrogate these processes. In the realm of the genomewide effects of epigenetic inhibitors on chromatin regulation, additional cell models
should be used to gain insight into more generalized and cell-type specific effects of these
inhibitors genome-wide.

Chapter 5.3: Implications of chromatin dynamics in breast cancer cell models
5.3.1: Overall outlook and contributions to the field
The work presented in Chapter 4 of this dissertation provides a report of the
dynamics of 3D chromatin structure across a time course of estradiol (E2) stimulation in
human estrogen receptor α (ERα) positive breast cancer cells in tamoxifen sensitive and
resistant cells. In addition to these new revelations regarding chromatin compartment
regulated through temporal estradiol stimulation, we proved new high-throughput
datasets available to the general public for further investigations. These datasets include:
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(1) genome-wide 3D architecture, (2) ChIP-sequencing and (3) RNA-sequencing
throughout temporal estradiol stimulation in tamoxifen sensitive and resistant cells.

5.3.2: Dynamics during temporal estradiol stimulation
In Chapter 4, we present our study in estrogen receptor positive (ER+) breast
cancer, where we investigate the dynamics of 3D chromatin reorganization. Our
integrative genomic analyses using ER-α positive breast cell models provided new insight
into epigenomic regulation of ER+ breast cancer mediated by ER-α. Also, we investigate
epigenetic alterations in tamoxifen resistant derivatives. We observed genome-wide
changes in chromatin compartments (open or closed) in breast cancer cells hormone
starved followed by temporal stimulation of estradiol, an estrogen derivative. Moreover,
we characterized the changes over five estradiol induction periods with respect to histone
modifications and gene expression. Our results revealed coordinated changes in
chromatin compartments in tamoxifen resistant cells, where frequently changed
compartments were associated with increased ER-α activity. We identify ERα-bound
promoter-enhancer loops within altered compartments that are linked to TamR
differential gene expression. Ultimately, this large 3D-scale chromatin data provides a
rich resource for studying the basic characteristics of hormone-dependent breast cancers
and provides further insight into the mechanisms of tamoxifen resistance.

5.3.3: Future Directions
When identifying genome-wide compartmentalization changes, we used two
different ER+ breast cancer cell-lines, MCF7 and T47D. Our goal in this Chapter was to
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characterize these compartments and associate epigenetics and gene expression programs
with these compartments using the MCF7 cell line; however, since these two breast
cancer cell-lines are of the same classification and contain the same estrogen,
progesterone and Her2 expression [14] we utilized T47D to confirm that the
identification of estradiol-induced compartments were consistent between both cell-lines.
Future studies using more cell-lines with diverse subtypes will provide additional insight
into the biology of re-compartmentalization in breast cancer models. Additionally,
carrying these investigations further into human primary samples with matched clinical
controls will provide more clinical perspective into these dynamic mechanisms in
tamoxifen resistance. Future studies incorporating high-throughput proteomics data for
ER-α with our datasets can isolate specific candidates for additional functional studies
regarding ER-α mediated chromatin regulation. Additionally, disrupting an ER-α region
within the highly dynamic compartments will allow us to identify the potential
implications of ER-α within these regulatory regions that are highly altered in response to
estradiol and also largely changed in response to tamoxifen.

Chapter 5.4: Concluding remarks
Chromatin-based mechanisms including higher-order chromatin organization and
histone modifications have been identified to alter chromatin accessibility and directly
influence transcriptional programs and furthermore biological outcomes. This dissertation
seeks to characterize these domains in cell models for pancreatic and breast cancer and to
ultimately investigate epigenetic plasticity in response to different conditions. We
observed dynamic changes in chromatin structure in pancreatic cancer in response to
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epigenetic inhibitors and in breast cancer in response to estrogen stimulation. Future
work exploring the molecular consequences of these genome-wide alterations are needed
and furthermore, studies in primary patient samples will provide direct insight into
clinical importance and can help narrow down directed targets for phenotypic studies.
Additionally, 3D-FISH experiments can be designed in these models to confirm our 3Dchromatin findings. This dissertation ultimately provides insight into dynamic epigenetic
processes. Importantly, this work contributes large genomic datasets that are publically
available for the scientific community, which provides opportunities for new research
projects. These datasets can be combined with other publically available data to
investigate SNPS, other epigenomic modifications and additional DNA binding factors to
conduct further meta-analyses for mechanistic perspectives.
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Abstract
Background: Due to the hyper-activation of WNT signaling in a variety of cancer types,
there has been a strong drive to develop pathway-specific inhibitors with the eventual
goal of providing a chemotherapeutic antagonist of WNT signaling to cancer patients. A
new category of drugs, called epigenetic inhibitors, are being developed that hold high
promise for inhibition of the WNT pathway. The canonical WNT signaling pathway
initiates when WNT ligands bind to receptors, causing the nuclear localization of the coactivator β-catenin (CTNNB1), which leads to an association of β-catenin with a member
of the TCF transcription factor family at regulatory regions of WNT-responsive genes.
The TCF/β-catenin complex then recruits CBP (CREBBP) or p300 (EP300), leading to
histone acetylation and gene activation. A current model in the field is that CBP-driven
expression of WNT target genes supports proliferation whereas p300-driven expression
of WNT target genes supports differentiation. The small molecule inhibitor ICG-001
binds to CBP, but not to p300, and competitively inhibits the interaction of CBP with βcatenin. Upon treatment of cancer cells, this should reduce expression of CBP-regulated
transcription, leading to reduced tumorigenicity and enhanced differentiation.
Results: We have compared the genome-wide effects on the transcriptome after treatment
with ICG-001 (the specific CBP inhibitor) versus C646, a compound that competes with
acetyl-coA for the Lys-coA binding pocket of both CBP and p300. We found that both
drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and
PANC1 pancreatic cancer cells and reverse some tumor-specific changes in gene
expression. Interestingly, although the epigenetic inhibitors affect cell cycle pathways in
both the colon and pancreatic cancer cell lines, the WNT signaling pathway was affected
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only in the colon cancer cells. Notably, WNT target genes were similarly downregulated
after treatment of HCT116 with C646 as with ICG-001.
Conclusion: Our results suggest that treatment with a general HAT inhibitor causes
similar effects on the transcriptome as does treatment with a CBP-specific inhibitor and
that epigenetic inhibition affects the WNT pathway in HCT116 cells and the cholesterol
biosynthesis pathway in PANC1 cells.

Background
Due to the hyper-activation of WNT signaling in a variety of cancer types (1,2),
there has been a strong drive to develop antagonists of WNT signaling for cancer
treatment. Standard inhibitors of the WNT signaling pathway include biologic inhibitors,
such as small interfering RNAs, antibodies, and recombinant proteins, and chemical
inhibitors, such as NSAIDs, vitamins, and polyphenols, that have fairly general (or
unknown) targets (1,3,4). However, a new category of drugs to target the WNT pathway
is being developed that holds high promise as chemotherapeutics. These drugs, called
epigenetic inhibitors, function to modify chromatin structure. Chromatin is composed of
nucleosomes, which are comprised of 146 bp of DNA wrapped around eight core histone
proteins (two copies each of H2A, H2B, H3, and H4). The N terminal tails of the core
histones that constitute the nucleosome are subject to various different types of
modifications that can influence chromatin structure and either enhance or inhibit the
ability of transcription factors to bind to and regulate their target genes. The pattern of
histone modifications throughout the genome, in combination with the pattern of DNA
methylation, is called the epigenome. Recent studies have revealed that different histone
227

modifications are associated with active vs. silenced chromatin, that different cell types
show different epigenomic patterns of silenced vs. active chromatin, and that changes in
chromatin structure can have a dramatic effect on cell proliferation, differentiation, and
survival. One widely studied histone modification is acetylation; histone acetylation is a
critical regulatory mechanism of gene expression and plays an important role in gene
expression. In fact, acetylation of histone H3 on lysine 27 is the epigenetic modification
that most precisely identifies distal regulatory regions that serve as active enhancers (5).
Because cancer genomes show changes in histone acetylation patterns, there is great
interest in the use of acetylation inhibitors that inhibit signaling pathways linked to
human cancers for epigenetic therapy (6).
Drugs that inhibit acetylation are particularly relevant for inhibition of the WNT
pathway. The canonical WNT signaling pathway initiates when WNT ligands bind to
receptors, resulting in the nuclear localization of the co-activator β-catenin (CTNNB1),
which leads to an association of β-catenin with a member of the TCF/LEF transcription
factor family at regulatory regions of WNT responsive genes (7,8). The TCF/β-catenin
complex can interact with co-activators such as CBP (CREBBP) and p300 (EP300)
which function in part through the acetylation of histone H3 on lysine 27 (5). Thus, it has
been proposed that the initiation of the WNT signaling pathway ultimately ends with
histone acetylation and a relaxing of the chromatin structure, a process necessary for gene
activation. The small molecule inhibitor ICG-001 binds to CBP and competitively
inhibits the interaction of CBP with β-catenin (9,10), with the expected result of loss of
active histone at promoters and enhancers regulated by TCF/β-catenin/CBP complexes
(Appendix A-1A). Importantly, ICG-001 does not bind to the highly related histone
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acetyltransferase (HAT) p300 and should not affect the activity of promoters or
enhancers bound by TCF/β-catenin/p300 complexes. Thus, ICG-001 is thought to
specifically decrease the expression of only the subset of WNT target genes regulated by
β-catenin/CBP interactions. These proposed effects of ICG-001 are in contrast to those of
C646 an inhibitor that competes with acetyl-coA for the Lys-coA binding pocket of p300
(Appendix A-1B). C646 is very selective for p300 versus six other unrelated histone
acetyltransferases (11). Although no direct comparisons have been performed, due to the
mode of action of C646 and because the HAT domains of p300 and CBP have greater
than 90% similarity, it has been proposed that C646 is a general inhibitor for both CBP
and p300 (11). Of importance for the role of ICG-001 as a chemotherapeutic drug, studies
suggest that CBP-driven transcription helps to maintain pluripotency whereas p300driven transcription pushes cells toward a differentiated state (3,12-15); examples of
genes thought to be regulated by CBP vs. p300 are shown in Appendix A-1C. However,
the hypothesis that ICG-001 specifically downregulates only the subset of WNT target
genes involved in proliferation (such as BIRC5 and CCND1) has not been tested on a
genome-wide scale. Because a derivative of ICG-001 called PRI-724 is now in clinical
trials (NCT01302405 and NCT01606579), it is critical to have a thorough understanding
of the specificity and effectiveness of this drug. Therefore, we have compared the
genome-wide effects on the transcriptome of ICG-001 versus C646 in two cancer cell
lines that constitutively express the components of the transcription complex that
mediates WNT signaling (Appendix A-1D).
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Results
ICG-001 and C646 have similar effects on the transcriptome of HCT116 colon cancer
cells.
Constitutive activation of WNT target genes via a TCF/β-catenin/CBP complex is
thought to be a major driver of colorectal cancer. Therefore, it has been proposed that
treatment of colon cancer cells with ICG-001 should specifically inhibit the WNT
pathway (by preventing recruitment of the co-activator CBP to TCF/β-catenin target
genes) and reduce the tumorigenicity of the cells. In support of this hypothesis, Emami et
al. (10) have shown that ICG-001 reduces growth of colon carcinoma cells in culture and
reduces the formation of colon and small intestinal polyps in a mouse model system. As
noted above, CBP is highly related to another HAT called p300 and many studies have
shown similar functions for p300 and CBP (16). In fact, a ChIP-seq analysis of p300 and
CBP in T98G glioblastoma cells immediately after release from serum starvation arrest
showed that almost all of the CBP genomic binding sites were also bound by p300 (17).
However, under the tested conditions, a small set of genomic sites were preferentially
bound by either CBP or p300, suggesting that there might be some specificity in their
action. It is also possible that cell type plays a critical role in specifying CBP vs. p300
contributions to regulating the transcriptome. For example, approximately 50% of
Rubinstein-Taybi syndrome patients have mutations in CBP but only 3% of patients have
mutations in p300 (18). Of course, functional specificity can also occur post-DNA
binding because the two HATs only share extensive, but not complete, homology. If, for
example, CBP and p300 recruit different interaction partners they could have opposite
effects on transcription at a given promoter. In support of this hypothesis, Ma et al. have
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shown that both CBP and p300 can bind to the BIRC5 promoter but they have opposite
effects on transcription (19).
To determine if the effects on the transcriptome after specifically inhibiting CBP
are different than the effects after inhibiting both CBP and p300, we treated HCT116
colon cancer cells with 0.05% DMSO, 10 μM ICG-001, or 10 μM C646 for 12 and 96 h.
Samples were prepared in replicate and Illumina HumanHT-12 v4 expression arrays were
used to detect changes in gene expression (Appendix A-2). Genes having a detection P
value less than 0.01 in any of the control or treated cell populations were selected for
further analysis; this constituted a total of 15,092 genes from HCT116 cells, of which
3,689 showed differential expression in drug-treated cells (differential expression P value
less than 0.05). After selecting the significant differentially expressed genes, the
expression fold change was calculated for each gene and Euclidean distance was used for
K-means clustering of expression fold change (Appendix A-3). We found that, contrary
to our initial expectations, a very similar response was observed for both drugs. Genes
that were downregulated by both drugs were involved in the cell cycle and WNT
signaling (Appendix A-3). However, some genes did show drug-specific changes in
HCT116 cells. According to the mechanism of action of each drug, genes with decreased
levels of expression only after treatment with ICG-001 should be regulated by CBP but
not by p300, whereas genes with decreased levels of expression only after treatment with
C646 but not with ICG-001 should be regulated by p300 but not by CBP. A gene
ontology analysis of the approximately 400 genes affected only by ICG-001 revealed a
strong enrichment for genes controlling the cell cycle whereas the approximately 500
genes only affected by C646 were not related to cell proliferation. Thus, in HCT116 cells,
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both drugs have a broad effect on gene regulation that includes downregulation of genes
involved in proliferation control. However, treatment of colorectal cancer cells with ICG001 alters the expression of a greater number of cell cycle-regulated genes than does
treatment with C646.

ICG-001 and C646 have similar effects on the transcriptome of PANC1 cells.
As noted above, the WNT/TCF/β-catenin/CBP path- way has been proposed to be
a major positive regulator of proliferation of colon cancer cells. Perhaps β-catenin/ CBP
complexes play a prominent role in WNT-mediated gene expression in HCT116 cells
(with little contribution by β-catenin/p300 complexes), explaining why the effects of
ICG-001 were so widespread and why treatment with the two drugs elicited similar
responses. To determine if ICG-001 has a similar widespread effect on other cancer cells,
we also examined pancreatic cancer cells. Pancreatic ductal adenocarcinoma, the most
common form of pancreatic cancer, displays activation of the WNT/β-catenin pathway
(20-25) and is therefore predicted to respond to treatment with ICG-001. We treated
PANC1 cells with ICG-001 or C646 and analyzed gene expression. Again, we found that
ICG-001 and C646 have similar effects on PANC1 cells (Appendix A-4), with genes
involved in cell cycle regulation being down-regulated by both drugs. However, in this
case, cell proliferation-related genes were not enriched categories in gene sets
downregulated specifically by either ICG-001 or C646. Interestingly, in PANC1 cells, the
cholesterol biosynthesis pathway was highly enriched for genes specifically
downregulated by ICG-001, suggesting that perhaps genes involved in cholesterol
biosynthesis are specific CBP, but not p300, target genes. In contrast, p300-specific genes
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(identified as those responsive only to C646) appear to be involved in various types of
signaling pathways, including PI3K/AKT signaling which is linked to cell survival. To
determine if gene responses to the drugs were cell type-specific, we compared the genes
whose expression was altered by ICG-001 or C646 in both HCT116 and PANC1 cells (a
total of 6,732 genes). Genes that were significantly detected in HCT116 or in PANC1
cells (P value <0.01) and which had a differential P value <0.05 and a fold change
greater than 1.2 (5,182 genes) were compared using hierarchical clustering with
Euclidean distance and average linkage measures (Appendix A-5). We found that
although some genes were altered in a cell type-specific manner, most genes were
similarly affected in both cell types. A gene ontology analysis revealed that the top two
categories of genes downregulated by ICG-001 or C646 in both HCT116 and PANC1
cells were oxidative phosphorylation and mitochondrial dysfunction. Genes that were
commonly upregulated by the drugs in both cell types are involved in pathways such as
death receptor signaling and INOS signaling.

Effectiveness of the epigenetic inhibitors in reverting a tumor cell phenotype.
The ultimate goal of epigenetic therapy is to revert the transcriptome from a
tumor-specific pattern of gene expression back to the expression patterns seen in nor- mal
cells. To determine the extent to which the epigenetic inhibitors ICG-001 and C646 are
effective in this goal, we obtained RNA-seq expression data for 41 normal and 274 tumor
colon cells from the TCGA Consortium. Using this data, we identified 16,416 genes that
were expressed in either normal or colon samples, using log2 (RSEM + 1) >2. Of these,
11,824 genes were differentially expressed (adjusted differential P value <0.001) in the
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tumor samples as compared to the normal tissues. To determine if the drugs were
effective in reverting the expression of these genes back to normal levels, we compared
the set of genes deregulated in the tumors with the set of genes responsive to the drug
treatments, identifying a set of 2,028 common genes. If the drugs are having an antitumor effect, then genes that are up- regulated in tumors should be downregulated by the
drugs and genes that are downregulated in tumors should be up- regulated by the drug.
Using a log2(RSEM + 1) cutoff of 2, we identified 2,029 genes that showed expression
changes (adjusted P value <0.05) in colon tumor cells, as compared to the normal tissues.
An analysis of these expression patterns (Appendix A-6) shows that many genes had
expression changes in the correct direction as a result of treatment with at least one drug
(that is, a gene that is upregulated in tumors was down- regulated by a drug or a gene that
is downregulated in tumors was upregulated by a drug). Analysis of four normal and 125
pancreatic tumor samples revealed a much smaller set of genes showing expression
changes in tumors. Using a log2(RSEM + 1) cutoff of 2, we identified only 167 genes
that showed expression changes (adjusted P value <0.05) in pancreatic tumor cells, as
compared to the normal tissues. It is unclear as to whether the small number of
differentially expressed genes in the pancreatic tumors as compared to the colon tumors
is due to real differences in cancer phenotypes, to the small number of normal pancreatic
samples, or other possibilities such as tumor heterogeneity. To increase the number of
analyzed genes, we also obtained a list of 596 genes that are differentially expressed in
normal hTERT-HPNE pancreatic cells as compared to PANC1 cells (26). We examined
the responses of the 167 genes that are differentially regulated in normal pancreatic tissue
vs. tumors and the 596 genes that are differentially regulated in normal HPNE cells
234

grown in culture vs. PANC1 cells to drug treatment. We found that many of the genes
whose expression is deregulated in pancreatic tumors or PANC1 cells showed
appropriate responses to at least one drug (that is, genes upregulated in tumors or PANC1
were downregulated by the drugs and genes downregulated in tumors or PANC1 were
upregulated by the drugs) (Appendix A-6). Thus, treatment with the epigenetic
inhibitors is effective in reverting some of the tumor-specific transcriptome to a normal
pattern.

Direct targeting of a component of the transcription complex that mediates WNT
signaling.
As described above, ICG-001 was developed to be a specific inhibitor of the
WNT pathway. We therefore directly analyzed the WNT pathway using a list of genes
previously implicated as components of this pathway (http://www.
stanford.edu/group/nusselab/cgi-bin/wnt/). We found that a subset of these proposed
WNT target genes were expressed in HCT116 and/or PANC1 cells and were significantly
affected by treatment with ICG-001 or C646 (Appendix A-7). The overall trend of the
effects of ICG-001 and C646 on WNT targets was similar in a given cell line. However,
the WNT pathway-related genes responded quite differently to the epigenetic inhibitors
in the different cell lines. In general, the response of the genes listed in Appendix A-1C
was more similar to what was predicted when HCT116 cells were treated with the
epigenetic inhibitors than when PANC1 cells were treated with the drugs. For example,
expression of the transcription factor JUN (which is involved in specifying differentiated
phenotypes) is increased by both drugs in HCT116 but is decreased by both drugs in
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PANC1. Conversely, the expression of MYC, a transcription factor involved in cell
proliferation, is reduced by both drugs in HCT116 but is increased by both drugs in
PANC1 cells. The gene ontology results suggest that ICG-001 and C646 affect the WNT
pathway in HCT116 cells but not in PANC1 cells. Of course, it is also possible that
different downstream target genes mediate the WNT pathway in pancreatic cancer cells
as compared to colon cancer cells. The HATs CBP and p300 are brought to genomic
regulatory elements by the DNA binding protein TCF7L2 via interaction with the
bridging protein β-catenin. If ICG-001 and C646, which block the recruitment or
function of the HAT activity of the co-activators CBP and p300, are specific inhibitors of
the WNT signaling pathway in PANC1 cells, then targeting TCF7L2 should result in
similar effects on the transcriptome as does drug treatment. In contrast, if the epigenetic
inhibitors are in fact targeting a different pathway in PANC1 cells, then genes affected by
reduction of TCF7L2 should be different than the set of genes affected by the drugs. To
identify genes affected by direct targeting of a component of the transcriptional complex
implicated in WNT regulation, we used siRNAs to knockdown TCF7L2 in PANC1 cells.
Cells were treated with control siRNAs or siRNAs specific for TCF7L2 and RNA was
analyzed by RNA-seq. We analyzed the top 1,000 genes that were affected by
knockdown of TCF7L2 and the top 1,000 genes affected by treatment with ICG-001
(Appendix A-8). Interestingly, there were very few genes affected by reduction of
TCF7L2 that were also affected by ICG-001. Specifically, the WNT pathway was
identified in the set of genes affected upon reduction of TCF7L2 but not by treatment
with ICG-001 (Appendix A-4). These results suggest that in PANC1 cells co-activators
other than CBP cooperate with TCF7L2 to regulate gene expression and support the
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hypothesis that the anti-proliferative effects of ICG-001 in PANC1 cells are not due to
inhibition of the WNT pathway.

Discussion
Recent studies have shown large changes in the epigenomic patterns in normal vs.
cancer cells, suggesting that epigenetic therapy may be commonly applicable to
treatments of various cancers. Drugs that target epigenetic regulators are being developed
(27-29), some of which are moving into clinical trials. However, the specificity of action
of many of these drugs has not yet been thoroughly examined. In particular, genomewide analyses of their effects have not been determined. In our study, we compare the
effects of treatment with C646, which is thought to compete with acetyl-coA for the
Lys-coA binding pocket of both p300 and CBP (11) to the effects of ICG-001, which
specifically binds to CBP and prevents its interaction with the co-activator β-catenin.
Theoretically, ICG-001 is expected to be of higher specificity than C646 because it
should only affect β-catenin/ CBP-driven transcription whereas C646 should affect all
genes regulated by either CBP or p300, regardless of whether β-catenin is involved.
However, it is possible that ICG-001 has broader effects than anticipated if the drug
affects the ability of CBP to interact with other as- of-yet unknown co-activators. In
addition, we note that CBP and p300 can acetylate non-histone proteins (30); thus, both
compounds could also have effects on non- chromatin bound proteins. Although we
initially expected cells to respond differently to C646 and ICG-001, our results suggest
that generally these two drugs have similar effects on the transcriptome of tumor cells.
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However, we did identify some cell-specific and drug-specific responses after epigenetic
inhibition.
We observed dramatic effects on the transcriptome upon treatment of HCT116
colon cancer cells with either ICG-001 or C646, with thousands of genes showing
differential expression. Interestingly, the responses to the two drugs were quite similar
overall, with both drugs causing a reduction in certain genes involved in the WNT
pathway. Because ICG-001 affects only CBP-driven transcription and not p300-driven
transcription, these results suggest that perhaps the majority of the WNT-related active
regulatory elements in HCT116 cells are bound by β-catenin/CBP complexes. We did
identify a set of approximately 500 genes whose expression was down- regulated by
ICG-001 and not by C646 (these are potential CBP-specific target genes) and a set of
approximately 500 genes whose expression was downregulated by C646 but not by ICG001 (these are potential p300-specific target genes). These results are similar to a
previous study of CBP and p300 in T98G glioblastoma cells that found that the two
factors bound mainly to the same sites but that some specific binding sites could be
identified (17). Interestingly, the genes specifically responsive to ICG-001 but not to
C646 in HCT116 cells showed enrichment for cell proliferation-related gene ontology
categories. Taken together, these results suggest that thousands of genes are regulated
both by p300 and CBP (many of which are involved in cell proliferation) and that CBPspecific genes may also include additional genes that regulate cell proliferation whereas
p300-specific genes are involved in other processes. In general, our results in HCT116
cells support the current model implicating WNT-mediated cell signaling as a critical
regulator of cancer cell proliferation.
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Although the WNT pathway has been implicated in the development of pancreatic
cancer, the studies are not as extensive as those related to WNT’s role in colon cancer
(20-25). We show that, in general, the effects of ICG-001 and C646 on the transcriptome
of PANC1 cells are similar to those observed upon treatment of HCT116 cells. For
example, a set of genes involved in cell proliferation show reduced expression upon
treatment of PANC1 with either ICG-001 or C646. However, we did observe several
differences in the response of PANC1 cells to the epigenetic inhibitors, as compared to
HCT116 cells. First, we found that many of the enriched gene categories that responded
specifically to ICG-001 treatment of PANC1 cells are involved in cholesterol
biosynthesis. Interestingly, many cancers have a high dependency on accelerated
biogenesis and uptake of lipids and cholesterol and inhibition of these pathways has been
proposed to be a therapeutic opportunity for metabolic targeting of cancer growth
(31,32). Cholesterol homeostasis in mammalian cells is maintained in part by a basichelix-loop-helix family of transcription factors called the sterol regulatory element
binding proteins (SREBPs) (33,34). The SREBP family members activate a number of
target genes involved in cholesterol and fatty acid metabolism through binding to sterol
regulatory elements in the promoters of target genes. In fact, SREBP transcription factors
have been suggested to be novel therapeutic targets (35). Interestingly, SREBP proteins
require interaction with CBP to mediate transcriptional activation (36). Thus, the
treatment of PANC1 cells with ICG-001 likely disrupts a functional interaction between
CBP and a SREBP family member, causing downregulation of genes involved in the
cholesterol biosynthetic pathway (Appendix A-9). Second, in PANC1 cells the WNT
pathway was not enriched in downregulated genes after treatment with either drug and
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several critical WNT target genes showed unexpected transcriptional responses. Notably,
expression of JUN (which promotes differentiation) was predicted to be increased upon
treatment but in PANC1 cells JUN expression was decreased (JUN did show the
expected response in HCT116 cells). Similarly, expression of MYC (which promotes
proliferation) was predicted to be de- creased upon treatment but in PANC1 cells MYC
expression was increased (MYC did show the expected response in HCT116 cells). The
transcriptional response of the MYC gene was particularly surprising because it is
considered to be a critical mediator of WNT signaling. Upregulation of MYC in PANC1
suggests that the drugs do not inhibit the WNT pathway in these cells. This hypothesis is
supported by our finding that in PANC1 cells knockdown of TCF7L2, the transcription
factor that brings β-catenin and CBP to regulatory elements to regulate WNT-responsive
genes, does not affect expression of the same genes as are affected by treatment with
ICG-001. While our work was in progress, another group reported treatment of pancreatic
cancer cells with ICG- 001 (37). They showed that treatment of PANC1 cells with 10uM
ICG-001 was effective at reducing cell proliferation in culture and reducing colony
formation in soft agar. Al- though global effects on the PANC1 transcriptome were not
examined in that study, the noted effects on proliferation are consistent with our finding
that cell cycle-related genes are downregulated in response to ICG-001 and C646. That
study did, however, perform microarray expression analysis after treatment of a different
pancreatic cancer cell line (AsPC-1) with ICG-001 and found that 569 transcripts were
upregulated and 150 transcripts were downregulated. Because only 117 of the 719 drugresponsive genes were altered in β-catenin knockdown cells, they concluded that ICG-
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001 had a broader effect than simply as a disrupter of WNT/β-catenin signaling in AsPC1 cells.
As noted above, epigenetic inhibitors are considered promising new drugs for
cancer treatment. One current clinical trial employs PRI-724, a derivative of ICG-001, in
combination with gemcitabine in patients with advanced or metastatic pancreatic
adenocarcinoma (NCT01764477). Gemcitabine is considered a first-line treatment for
pancreatic adenocarcinoma but has poor overall efficacy because pancreatic cancer cells
develop resistance to the drug (38). While investigating the pathways that lead to drug
resistance, the transcriptional regulator NUPR1 (also known as anti-apoptotic protein p8
or Candidate of Metastasis-1) was identified as being involved in the acquisition of
gemcitabine resistance by pancreatic cancer cells (39). NUPR1 normally functions as a
stress response gene in the pancreas, but it has been shown to contribute to metastasis,
anti-apoptotic activity and pancreatic cancer development (40,41). Interestingly, our
genome-wide analyses identified NUPR1 as one of the top upregulated genes after
treatment of PANC1 cells with ICG-001. The upregulation of NUPR1 by ICG-001 may
explain why ICG-001 plus gemcitabine did not increase overall lifespan in an in vivo
pancreatic cancer cell xenograft model (37). Although the mechanism by which NUPR1
promotes oncogenesis and/or drug resistance in pancreatic cells is not yet known, NUPR1
has been shown to form a complex with p300 and TP53 to upregulate and promote
cytoplasmic translocation of CDKN1A (p21) in breast cancer cells (42). Although
nuclear p21 is a negative regulator of cell cycle progression, studies have associated
cytoplasmic p21 with drug resistance and oncogenic activity in breast and testicular
cancer (43-45). Vincent et al. (44) showed that treatment of NUPR1-expressing cells with
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PI3K-AKT inhibitors could reverse cytoplasmic p21 localization and re-sensitize cells to
doxorubicin. Importantly, studies have also shown that inhibition of the PI3K-AKT
pathway in pancreatic cancer helps re-sensitize cells to gemcitabine (46,47). Thus, adding
a PI3K-AKT inhibitor to the combined usage of ICG-001 plus gemcitabine may be the
most effective treatment combination. However, it should also be noted that C646 caused
only a modest increase in NUPR1 in PANC1 cells and that C646, but not ICG- 001,
specifically inhibited the PI3K-AKT pathway (see Figure 4). Taken together, these
results suggest that per- haps C646 plus gemcitabine would be more effective than ICG001 plus gemcitabine in the treatment of pancreatic cancer.

Conclusions
We have compared the genome-wide effects on the transcriptome of ICG-001 (a
specific CBP inhibitor) versus C646 (a compound that competes with acetyl-coA for the
Lys-coA binding pocket of both CBP and p300). We found that ICG-001 has a similar
broad specificity as C646 in HCT116 colon cancer, with both drugs decreasing the
expression of cell cycle-related and WNT pathway genes. In contrast, ICG-001 and C646
affect cell cycle- related genes but do not result in appropriate responses of critical WNT
target genes in PANC1 cancer cells. The effects of ICG-001 on PANC1 cells and
comparison to gene expression patterns in TCF7L2 knockdown cells suggests that ICG001 inhibits proliferation of pancreatic cancer cells via a mechanism different than the
WNT pathway. Gene ontology analyses point toward disruption of SREBP-CBP
functional interactions as a possible cause of the anti-proliferative function of ICG-001 in
pancreatic cancer cells. Importantly, both epigenetic inhibitors are effective at reversing
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some tumor-specific changes in gene expression that are observed in colon or pancreatic
tumor cells.

Methods
Cell growth conditions
The human cell lines HCT116 (ATCC #CCL-247) and PANC1 (ATCC #CRL1469) were obtained from the American Type Culture Collection. HCT116 and PANC1
cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin. Michael Kahn (University of Southern
California) provided ICG-001 and C646 was obtained from VWR (catalog # 102516–
240). Cells were treated with 10 μM ICG-001, 10 μM C646, or 0.05% DMSO and
collected after 12 or 96 h. Cells for the 12-h treatments were grown to 70% confluency
before addition of the drugs or DMSO. Cells for the 96-h treatments were grown at 40%
to 50% confluency before addition of the drugs or DMSO and were passaged before they
could reach 90% confluency. New media and drugs were added every 24 h. After
treatment, gene expression was analyzed using Illumina BeadChips.

Microarray RNA expression
Total RNA was collected using Trizol according to the manufacturer’s
instructions (Life Technologies). To confirm RNA samples were not degraded, RNA
quality was checked with the Experion StdSens kit (Bio-Rad) prior to amplification and
labeling. The Illumina TotalPrep RNA Amplification Kit (Life Technologies catalog #
AMIL1791) was used according to the manufacturer’s instructions to amplify and label
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RNA samples for Illumina array hybridization. Labeled RNAs were analyzed with
Illumina HT-12 v4 Expression BeadChips (Catalog #: BD-103-0204) with the Direct
Hybridization Assay and then scanned on an Illumina HiScan (catalog # BD-103- 0604).
The data were analyzed and exported from Illumina’s GenomeStudio software using
quantile normalization with- out background subtraction. Each drug/DMSO treatment
and time point was performed using two independent bio- logical replicates. The
correlation between replicates was calculated to ensure that the data were reproducible,
replicate samples were averaged together and genes with a detection P value <0.01 were
considered for further analysis. Differential expression analysis was performed using
Illumina’s custom differential expression error model, which assumes a normal
distribution of the target signal intensity and takes into account biological variation, nonspecific biological variation, and technical error. For more detail on Illumina’s custom
error model, see GenomeStudio Gene Expression Module v1.0 User Guide (pages 103
and 104). Genes with a differential expression P value <0.05 were considered to be
significantly differentially expressed.

TCF7L2 knockdown
TCF7L2 knockdown was performed in triplicate by siRNA transfection.
Transfections were performed using Lipofectamine RNAiMax (Life Technologies)
according to manufacturer’s instructions. A final concentration of 40nM siRNAs
targeting either TCF7L2 (catalog # 4392420, Life Technologies) or a non-specific
negative control siRNA (catalog # AM4611, Life Technologies) were used using reduced
serum OptiMEM media (Life Technologies). Media was changed 12 h post transfection
244

and total RNA was collected 48 h post transfection using Trizol according to
manufacturer’s instructions (Life Technologies). Knockdown efficiency was detected
using RT-qPCR and then samples were analyzed by RNA-seq.

RNA-Seq
Total RNA was used for polyA+ RNA selection using oligo-dT beads and
subjected to library construction by True-Seq library preparation kits (Illumina), followed
by Illumina HiSeq2000 sequencing. The RNA-seq reads were aligned to the human
genome hg19 using Bowtie2 with ultrasensitive parameters. The RNA-seq reads were
counted over gene exons using HTSeq (48). EdgeR was used for statistical analyses of
siControl and siTCF7L2 samples, and a fold change of 2 was used to call the
differentially expressed genes (49).

Ingenuity pathway analysis
Gene network diagrams in Appendix A-9 were created through use of IPA. The
expression data were analyzed through the use of QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). For each subset of
genes, a core analysis was run with parameters set to consider only direct relationships
and relationships between molecules that have been experimentally observed. The
reference gene set used for P value calculations was the Ingenuity Knowledge Base
(genes only).
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Data access
Expression array analyses for control and treated cells and RNA-seq datasets for
TCF7L2 knockdown experiments have been deposited in GEO (GSE64039 and
GSE63776). The TCGA RNA-seq can be downloaded at https://tcgadata.nci.nih.gov/tcga/tcgaDownload.jsp.
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Figures
Appendix A-1: Targeting the WNT pathway using epigenetic inhibitors
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Appendix A-1. Targeting the WNT pathway using epigenetic inhibitors. WNT
signaling culminates when, upon recruitment of β-catenin/CBP or β-catenin/p300
complexes to the DNA via a TCF/LEF family member, CBP and p300 activate
transcription by acetylating histone H3. (A) Treatment with ICG-001 disrupts the
interaction of CBP with β-catenin, blocking CBP-driven, but not p300-driven
transcription. (B) In contrast to the effects of ICG-001, C646 competes with acetyl-coA
for the Lys-coA binding pocket of both CBP and p300, preventing HAT activity of both
complexes. (C) Examples of predicted gene expression differences mediated by βcatenin/CBP vs. β-catenin/p300 complexes (15). (D) RNA levels in HCT116 and PANC1
cells of the various components of the WNT signaling model.
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Appendix A-2. The effects of epigenetic inhibitors on the transcriptome of HCT116 and
PANC1 cells

Appendix A-2. The effects of epigenetic inhibitors on the transcriptome of HCT116
and PANC1 cells. HCT116 colon cancer cells and PANC1 pancreatic adenocarcinoma
cells were treated in duplicate with DMSO or 10 μM ICG-001 or C646 for 12 or 96 h (12
samples per cell line). Cells were harvested and RNA was analyzed using Illumina
HumanHT-12 v4 expression arrays. Any gene having a detection P value <0.01 in any of
the samples was selected for differential gene analysis; genes having a differential P
value <0.05 were further analyzed. The number of upregulated (red) and downregulated
(green) genes under each condition for each cell line is shown.
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Appendix A-3. Effects of epigenetic inhibitors on gene expression in HCT116 cells
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Appendix A-3. Effects of epigenetic inhibitors on gene expression in HCT116 cells.
(A) Genes differentially expressed after treatment of HCT116 cells with ICG-001 or
C646 (see Figure 2) were analyzed using Euclidean distance and K-means clustering of
expression fold change. (B) Gene ontology analyses are shown for the genes commonly
up- and downregulated by both drugs and for the genes that are downregulated only by
one of the drugs in HCT116 cells. Terms related to the cell cycle are shown in red and
terms related to WNT signaling are shown in blue. The numbers 1 to 6 in the brackets in
panel A refer to different clusters that were used in the gene ontology analyses shown in
panel B.
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Appendix A-4. Effects of epigenetic inhibitors on gene expression in PANC1 cells
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Appendix A-4. Effects of epigenetic inhibitors on gene expression in PANC1 cells.
(A) Genes differentially expressed after treatment of PANC1 cells with ICG-001 or C646
(see Figure 2) were analyzed using Euclidean distance and K-means clustering of
expression fold change. (B) Gene ontology analyses are shown for the genes commonly
up- and downregulated by both drugs and for the genes that are downregulated only by
one of the drugs in PANC1 cells. Terms related to the cell cycle are shown in red. The
numbers 1 to 6 in the brackets in panel A refer to different clusters that were used in the
gene ontology analyses shown in Panel B.
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Appendix A-5. ICG-001 and C646 affect many of the same genes in HCT116 and PANC1
cells
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Appendix A-5. ICG-001 and C646 affect many of the same genes in HCT116 and
PANC1 cells. (A) Genes that were significantly detected in both HCT116 or in PANC1
cells (P value <0.01) were analyzed for expression differences caused by drug treatment.
All genes having a differential P value <0.05 and a fold change greater than 1.2 were
analyzed using Euclidean distance and hierarchical clustering. (B) Gene ontology
analyses are shown for the genes commonly up- or downregulated in HCT116 and
PANC1 cells by the drugs. Terms related to the cell cycle are shown in red.
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Appendix A-6. Epigenetic inhibitors can partially restore a normal expression pattern to
tumor cells

Appendix A-6. Epigenetic inhibitors can partially restore a normal expression pattern to
tumor cells. Genes that showed tumor-specific changes in expression in TCGA colon
RNA-seq samples (left), TCGA pancreatic RNA-seq samples (right, top), plus
differentially expressed genes identified by comparison of normal to tumor pancreatic
cell lines (right bottom) were analyzed for responses to drug treatments. In the T/N
columns, green indicates that the gene was downregulated in the tumor cells whereas red
indicates the gene was upregulated in the tumor cells. The blue brackets indicate genes
that were downregulated in the tumor cells and upregulated by the drugs (resulting in an
expression level closer to that in normal cells) whereas the black brackets represent the
genes that were upregulated in the tumor cells and downregulated by the drugs (resulting
in an expression level closer to that in normal cells). The color scale indicates the fold
change of gene expression in HCT116 or PANC1 cells after treatment with ICG-001
(ICG) or C646.
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Appendix A-7. Effects of drug treatments on WNT pathway genes
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Appendix A-7. Effects of drug treatments on WNT pathway genes. (A) Shown are the
expression changes in previously identified WNT pathway genes
(http://www.stanford.edu/group/nusselab/cgi-bin/wnt/) that have a detection P value
<0.01 and a differential P value <0.05 after 96 h of treatment of HCT116 or PANC1 cells
with either ICG-001 (ICG) or C646. (B) Shown are the predicted results (based on the
model shown in Figure 1) and the actual responses to the drugs after treatment of
HCT116 or PANC1 cells for a set of WNT target genes. In the prediction column, a red
arrow indicates that the gene should have been upregulated by ICG-001and the green
arrow indicates that the gene should have been downregulated by ICG-001, according to
the model. For each cell type, the actual response is shown for both drugs: a red arrow
indicates that expression was increased as predicted by the model, a green arrow indicates
expression was decreased as predicted by the model, a gray arrow indicates that the
expression pattern upon treatment did not correspond to the prediction, and an x indicates
that the gene was not expressed in that cell line.
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Appendix A-8. In PANC1 cells, treatment with ICG-001 does not affect the same genes as
does reduction in levels of TCF7L2
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Appendix A-8. In PANC1 cells, treatment with ICG-001 does not affect the same genes
as does reduction in levels of TCF7L2. (A) PANC1 cells were treated with siRNAs to
TCF7L2 and RNA-seq was performed. The top 1,000 differentially expressed genes after
knockdown of TCF7L2 were compared to the top 1,000 genes identified to be responsive
to ICG-001 in PANC1 cells. (B) Gene ontology analyses are shown for the genes
commonly up- and downregulated by knockdown of TCF7L2 and treatment with ICG001 and genes that are only affected by knockdown of TCF7L2. Terms related to the cell
cycle are shown in red and terms related to the WNT pathway are shown in blue.
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Appendix A-9: ICG-001 negatively regulates the cholesterol biosynthesis network

Appendix A-9: ICG-001 negatively regulates the cholesterol biosynthesis network.
IPA was used to show the rela0onships between SREBF1 and other genes involved in
cholesterol biosynthesis that are affected by treatment of PANC1 cells with ICG-001 or
C646. The arrows indicate direction interactions between the SREBF1 transcription
factor and the other genes. Each of the indicated genes was down-‐regulated (indicated by
the green color) by ICG-001 but up-regulated or unaffected by C646 (indicated by the red
color); fold change for each gene is shown in the table.
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Appendix B-1: Comparison of TCC and HiC TADs and boundaries

Appendix B-1: Comparison of TCC and HiC TADs and boundaries. A comparison of
the number of topological associated domains and TAD boundaries between PANC1 TCC
and HiC datasets.
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Appendix B-2: Visualization of Repeated HMM state S1/S7/S9

Appendix B-2: Visualization of Repeated HMM state S1/S7/S9. IGV snapshot of
S1/S7/S9 state.

270

Appendix B-3: Length distribution of topological domains in drug treated PANC1

Appendix B-3: Length distribution of topological domains in drug-treated PANC1.
Distribution of TAD length by chromosome for ICG001 (A) and C646 (B) treated PANC1
cells.
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Appendix B-4: Pearson correlation between sub-domain and change of sub-domain
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Appendix B-4: Pearson correlation between sub-domain and change of sub-domain.
Heatmap displaying the Pearson correlation scores for different domains and domain
changes.
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Appendix C-1: Identification of super-enhancers in PANC1 cells
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Appendix C-1. Identification of super-enhancers in PANC1 cells. A. Super-enhancers
were identified using Ranked Ordering of Super-Enhancers (ROSE) [5, 60], where
H3K27ac signal relative to input is ranked and visualized. The dashed line distinguishes
between typical-enhancers and super-enhancers. B. We visualized the signal of core
histone modifications including: H3K27ac, H3K4me1 and H3K4me3 within typical- or
super-enhancers relative to gene regions (proximal <5 kb and distal >5 kb from the TSS).
The signal is represented as log2 fold enrichment over input signal. C. Genome snapshots
of representative gene regions marked by super-enhancers in PANC1. D. Gene ontology
analysis for ‘Biological Process’ was performed for typical- and super-enhancers.
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Appendix C-2: Identifying Broad H3K4me3 domains in PANC1 cells
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Appendix C-2. Identifying Broad H3K4me3 domains in PANC1 cells. A. Broad
H3K4me3 domains were determined by MACS2 with the –broad flag activated. We then
ranked the size of the domains and visualized them. The dashed line represents the cutoff
of the top 5% of H3K4me3, which are defined as broad H3K4me3 domains. B. We then
investigated the signal of core histone modifications including: H3K27ac, H3K4me1 and
H3K4me3 within typical- and broad- H3K4me3 regions proximal (<5 kb) or distal (>5
kb) to TSS. C. Representative genome snapshots of regions containing broad H3K4me3
marks.
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Appendix C-3: Pathway analysis of super-enhancers and broad H3K4me3 domains in
different PDAC grade groups
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Appendix C-3. Pathway analysis of super-enhancers and broad H3K4me3 domains
in different PDAC grade groups. Gene ontology for PDAC grade groups within broad
regions.
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Appendix C-4: Gene expression relative to broad domains
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Appendix C-4. Gene expression relative to broad domains. Heatmaps showing the
relative expression levels of genes marked by A. super-enhancers, B. broad H3K4me3, or
C. both broad domains across 7 human PDAC cell lines. The number of genes belonging
to each domain type is indicated. HGU corresponds to High-Grade Unique and LGU
corresponds to Low-Grade Unique.
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Appendix C-5: The impact of ICG-001 treatment on broad H3K4me3 domains
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Appendix C-5. The impact of ICG-001 treatment on broad H3K4me3 domains. A.
Differential analysis of H3K4me3 genome-wide enrichment in PANC1 cells treated with
ICG-001. Significantly altered regions are indicated by the colored dots (FDR <0.1). B.
Genome browser snapshots of altered H3K4me3 regions. C. Differential binding analysis
of broad H3K4me3 regions. D. Venn diagrams showing overlap of super-enhancers and
broad H3K4me3 regions with increased histone modification levels.
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Appendix C-6: Chromatin-interacting domains in PANC1 cells
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Appendix C-6: Chromatin-interacting domains in PANC1 cells. A. Genome-wide
interaction matrix of chromosome contacts identified from TCC. B. Distribution of
identified domain types using TopDom (40 kb resolution).
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Appendix C-7: Domains with increased ChIP-seq signal after HAT inhibitor treatment
are enriched in boundary regions

Appendix C-7: Domains with increased ChIP-seq signal after HAT inhibitor
treatment are enriched in boundary regions. Feature enrichment analysis of superenhancers (A) and broad H3K4me3 domains (B) increasing or decreasing in signal.
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Appendix D-1: Identification of 24 patterns of dynamic compartments
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Appendix D-1. Identification of 24 patterns of dynamic compartments. The
continuous genomic regions of positive first eigenvector were defined as compartment A
(open chromatin) and the coutinuous genomic regions of negative first eigenvector was
defined as compartment B (close chromatin). The time series compartments (A or B
individually) were compared as follows: First, two kinds of compartments: T0 vs T1
Common and T0 vs T1 Transit were identified by comparing compartments T0/T1. The
“Common” compartments are the overlapping compartments and the “Transit”
compartments are differential compartments, which were used in the following steps as
well. Next, the common compartments identified from T0 vs T1 and Transit
compartments identified from T0 vs T1 were compared with T4, T16, T24 independently
to generate the (a) T0 vs T1 Common vs T4/T16/T24 Common, (b) T0 vs T1 Common vs
T4/T16/T24 Transit, (c) T0 vs T1 Transit vs T4/T16/T24 Common, (d) T0 vs T1 Transit
vs T4/T16/T24 Transit.Lastly, the patterns denoted as 1-15 were produced by comparing
the various time points (T4, T16 and T24) of subsets (a, b, c, and d) identified from the
previous step, which we refer to as “vs T4”, “vs T16”, “vs T24” as shown in the Venn
diagram. The rest of the subsets (X shown in Venn diagram) were divided into patterns
16-24 according to the numbers of converted bins (Suppl. Figure S15). Left column:
compartment A, right column: compartment B. In the Venn diagram, numbers without
parentheses are the numbers of compartments, numbers with parenthases are the patterns.

291

Appendix D-2. Validation of 3C-qPCR for HOMER loops

MCF7: MCF7 cell lines
MCF7Lp: MCF7L parental cells
MCF7L TamR: MCF7L Tamoxifen resistant cells
*: p < 0.05; **: p < 0.01, t-test

Appendix D-2. Validation of 3C-qPCR for HOMER loops. HOMER interaction loops
are named as genes located at the interaction loops. Three 3C-qPCRs were performed for
each loop. The MCF7L TamR group was compared with MCF7 or MCF7Lp by ANOVA
analysis.
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Appendix D-3. False Discovery Rate (FDR) and percentage of compartments

Appendix D-3. For each 100 kb bin, the p values of first eigenvectors of compartments
of T0 vs TamR, T1 vs TamR, T4 vs TamR, T16 vs TamR, T24 vs TamR were computed
by Wilcoxon rank-sum test. Then False Discovery Rate (FDR) was determined by the
adjustment methods of the Benjamini–Hochberg procedure.
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Abstract
Tacaribe virus (TCRV) is a mammalian arenavirus that was first isolated from
artibeus bats in the 1950s. Subsequent experimental infection of Jamaican fruit bats
(Artibeus jamaicensis) caused a disease similar to that of naturally infected bats.
Although substantial attention has focused on bats as reservoir hosts of viruses that cause
human disease, little is known about the interactions between bats and their pathogens.
We performed a transcriptome-wide study to illuminate the response of Jamaican fruit
bats experimentally infected with TCRV. Differential gene expression analysis of
multiple tissues revealed global and organ-specific responses associated with innate
antiviral responses, including interferon alpha/beta and Toll-like receptor signaling,
activation of complement cascades, and cytokine signaling, among others. Genes
encoding proteins involved in adaptive immune responses, such as gamma interferon
signaling and co-stimulation of T cells by the CD28 family, were also altered in response
to TCRV infection. Immunoglobulin gene expression was also elevated in the spleens of
infected bats, including IgG, IgA, and IgE isotypes. These results indicate an active
innate and adaptive immune response to TCRV infection occurred but did not prevent
fatal disease. This de novo assembly provides a high-throughput data set of the Jamaican
fruit bat and its host response to TCRV infection, which remains a valuable tool to
understand the molecular signatures involved in antiviral responses in bats.

Importance
As reservoir hosts of viruses associated with human disease, little is known about
the interactions between bats and viruses. Using Jamaican fruit bats infected with
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Tacaribe virus (TCRV) as a model, we characterized the gene expression responses to
infection in different tissues and identified pathways involved with the response to
infection. This report is the most detailed gene discovery work in the species to date and
the first to describe immune gene expression responses in bats during a pathogenic viral
infection.

Introduction
Bats are a phylogenetically and geographically diverse group of mammals, with
about 1,150 species (1, 2). Certain bat species have been identified as reservoir hosts of
zoonotic viruses associated with significant human morbidity and mortality, including
rabies virus and other lyssaviruses, Marburg virus, Nipah virus, and Hendra virus (3).
They also are suspected reservoirs of other viruses, such as the ebolaviruses, and Middle
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS)
coronaviruses (CoVs) (4–6). Each of these viruses can cause severe disease in humans
but are not known to cause disease in their reservoir hosts (3, 7). Although nearly 200
viruses have been associated with bats, there are likely many more (8). As non-model
organisms, virtually nothing is known about bat immune responses. Although bats appear
to have small genomes relative to other mammals (9), genomic analyses suggest that bats
share most features of other mammals (8, 10–12).
Despite serving as reservoir hosts of several zoonotic viruses, some bats are also
susceptible to infectious diseases. White nose syndrome, which has caused the deaths of
millions of bats in North America, is a fungal disease threatening some species with
extinction (13–16). Bats can shed rabies virus and other lyssaviruses for prolonged
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periods, but the infection is always fatal (3, 17–21). Because bats are important members
of their ecosystems, a better understanding of the immune responses and subsequent
pathogenesis to infectious agents is essential. To this end, we developed a laboratory
model for the study of infection of Jamaican fruit bats (Artibeus jamaicensis) by a natural
bat pathogen, Tacaribe virus (TCRV) (11, 21, 22).
TCRV is a mammarenavirus first isolated from two species of diseased artibeus
bats in the late 1950s near Port-of-Spain, Trinidad, and is most closely related to Junïn
and Machupo viruses, which cause Argentine and Bolivian hemorrhagic fevers,
respectively (23–25). Each arenavirus is associated with a specific host species, and the
distribution of the host therefore dictates the distribution of the virus. All known reservoir
hosts of mammarenaviruses are rodents; however, the reservoir host of TCRV remains
unclear. It was suspected that artibeus bats were reservoirs of TCRV given its original
isolation from multiple artibeus bats and the inability to detect it in other mammals (25–
27). Interestingly, TCRV was isolated from lone star ticks collected in Florida in 2012
(28). The tick-derived isolate was nearly identical to the TCRV isolate from Trinidad
(TRVL-11573), with 99.6% nucleotide identity across its genome (28). Recent studies by
our group found that TCRV causes fatal disease or is cleared without pathology in
Jamaican fruit bats, features that are inconsistent for a reservoir host (22). In many of
these bats, substantial neutrophil and lymphocytic infiltration into tissues occurred, which
suggests a role for these cells in the host response to TCRV (22).
The present study was designed to characterize the transcriptional responses of
bats with TCRV disease. Accordingly, we performed RNA sequencing of spleens and
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liver and kidney samples from experimentally infected bats and generated a broad bat
transcriptome rich in annotated genes. These target tissues were chosen because they
represent the organs with the most significant pathology in our previous report (8). This
report is the most comprehensive gene discovery work in the species to date and the
first to describe immune gene expression responses in bats during an arenavirus
infection.

Results
High-quality de novo assembly and annotation of the Jamaican fruit bat transcriptome
We previously reported a high mortality rate in Jamaican fruit bats experimentally
infected with TCRV, in which high-dose inoculations (106 50% tissue culture infective
doses [TCID50]) caused significant and fatal disease as early as 10 days post infection
(22). Histopathologic findings revealed multiple organ involvement in TCRV disease,
including acute neutrophilic splenitis and white pulp hyperplasia, as well as plasmacytic
and histiocytic splenitis. To profile the host pathogenic transcriptional response, we
generated stranded poly(A) Illumina RNA-Seq (transcriptome sequencing) libraries using
RNA extracted from the organs of experimentally infected bats. For this analysis, we
harvested the livers, kidneys, and spleens from 2 control bats (Dulbecco’s phosphatebuffered saline [DPBS] treated) and 2 TCRV-infected bats with fatal disease (Appendix
E-1). Our previous analysis indicated TCRV RNA was present in each of these tissues at
time of collection (22). A total of 12 pooled samples were sequenced, generating
693,106,150 raw 100-bp paired-end reads. After demultiplexing, trimming of poorquality reads and adapter sequences, and removing duplicate reads, 691,108,820
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nonredundant reads per sample were used for the transcriptome assembly. De novo
assembly of the global transcriptome was performed using Trinity, resulting in 349,855
assembled transcripts of greater than or equal to 300 bp (mean length of 997 bp) with an
N50 of 3,419 bases that were clustered into 175,144 nonredundant clustered transcripts
(unigenes) (Appendix E-2A) (29). Inspection of these unigenes identified from the
combined transcriptome showed that 35% of the contigs (12,600) are expressed in each
of the three different tissues (fragments per kilobase per million [FPKM]), whereas the
expression of many tissue-specific contigs was identified in the spleen, liver, and kidney
(Appendix E-2B).
The combined Jamaican fruit bat transcriptome was systematically annotated
using the Trinotate pipeline, a software suite that automates the functional annotation of
the assembled contigs (30). The annotation report for the combined assembly from the
Trinotate pipeline represents the predicted coding sequences of Jamaican fruit bat genes
and the results of homology searches against the databases listed in Data Set S1. Among
the 227,656 transcripts containing complete open reading frame (ORF) sequences,
124,204 non-redundant ORFs (54%) were associated with high-confidence coding
predictions, BLAST homology and PFAM domain content. We compared this combined
Jamaican fruit bat transcriptome assembly to those of other mammals through BLASTX
analysis. The bat Brandt’s myotis (Myotis brandtii) had the highest number of related
sequences (8,060 similar sequences). Among other mammals were the big brown bat
(Eptesicus fuscus) and the black flying fox (Pteropus alecto) (with 7,947 and 6,955
similar sequences, respectively) (Appendix E-2C).
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Differential gene expression following TCRV infection
To investigate the molecular response of bats to TCRV infection, differential gene
expression analysis was performed. We used a pairwise comparison of TCRV-infected
samples against the corresponding controls and found that the expression levels of
hundreds of different genes were altered during TCRV infection (Appendix E-3A). The
spleen had the largest number of differentially expressed genes (DEGs); among these
1,912 DEGs, 1,187 were upregulated and 725 were downregulated following infection
(Appendix E-3C; false discovery rate [FDR], =0.01; log2 fold change =2). We also
determined that the kidney and liver each had a greater number of upregulated genes (251
and 188, respectively) compared to the number of downregulated genes in these tissues
following TCRV infection (123 and 72, respectively). A comparison of all TCRVinfected tissues against all of the uninfected controls revealed 62 upregulated and 16
downregulated genes (Appendix E-3B and C).

Immune gene expression profile in response to TCRV infection
To gain specific insight into the immune-related gene expression altered in
response to TCRV infection, we utilized the ImmPort database to identify those TCRValtered genes that relate to immune-system functions (31). Approximately 23% of the
4,723 genes available in the database corresponded to the differentially expressed genes
annotated in our analysis. The coordinating transcript expression values of these
identified immune genes were used to evaluate the relationship between the specific
uninfected and infected tissues (Appendix E-4A). While all three tissue types studied
had unique expression profiles in the infected samples, we further analyzed the
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transcripts contained in cluster 3, which represent sequences with overall shared
expression patterns and found that these corresponding genes map to pathways identified
to be affected in response to viral infection (Appendix E-4B). Notably, with the use of
Ingenuity Pathway Analysis (IPA [Qiagen]), we identified the interferon (IFN) signaling
pathway to be among the top pathways altered upon TCRV infection. IFNs are a family
of cytokines secreted by host cells in response to viruses and other pathogens to confer
antiviral states upon uninfected neighboring cells in an effort to prevent spread of
infection (32). Given that the IFN response has been explored in bats in regard to
pathogen-host response (33), we then further examined the relationship between these
factors within the spleen, kidney, and liver in response to TCRV infection and found that
while most of the identified IFN pathway-related genes were upregulated, all of the
factors identified in this pathway had statistically significant differential expression (log2
fold change =2; FDR=0.01) in the spleen (Appendix E-4C). We validated differential
expression of select immune genes via reverse transcription-quantitative PCR (RT-qPCR)
and confirmed upregulation of ISG15 and IRF7 in the spleen and kidney tissues and
downregulation of HLA-DRA in the kidney.
In addition to the IFN-signaling pathway, we identified signaling pathways for
Toll-like receptors (TLRs) and interleukin-6 (IL-6) (among other cytokines), as well as
pathways for T-helper cell differentiation and the Th1 pathway (Appendix E-4B).
Further analysis of all DEGs via the Reactome plugin (Cytoscape) identified additional
key pathways involved in the immune response. Specifically, we identified increased
transcript levels of several cytokine genes (IL6, IL8, IL1A, IL1B, and IFNG) and
chemokine genes (CXCL1, CXCL2, CXCL3, CXCL5, and CXCL6). To highlight
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markers associated with circulating immune cells, we focused on those DEGs that were
common to two or more tissues, and the data are consistent with increased infiltration of
neutrophils into the infected tissues. In kidneys, neutrophil infiltration can cause hyperinflammation and kidney damage (34). This is further supported by the presence of
enriched expression levels of neutrophil gelatinase-associated lipocalin (NGALl) in all
three tissues, which is a biomarker for renal damage in humans (35).
Transcripts for IgG, IgM, IgA, and IgE were identified in the spleen data, and the
level of each was significantly elevated in the infected bats. Six transcripts of IgG heavy
chains were identified, including 5 with complete and distinct V regions. The six IgG
constant regions were identical, other than one that contained a Thr in place of an Ala,
which could represent an allele or a sequencing error. The hinge regions, which are
frequently different between IgG subclasses within a species, were identical in all 6
transcripts. These two features suggest that Jamaican fruit bats have a single IgG isotype.
The 5 V regions contain the canonical mammalian Ig sequences, including 4 framework
regions (FR) and 3 complementarity-determining regions (CDRs) (Appendix E-5). Three
distinct CDR3 sequences were present in these 5 transcripts. Two had 2 tyrosine residues,
whereas the three that were identical had 6, substantially more than what has been
reported in the CDR3s of other bat species (36, 37). Sequences for T-cell receptor alpha
constant region domains were present in the assembly, although none had complete V
regions. Expression of TCR-α was identified in all uninfected and infected tissues, TCRβ in all spleen and liver tissues, TCR-γ in all spleen and liver tissues, and TCR-δ in all
spleen and uninfected liver tissues.
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Gene ontology of annotated differentially expressed genes in TCRV-infected tissues
To characterize the overall transcriptome in response to TCRV infection, we
performed an unbiased evaluation of the top 10 Reactome pathways (ranked by
P value) associated with DEGs in various organs. In all three tissues, genes controlling
cell cycle progression were elevated, including many associated with hypoxia, cell stress,
senescence, and chromatin organization.
Spleen differential expression analysis indicated that immune system pathways
were significantly elevated, including type I and II IFN signaling, antiviral IFNstimulated genes (ISGs), interleukin signaling, and T and B cell activation pathways.
Interestingly, genes involved in the complement cascade were repressed, including the
genes for phosphatidylinositol 3-kinase and complement receptor 1. SH2B1, a gene
encoding an important signal transduction adaptor in several pathways, including JAK,
prolactin, platelet-derived growth factor, and nerve growth factor signaling, was also
significantly downregulated in the spleen (38). We also identified repression of proapoptotic genes BMP and PMAIP1 as well as repression of genes involved in calcium
mobilization following TCRV infection (39).
In the liver, Reactome analysis revealed strong immune activation signatures,
including T-cell receptor and CD28 costimulatory signaling. No evidence of B-cell or
NK cell activities was present. TLR and RIG-I/MDA5 signaling for type I IFN responses
was also elevated, despite no evidence of differentially expressed type I IFN genes.
Unlike the spleen, complement pathways were also enriched. The IFN-γ signaling
pathway was also identified, although IFNG itself was not differentially expressed.
Despite these findings, further indications of apoptotic activation were not differentially
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expressed in the livers. As in the spleen, many metabolic genes were elevated, whereas
genes involved in calcium mobilization were repressed. In the kidneys, Reactome
analysis suggested that platelet calcium-associated degranulation may occur; the genes
F13A1 and TMSB4X were elevated along with other genes involved in calcium
mobilization. As in the other tissues, evidence of innate antiviral responses was present,
including TLR signaling, RIG-I/MDA5 activity, and type I IFN signaling genes.
Interleukin and IFN-γ signaling were also among the pathways characterized secondary
to gene upregulation in the kidneys.

Discussion
Our previous work demonstrated that TCRV is pathogenic to Jamaican fruit bats
and has allowed us to perform the most complete examination to date of a pathogenic
virus infection in a bat species (22). Despite their importance to human health as
reservoirs of emerging viruses, the characterization of infections in bats at the cellular
and molecular levels has been limited relative to other model organisms, such as
rodents. Fortunately, the emerging advantage of next-generation sequencing technologies
has been fundamental to our understanding of disease responses; however, minimal
reference data sets are available for bats. To this end, our group was among the first to
perform next-generation sequencing on bats with a small-scale Illumina sequencing of
kidney and lung tissues in a single library from the Jamaican fruit bat (8,11).
Furthermore, in the present study we generated a high-quality transcriptomic data
set for the Jamaican fruit bat and comprehensively profiled the altered immune genes
in response to TCRV infection.
304

To gain insight into the pathogenic infection of Jamaican fruit bats, we performed
high-throughput RNA sequencing of TCRV-infected spleen, liver, and kidney tissues and
corresponding sham-inoculated controls. We produced high-quality non-redundant reads,
and our Trinity de novo assembly resulted in 349,855 transcripts, which were further
assembled into 124,204 contigs. The number of non-redundant contigs we identified is
similar to those from other transcriptome assemblies reported for the black flying fox
(126,378) (10), Rickett’s big-footed bat (104,987), and the greater short-nosed fruit bat
(171,394) (40).
We employed a pairwise comparison of all infected tissues versus shaminoculated controls to identify altered gene expression levels upon pathogenic TCRV
infection. We utilized a log2 fold change cutoff of >2 with an FDR of <0.01. We chose a
stringent cutoff because of our small sample size (n = 2) for each tissue type under each
condition. This revealed approximately 25% more genes upregulated than
downregulated. The spleen is instrumental in systemic and local immune responses and
has been used to study viral responses in many organisms, including bats (3, 41). We
observed the greatest number of differentially expressed genes in spleen tissues compared
to the liver and kidneys. Further analysis revealed that the majority of these differentially
expressed genes identified in the spleen belonged to immune-related pathways.
Ingenuity Pathway Analysis identified enrichment of the helper T cell
differentiation and Th1 pathway (Appendix E-4B) genes IFNG, IFNGR2, IL12RB2,
IL6ST, SOCS1, and SOCS2, supporting a role for mobilization of a Th1 response.
Despite this, levels of helper T cell genes, such as CD4 or T-cell receptor (TCR) genes,
were not statistically different in infected bats. CD4 sequences were not in the assembly,
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suggesting the CD4 level was below the threshold of depth of RNA-Seq. TCR-α, TCR-β,
TCR-γ, and TCR-δ sequences were present in the assembly, and they appear to share
features found in TCRs of other species. There was insufficient sequence data to evaluate
TCR variable, diversity, or joining segments for T-cell receptors. Further studies using
next-generation repertoire sequencing will be required to fully examine the TCR loci.
Unfortunately, without monoclonal antibodies to identify CD4+ or CD8- cells by flow
cytometry, it is difficult to determine whether T cells are expanding in response to
infection. Other indicators of T-cell activation include the elevated expression of
granzyme A and B genes (GZMA, GZMB), IL-12 and CCL5 (RANTES), and the
activated T-cell chemotactic factor gene CXCL1 in the spleens of infected bats.
Transcripts for IgG, IgM, IgA, and, interestingly, IgE were significantly higher in
the infected bats. IgE is not typically associated with viral infections, but has been
associated with anaphylaxis after influenza vaccinations (42–44). No transcripts for IgD
were present in the transcriptome, similar to what has been observed for other microbats
(45). Alignments of the 6 IgG transcripts were identical, except for one transcript that
had a Thr instead of Ala at position 395, which likely represents an allele or sequencing
error. Only one IgG transcript has been found in Seba’s fruit bat (Carollia perspicillata)
(45); thus, it is not unexpected that Jamaican fruit bats may only have a single IgG
isotype. The Jamaican fruit bat IgG shares 94% identity and 96% similarity with the
Seba’s fruit bat IgG constant region. The hinge regions of all IgG transcripts were also
identical and distinct from those of Seba’s fruit bat IgG. Hinge regions are generally
considered hallmark indicators of IgG subclasses (46). It is possible that Jamaican fruit
bats have IgG subclasses but without a genome or transcriptome profiling of Ig
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transcripts this question could be difficult to address.
The heavy-chain variable regions of the 5 Jamaican fruit bat transcripts showed
many differences, suggesting they represent distinct segments and multiple V region
gene families. The limited number of V regions makes it difficult to assign Jamaican fruit
bat sequences to gene families. We are unable to estimate the number of V, D, or J
segments with the transcriptome data; however, bats appear to have much larger
numbers of these segments than most mammals (36, 37). It is noteworthy that the
three CDR3 regions have more tyrosine residues than are found in most other bat
species immunoglobulins. The presence of tyrosines is thought to contribute to antibody
interactions with a spectrum of epitopes (47–49), and the lack of these in bat
antibodies has been postulated to account for why bats have generally poorer responses
to infectious agents (50, 51).
Only a single variable region light-chain sequence was significantly elevated in
the infected bats, which had most similarity to the IgLV7 variable gene family. Studies of
big brown bats (Eptisicus fuscus) suggest they express predominantly, if not exclusively,
λ light chains; thus our findings are similar (52). Considering that a single light chain was
elevated in infected bats, it may be possible to clone this cDNA and co-express it with
each of the 5 heavy-chain sequences described herein to determine if the antibodies
are reactive to TCRV antigens.
We also detected elevated expression of polymeric immunoglobulin receptor
(PIGR), which exports IgA antibodies across the epithelium into mucosa (53), in the
spleens of infected bats. Considering the presence of TCRV in oral and rectal swabs and
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in the lungs (22), it is likely that virus-specific IgA is present at these sites. The
development of antibodies to artibeus IgA will be necessary to verify this.
The principal gene for somatic hypermutation (SHM) that leads to affinity
maturation is activation-induced cytidine deaminase (AID) (54); however, despite its
presence in all four bats in this study, its expression was not significantly elevated in the
spleens. Other genes involved in SHM (54) were elevated, including those coding for
DNA polymerase θ (POLQ), polymerase (POLN), and replication protein A (RPA). The
level of APOBEC3, coding for another RNA-editing enzyme with lower SHM activity
(55), was not elevated. Examination of little brown bat (Myotis lucifugus) antibody
cDNA sequences suggests bats do not use SHM to a great extent (36), and our findings
are congruent with this observation. In our previous work with TCRV and MERS
coronavirus (CoV) infection of Jamaican fruit bats (22, 56), antibody responses were
poor, suggesting that affinity maturation is limited in bats.
Global differential expression evaluation of TCRV-infected tissues revealed
alterations in calcium mobilization, a characteristic mechanism of host response to
infection by viruses, including arenaviruses (57). Additionally, our analysis revealed few
indications of NK cell activation and minimal expression of genes that are associated
with T-cell exhaustion (i.e., Ly6e and Fcgr3). It is noteworthy that bats appear to be
missing many NK cell-associated genes (10, 58, 59); thus it may be that the functions of
bat NK cells are substantially different from those of human or mouse NK cells. We
detected increased IFNG, GZMA, and GZMB expression in the spleen infected tissues,
and while these proteins are produced by both NK cells and T cells, we believe their
presence correlates more strongly with a T-cell origin due to the increased number of T308

cell associated genes upregulated relative to NK cell genes. Moreover, the bats in this
report were euthanized on days 10 and 11, a time point at which T-cell activation should
be occurring. Thus, T-cell exhaustion, a feature of some lymphocytic choriomeningitis
virus (LCMV) isolates, is likely not occurring in bats infected with TCRV (60, 61).
We identified several genes associated with neutrophil activation. These results
areconsistent with our previous histopathological findings in this species, where we noted
neutrophilic infiltration that was likely a result of proliferating lymphocytes (22).
Additionally, our results are also consistent with a recent Lassa virus isolate from Mali
that similarly induces neutrophil infiltration in nonhuman primates (62). The abundant
expression of NGAL may provide a diagnostic tool; its protein, neutrophil gelatinase
associated lipocalin, is secreted in the urine, which is detectable with commercially
available diagnostic kits (e.g., Pacific Biomarkers, Seattle, WA).
A recent study looked at differential gene expression in an embryonic cell line
from Egyptian fruit bats infected with Marburg virus (63). In contrast to the observed
host responses in the Egyptian fruit bat cells, we identified the JAK/STAT signaling
pathway as one of the immune-related pathways upregulated in response to pathogenic
TCRV infection, suggesting a contributory role for this pathway in pathogenesis.
Additionally, a study exploring the innate immune response to Newcastle disease virus in
large flying fox cells, a newly characterized a subset of antiviral factors was found (64).
Among these factors was the CHAC1 gene, which we identified to be 4-fold upregulated
in spleen and kidney tissues. Together, this evidence along with our previous
pathogenicity studies shows that a typical antiviral response occurs to TCRV in Jamaican
fruit bats.
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We focused additional analyses on immune genes with similar expression in all
tissues (cluster 3 [Appendix E-4A]). Among the top pathways identified was the IFN
signaling pathway. The signaling factors in this pathway exert their antiviral activities
through the induction of other antiviral proteins (32). The IFN response has been
explored in bat cells (33), and in all bat species examined, the type I IFN locus has
undergone substantial contraction, with only three functional IFN-α genes but with
constitutive IFN-α expression in at least one species (65). Specifically, recent discoveries
have revealed enhanced IFN signaling in antiviral immunity and have identified its
involvement in arenavirus response mechanisms. We therefore furthered our analysis
regarding these pathways (51, 66). We found that most IFN signaling genes identified in
this subset were upregulated in all tissues; however, 5 of these genes had no significant
differential expression identified in the kidney and 2 had none in the liver. Notably, of the
differentially expressed factors, the IFNAR1 gene was downregulated in the spleen and
BCL2 was downregulated in the kidney. Apoptotic pathways play a critical role as
defense mechanisms for a host when infected by a viral pathogen; BCL2 encodes an antiapoptotic protein that is known to be involved in a typical antiviral response (67), and the
observed downregulation of BCL2 in the kidneys upon TCRV infection suggests
promotion of apoptotic pathways stimulated by IFN signaling in response to infection.
In contrast, BCL2 was determined to be upregulated in spleen and liver tissues.
Additionally, another anti-apoptotic factor gene, Mcl-1, was also upregulated in these
tissues. Recent work with mice infected with LCMV, as well as other studies, has
demonstrated the involvement of these factors in promoting naive T-cell survival and
memory T cell activation (68, 69). Together, these results support congruency of our
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annotated transcriptome given what is known about the coordination of immune genes
altered in response to viral infection as well as the identification of genes specific to the
antiviral response in bats (61).
As might be expected during an acute antiviral response, IFN-stimulated gene 15
(ISG15) was elevated in infected tissues. Reactome pathway analysis identified ISG15 in
several immune pathways, including the innate immune response, cytokine signaling,
IFN-α/β signaling, and RIG-I/MDA5-mediated induction of IFN-α/β pathways, which
has also been previously identified in a bat pathogenic viral response (64). ISG15 is an
important gene in the innate immune response, particularly the type I IFN antiviral
response; however, the ISG15-encoded protein has recently been demonstrated to have
additional functions as a ubiquitin-like modifier that covalently conjugates to other
cellular proteins to form an “ISGylated” complex (70). Various roles of ISG15 have been
identified in immune responses; when secreted extracellularly, ISG15 can act to drive
expression of IFN-γ, which was elevated in the spleen. Alternatively, intracellular
expression can modulate type I IFN signaling (71).
Although IFN-α, IFNB, IFNL, and IFNG transcripts were present in all of the
tissues analyzed, the only differentially expressed transcript was IFNG in the spleen. In
contrast, indications of downstream signaling initiated by IFN type I and type II were
present, suggesting either transcript turnover prior to the time of sample collections or the
potential for alternative routes of pathway activation. Previous work examining in vitro
infection of the black flying fox with Tioman virus suggests a prominent role for IFN-γ
(72). To this end, there are potential differences between bat species in terms of their
responses to viruses that may account for apathogenic infections (e.g., reservoir hosts) or
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disease. Future work with cell culture from our model system may help to clarify these
points. Furthermore, the DEGs involved in IFN-α/β signaling suggest that a typical
antiviral innate immune response occurred in the bats. Within the spleen, expression of
36% of the genes was upregulated in the IFN-α/β signaling pathway, whereas the
kidneys and livers had approximately 16% and 34% elevated expression of these same
genes, respectively. This indicates a more robust type I IFN response in the spleen.
Together, de novo transcriptome analysis of our high-throughput RNA-Seq data
from Jamaican fruit bats infected with TCRV provides a high-quality data set and also
a comprehensive gene expression analysis of immune gene expression responses in
bats during a pathogenic infection. This data set will provide a strong basis for additional
analyses. Further investigation of our identified pathways in vitro and in vivo will
significantly contribute to our understanding of pathogenic viral infections in bats.
Moreover, the data here will facilitate future experimental studies of artibeus bats and
their cells, which have been used as models for MERS CoV and Zaire Ebola virus and
which are suspected reservoirs of the recently discovered bat influenza viruses (56,73,
74).

Conclusion
This study provides a comprehensive analysis of the transcriptional landscape of
Jamaican fruit bats during infection with Tacaribe virus. This natural pathogen of artibeus
bats causes high-mortality disease with similar clinical manifestations to the South
American hemorrhagic fevers and Lassa fever. In summary, this analysis identified the
global response to TCRV infection. Our results suggest diverse immune responses,
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including alterations in neutrophil activation, interferon signaling, markers for
lymphocytes, and antibodies. We found substantial signatures of neutrophil activation in
the spleen, kidney, and liver of bats with fatal disease. The innate and adaptive immune
response appeared to be functional and typical of the canonical antiviral response. Many
activation markers of T and B lymphocytes were also found; however, few indications of
NK cell activity or T-cell exhaustion were apparent. IgG, IgM, IgA, and IgE sequences
were abundantly expressed in the spleens of infected bats, and five immunoglobulin
heavy-chain V segments were identified. Despite the clear evidence of antibody synthesis
during infection, AID expression was not elevated, suggesting somatic hypermutation
and affinity maturation were absent or minimal. Analysis of immunoglobulin heavychain and TCR V regions suggests that Jamaican fruit bats have canonical
immunoglobulin and TCR genes found in most mammals. Moreover, the species appears
to have a single IgG subclass. These results are the most extensive gene discovery work
completed in Jamaican fruit bats to date and the first to describe differential immune gene
expression in bats during a pathogenic virus infection.

Materials and Methods
Experimental TCRV infection in bats, sample collection, and RNA extraction
Experimental infections of Jamaican fruit bats were previously reported (22).
Briefly, two Jamaican fruit bats were inoculated with 100 μl of sterile Dulbecco’s
phosphate-buffered saline (DPBS) as negative controls (bat IDs 688 and 689), and two
bats were inoculated with 100 μl containing 106 TCID50 TCRV (bat IDs 714 and 729).
Negative control bats were euthanized at the end of the experimental period (45 days),
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whereas TCRV-infected bats were euthanized as they became moribund (days 11 and 18,
respectively). Necropsies were performed directly following euthanasia, and organs were
harvested and collected in RNAlater stabilization reagent (Qiagen). RNA was extracted
from flash-frozen tissues by homogenization with a Mini Bead Beater (BioSpec Products,
Inc.), using QiaShredder columns with the RNeasy kit (Qiagen).

RNA-Seq
Stranded Illumina libraries for each tissue were prepared from total RNA using
the NEB Ultra Directional RNA library prep kit with poly(A) selection. Sequencing
(paired-end 100 bp) was performed on the Illumina HiSeq-2000 platform at the UC
Denver Genomics core.

Read processing and assembly
For transcriptome assembly, raw reads were filtered for adapter sequences and
low-quality reads, and assembly was performed using Trinity (30) with the following
parameters: —min_contig_length 300 —min_glue 3—min_kmer_cov 2. Resulting
contigs were processed for read alignment and abundance estimation with Bowtie and
RSEM (75, 76). Differential expression was performed using the edgeR package within
the Trinity differential analysis pipeline using default parameters (77). A pairwise
comparison was made between TCRV-infected samples and control uninfected samples.
Genes were considered differentially expressed with an FDR of <0.01 and a log2 fold
change > 2.
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Gene ontology and pathway analysis
BLAST alignments and functional annotations were performed using Blast2GO
Pro or Ingenuity Pathway Analysis (78, 79). Direct pathway analysis for immune-related
genes was performed using the gene list from the ImmPort database (31).

Immunoglobulin sequence analysis
Contigs for immunoglobulins were translated using the default translation table of
MacVector software. MUSCLE alignments were made to identify leader, framework
regions, and complementarity-determining regions of the V segments using a black flying
fox sequence as a reference (NCBI GenBank accession no. ADD71702.1) (50). Heavy
chains and hinge regions were identified by BLAST against other Chiroptera.

RT-qPCR validation of RNA-Seq data
The experimental primer sequences used in RT-qPCR analysis are listed in Fig.
S2. cDNA was generated using SuperScript III reverse transcriptase (Thermo Scientific)
and SYBR Select master mix for CFX (Applied Biosystems). The same two Jamaican
fruit bats that were used for uninfected samples in RNA-Seq were also used as uninfected
samples for RT-qPCR.

Accession number(s)
Raw reads have been deposited into GenBank under GenBank accession no.
GSE75771.
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Figures
Appendix E-1: Transcriptomic analysis of Jamaican fruit bats infected with Tacaribe
virus (TCRV)

Appendix E-1: Transcriptomic analysis of Jamaican fruit bats infected with Tacaribe
virus (TCRV). Jamaican fruit bats were inoculated with either TCRV or DPBS (n=2 for
each condition). De novo assembly of the Jamaican fruit bat transcriptome was
performed using RNA-Seq data from kidney, liver, and spleen tissues. Differentially
expressed genes were then identified in the uninfected and infected tissues using edgeR.
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Appendix E-2: De novo assembly of the Jamaican fruit bat transcriptome

Appendix E-2: De novo assembly of the Jamaican fruit bat transcriptome. (A)
Trinity assembly resulted in the construction of the de novo-assembled Jamaican fruit bat
transcriptome with 644,933,364 assembled bases. (B) Examination of the identified
contigs from the transcriptome assembly showed that 35% (12,600) are expressed in the
spleen, kidney, and liver tissues (FRKM, greater than 1). (C) We compared this
transcriptome assembly to those of other mammals through BLASTX analysis and
identified transcripts similar to those present in other bat species.

317

Appendix E-3: Differential gene expression analysis following TCRV infection in
Jamaican fruit bats

Appendix E-3: Differential gene expression analysis following TCRV infection in
Jamaican fruit bats. We used a pairwise comparison of TCRV-infected samples against
the corresponding control uninfected samples and found that the expression levels of
hundreds of genes were altered with TCRV infection in the different tissues. (A)
Differential expression analysis revealed upregulated genes (green) and downregulated
genes (orange) defined by edgeR (log2 fold change > 2 and FDR < 0.01). (B) Inspection
of altered genes in all infected tissues versus control tissues showed fewer changed genes
common to all tissues. (C) Quantification of differentially expressed genes from panels A
and B.
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Appendix E-4: Immune-specific expression analysis of TCRV-infected Artibeus
jamaicensis bats

Appendix E-4: Immune-specific expression analysis of TCRV-infected Artibeus
jamaicensis bats. (A) Immport database immune-related genes and their expression
values (FPKM) were clustered (k-means = 6) to investigate the relationship between
uninfected and infected tissues. (B) We performed Ingenuity Pathway Analysis to
characterize the specific immune pathways for those genes identified in cluster 3 (n =
117) from panel A. (C) Interferon signaling was among the top pathways identified to be
altered after TCRV infection. We then identified these specific genes involved in
interferon signaling and explored their alterations in the different tissues in response to
TCRV infection. Green corresponds to upregulated and orange to downregulated (FDR,
<0.01; log2 fold change, >2); gray indicates no significant differential expression.
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Appendix E-5: Amino acid alignment of Jamaican fruit bat IgG V regions

Appendix E-5: Amino acid alignment of Jamaican fruit bat IgG V regions. Five V
region transcripts were identified in the Jamaican fruit bat spleen transcriptomes and
aligned with a V region of an annotated black flying fox V region (50). Framework
regions (FR1 to FR4) and complementarity-determining regions (CDR1 to CDR3) were
identified and exhibited differences between each transcript.
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Data access for publically available datasets
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The following tables contain data access information for publically available datasets
discussed in this dissertation.

Table 1: Data accession corresponding to publically available datasets (abbreviations:
Ch=Chapter; Rep=Replicate)
Ch

Type

Cell line

Sample

Target

Rep

Database

Accession

PANC1

parental

TCF7L2

1

ENCODE

ENCLB828OGC

PANC1

parental

TCF7L2

2

ENCODE

ENCLB718WRS

PANC1

parental

H3K27ac

1

ENCODE

ENCLB737KTI

PANC1

parental

H3K27ac

2

ENCODE

ENCLB797ODR

PANC1

parental

H3K4me1

1

ENCODE

ENCLB482XLE

PANC1

parental

H3K4me1

2

ENCODE

ENCLB346ZDV

PANC1

parental

H3K4me3

1

ENCODE

ENCLB792WMR

PANC1

parental

H3K4me3

2

ENCODE

ENCLB135CDR

PANC1

parental

H3K36me3

1

ENCODE

ENCLB555ABM

PANC1

parental

H3K36me3

2

ENCODE

ENCLB555ABN

ChIP2
seq
ChIP2
seq
ChIP2,3
seq
ChIP2,3
seq
ChIP2,3
seq
ChIP2,3
seq
ChIP2,3
seq
ChIP2,3
seq
ChIP2
seq
ChIP2
seq
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ChIP2

PANC1

parental

H3K27me3

1

ENCODE

ENCLB555ABQ

PANC1

parental

H3K27me3

2

ENCODE

ENCLB555ABR

PANC1

parental

H3K9me3

1

ENCODE

ENCLB555ABO

PANC1

parental

H3K9me3

2

ENCODE

ENCLB555ABP

PANC1

parental

Input

1,2

ENCODE

ENCLB499BUK

PANC1

parental

1

ENCODE

ENCLB941MSL

PANC1

parental

2

ENCODE

ENCLB342MOC

CAPAN1

parental

H3K27ac

1,2

GEO

GSM1574235

CAPAN2

parental

H3K27ac

1,2

GEO

GSM1574236

CFPAC1

parental

H3K27ac

1,2

GEO

GSM1574237

HPAF2

parental

H3K27ac

1,2

GEO

GSM1574238

MiaPaca2

parental

H3K27ac

1,2

GEO

GSM1574239

PANC1

parental

H3K27ac

1,2

GEO

GSM1574240

seq
ChIP2
seq
ChIP2
seq
ChIP2
seq
ChIP2,3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
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ChIP3

PT45P1

parental

H3K27ac

1,2

GEO

GSM1574241

CAPAN1

parental

H3K4me3

1,2

GEO

GSM1574256

CAPAN2

parental

H3K4me3

1,2

GEO

GSM1574258

CFPAC1

parental

H3K4me3

1,2

GEO

GSM1574259

HPAF2

parental

H3K4me3

1,2

GEO

GSM1574260

MiaPaca2

parental

H3K4me3

1,2

GEO

GSM1574261

PANC1

parental

H3K4me3

1,2

GEO

GSM1574262

PT45P1

parental

H3K4me3

1,2

GEO

GSM1574263

CAPAN1

parental

Input

1,2

GEO

GSM1574271

MiaPaca2

parental

Input

1,2

GEO

GSM1574272

MCF7

parental/0hr

Input

1,2

GEO

GSM2913215

MCF7

parental/0hr

H3K4me3

1,2

GEO

GSM2913216

MCF7

parental/0hr

H3K27ac

1,2

GEO

GSM2913217

seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP3
seq
ChIP4
seq
ChIP4
seq
ChIP4
seq
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ChIP4

MCF7

parental/0hr

H3K4me1

1,2

GEO

GSM2913218

MCF7

parental/0hr

H3K27me3

1,2

GEO

GSM2913219

MCF7

parental/0hr

H3K9me3

1,2

GEO

GSM2913220

MCF7

parental/0hr

ER-alpha

1,2

GEO

GSM2913221

MCF7

parental/0hr

CTCF

1,2

GEO

GSM2913222

Input

1,2

GEO

GSM2913223

H3K4me3

1,2

GEO

GSM2913224

H3K27ac

1,2

GEO

GSM2913225

H3K4me1

1,2

GEO

GSM2913226

H3K27me3

1,2

GEO

GSM2913227

H3K9me3

1,2

GEO

GSM2913228

ER-alpha

1,2

GEO

GSM2913229

CTCF

1,2

GEO

GSM2913230

seq
ChIP4
seq
ChIP4
seq
ChIP4
seq
ChIP4
seq
ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr

ChIP4

100nM
MCF7

seq

Estradiol/1hr
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ChIP4

100nM
MCF7

seq
ChIP4
seq

seq

seq

seq

seq

seq

H3K4me1

1,2

GEO

GSM2913234

H3K27me3

1,2

GEO

GSM2913235

H3K9me3

1,2

GEO

GSM2913236

ER-alpha

1,2

GEO

GSM2913237

CTCF

1,2

GEO

GSM2913238

Input

1,2

GEO

GSM2913239

H3K4me3

1,2

GEO

GSM2913240

H3K27ac

1,2

GEO

GSM2913241

H3K4me1

1,2

GEO

GSM2913242

H3K27me3

1,2

GEO

GSM2913243

Estradiol/4hr

ChIP-

100nM
MCF7

seq

Estradiol/4hr

ChIP-

100nM
MCF7

seq

Estradiol/16hr

ChIP-

100nM
MCF7

seq

Estradiol/16hr

ChIP-

100nM
MCF7

seq

Estradiol/16hr

ChIP-

100nM
MCF7

seq

Estradiol/16hr

ChIP-

100nM
MCF7

seq

GSM2913233

100nM
MCF7

4

GEO

Estradiol/4hr

ChIP-

4

1,2

100nM
MCF7

4

H3K27ac

Estradiol/4hr

ChIP-

4

GSM2913232

100nM
MCF7

4

GEO

Estradiol/4hr

ChIP-

4

1,2

100nM
MCF7

4

H3K4me3

Estradiol/4hr

ChIP-

4

GSM2913231

100nM
MCF7

4

GEO

Estradiol/4hr

ChIP-

4

1,2

100nM
MCF7

4

Input
Estradiol/4hr

Estradiol/16hr

340

ChIP4

100nM
MCF7

seq
ChIP4
seq

seq

seq

seq

seq

GSM2913246

Input

1,2

GEO

GSM2913247

H3K4me3

1,2

GEO

GSM2913248

H3K27ac

1,2

GEO

GSM2913249

H3K4me1

1,2

GEO

GSM2913250

H3K27me3

1,2

GEO

GSM2913251

H3K9me3

1,2

GEO

GSM2913252

ER-alpha

1,2

GEO

GSM2913253

CTCF

1,2

GEO

GSM2913254

DNase

1

ENCOD

ENCLB574ZZZ

100nM
MCF7

seq

Estradiol/24hr

ChIP-

100nM
MCF7

seq

Estradiol/24hr

ChIP-

100nM
MCF7

seq

Estradiol/24hr

ChIP-

100nM
MCF7

seq

Estradiol/24hr

ChIP-

100nM
MCF7

seq

DNase-

GEO

Estradiol/24hr

ChIP-

2

1,2

100nM
MCF7

4

CTCF

Estradiol/24hr

ChIP-

4

GSM2913245

100nM
MCF7

4

GEO

Estradiol/24hr

ChIP-

4

1,2

100nM
MCF7

4

ER-alpha

Estradiol/16hr

ChIP-

4

GSM2913244

100nM
MCF7

4

GEO

Estradiol/16hr

ChIP-

4

1,2

100nM
MCF7

4

H3K9me3
Estradiol/16hr

Estradiol/24hr

PANC1

parental

seq
2
A

DNaseseq
express
ion

E
PANC1

parental

DNase

2

PANC1

10μM ICG001

12hr

1,2
,3
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ENCOD
E
GEO

ENCLB573ZZZ
GSM1563237

2,A

A

2,A

A

2,A

2
2
2,A
2,A
2,A
2,A
2,A
2,A
3
3
3
3
3

beadch
ip
express
ion
beadch
ip
express
ion
beadch
ip
express
ion
beadch
ip
express
ion
beadch
ip
express
ion
beadch
ip
HiC
HiC
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq

PANC1

10μM ICG001

96hr

1,2

GEO

GSM1563238

PANC1

10μM C646

12hr

1,2

GEO

GSM1563239

PANC1

10μM C646

96hr

1,2

GEO

GSM1563240

PANC1

0.05%
DMSO

12hr

1,2

GEO

GSM1563235

PANC1

0.05%
DMSO

96hr

1,2

GEO

GSM1563236

PANC1

parental

1

GEO

GSM2827313

PANC1
PANC1

parental
siTCF7L2

48hr

2
1

GEO
GEO

GSM2827314
GSM1556985

PANC1

siTCF7L2

48hr

2

GEO

GSM1556986

PANC1

siTCF7L2

48hr

3

GEO

GSM1556987

PANC1

siControl

48hr

1

GEO

GSM1556982

PANC1

siControl

48hr

2

GEO

GSM1556983

PANC1

siControl

48hr

3

GEO

GSM1556984

CAPAN1

parental

1

GEO

GSM1574297

CAPAN1

parental

2

GEO

GSM1574298

CAPAN2

parental

1

GEO

GSM1574299

CAPAN2

parental

2

GEO

GSM1574300

CFPAC1

parental

1

GEO

GSM1574301
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3

CFPAC1

parental

2

GEO

GSM1574302

HPAF2

parental

1

GEO

GSM1574303

HPAF2

parental

2

GEO

GSM1574304

MiaPaca
2
MiaPaca
2
PANC1

parental

1

GEO

GSM1574305

parental

2

GEO

GSM1574306

parental

1

GEO

GSM1574307

PANC1

parental

2

GEO

GSM1574308

PT45P1

parental

1

GEO

GSM1574309

PT45P1

parental

2

GEO

GSM1574310

MCF7

Parental

1

GEO

GSM2913255

MCF7

Parental

2

GEO

GSM2913256

MCF7

Parental

3

GEO

GSM2913257

MCF7

TamR

1

GEO

GSM2913267

MCF7

TamR

2

GEO

GSM2913268

MCF7

TamR

3

GEO

GSM2913269

2,3
4
4

RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
TCC
TCC
TCC

PANC1
MCF7
MCF7

0hr
1hr

1,2
1
1

GEO
GEO
GEO

GSM1684570
GSM2913210
GSM2913211

4

TCC

MCF7

4hr

1

GEO

GSM2913212

4

TCC

MCF7

16hr

1

GEO

GSM2913213

4

TCC

MCF7

24hr

1

GEO

GSM2913214

4
4
4
4
4

TCC
TCC
TCC
TCC
TCC

MCF7
MCF7
MCF7
MCF7
MCF7

parental
parental
100nM
Estradiol
100nM
Estradiol
100nM
Estradiol
100nM
Estradiol
TamR
TamR
TamR
TamR
TamR

Input
H3K4me3
H3K27ac
H3K4me1

1
1,2
1,2
1,2
1,2

GEO
GEO
GEO
GEO
GEO

GSM2913258
GSM2913259
GSM2913260
GSM2913261
GSM2913262

4

TCC

MCF7

TamR

H3K27me3

1,2

GEO

GSM2913263

3
3
3
3
3
3
3
3
4
4
4
4
4
4

343

4
4
4

TCC
TCC
TCC

MCF7
MCF7
MCF7

TamR
TamR
TamR

H3K9me3
ER-alpha
CTCF

1,2
1,2
1,2

GEO
GEO
GEO

GSM2913264
GSM2913265
GSM2913266

4
4

TCC
TCC

T47D
T47D

0hr
1hr

1,2
1,2

GEO
GEO

GSM3386607
GSM3386608

4

TCC

T47D

4hr

1,2

GEO

GSM3386609

4

TCC

T47D

16hr

1,2

GEO

GSM3386610

4

TCC

T47D

24hr

1,2

GEO

GSM3386611

4
E

TCC
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq
RNAseq

T47D
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
fruit bat
Jamaican
Fruit bat

parental
100nM
Estradiol
100nM
Estradiol
100nM
Estradiol
100nM
Estradiol
TamR
Spleen

Control

1,2
1

GEO
GEO

GSM3386612
GSM1967338

Spleen

Control

2

GEO

GSM1967339

Spleen

Infected

1

GEO

GSM1967340

Spleen

Infected

2

GEO

GSM1967341

Kidney

Control

1

GEO

GSM1967342

Kidney

Control

2

GEO

GSM1967343

Kidney

Infected

1

GEO

GSM1967344

Kidney

Infected

2

GEO

GSM1967345

Liver

Control

1

GEO

GSM1967346

Liver

Control

2

GEO

GSM1967347

Liver

Infected

1

GEO

GSM1967348

Liver

Infected

2

GEO

GSM1967349

E
E
E
E
E
E
E
E
E
E
E

344

